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Ostrich products have internationally become very popular with South Africa being the world 
leader in this industry. An increase in the demand for ostrich products has influenced production 
strategies by intensifying rearing conditions through the use of feedlot systems. Intensive rearing 
creates ideal conditions for the spread of pathogens such as mycoplasmas, which is associated with 
a respiratory disease syndrome amongst feedlot ostriches. The three ostrich-infecting mycoplasmas, 
Ms01, Ms02 and Ms03, together with other secondary pathogens result in reduced production. 
Since there are no vaccines available against these ostrich-infecting mycoplasmas, three DNA 
vaccines have been developed in this laboratory. Each vaccine consisted of a eukaryotic expression 
vector (pCI-neo, VR1020 or VR1012) containing the Ms03 oppA gene as antigen.  
The first objective of this study was to re-evaluate the anti-OppA immune response elicited by the 
pCI-neo and VR1020vaccines in ostriches. A vaccination trial was conducted and both vaccines 
were administered intramuscularly at 100, 600 and 1200 µg/ml doses followed by a booster 
vaccination. The anti-OppA immune response elicited by these vaccines in the ostriches was 
measured by means of the ELISA technique. All of the VR1020 vaccine doses as well as the 100 
and 600 µg/ml doses of the pCI-neo vaccine were able to elicit a statistically significant anti-OppA 
immune response after administration of a booster vaccination. 
Since mycoplasmas target the respiratory system of ostriches a mucosally administered vaccine 
should also be considered. Opposed to the intramuscular route of vaccination, which results in 
humoral immunity represented predominantly by IgG, mucosal administration would result in 
mucosal immunity represented by IgA production. For the measurement of IgA production, the 
ELISA requires secondary anit-IgA antibodies. Although the whole antibody is typically used for 
the production of secondary antibodies, it is possible to use only the region representing the heavy 
chain constant region. This can then be produced as a recombinant protein that will allow an easy 
reproducible source for the production of secondary antibodies. The second objective of this study 
was therefore to evaluate the baculovirus-insect expression system for the production of the ostrich 
IgA heavy chain constant region (IgAH) protein, as this system will allow glycosylation of the 
protein product. The IgAH gene was inserted into the pAB-6xHis

 transfer plasmid and together 
with the ProFold

-ER1 baculovirus used to co-transfect Sf9 insect cells for the production of 
ProFold

-ER1_IgAH by means of homologous recombination. The IgAH protein was successfully 
expressed as confirmed by using HisProbe-HRP as well as previously produced rabbit anti-ostrich 
IgA antibodies during western blot analysis.  




Volstruisprodukte het internasionaal baie gewild geword en Suid-Afrika is die wêreld leier in 
hierdie industrie. Die verhoogde aanvraag na volstruisprodukte het 'n invloed op produksie 
strategieë deur intesivisering van grootmaak kondisies deur die gebruik van voerkrale. Intensiewe 
grootmaak kondisies skep ideale toestande vir die verspreiding van patogene soos mikoplasmas wat 
geassosieer word met ‘n respiratoriese siektesindroom in voerkraalvolstruise. Drie volstruis-
infekterende mikoplasmas, Ms01, Ms02 en Ms03, tesame met ander sekondêre patogene het 'n 
afname in produksie tot gevolg. Aangesien daar geen entstof teen hierdie volstruis-infekterende 
mikoplasmas beskikbaar is nie, is daar drie DNS entstowwe in hierdie laboratorium ontwikkel. Elke 
entsof bestaan uit ‘n eukariotiese ekspressievektor (pCI-neo, VR1020 of VR1012) wat die Ms03 
oppA geen bevat wat dien as antigeen. 
Die eerste doelwit van hierdie studie was om die anti-OppA immuunreaksie, soos ontlok deur die 
pCI-neo en VR1020 entstowwe, te herevalueer. 'n Inentingsproef was deurgevoer waar beide 
entstowwe binnespiers toegedien was aan volstruise met onderskeidelik 'n 100, 600 en 1200 µg/ml 
dosis, gevolg deur 'n skraagdosis. Die gevolglike anti-OppA immuunreaksie was gemeet deur die 
ELISA tegniek. Alle VR1020 entstof dosisse asook die pCI-neo entstof se 100 en 600 µg/ml dosisse 
was daartoe in staat om 'n anti-OppA immuunreaksie te ontlok na die skraagdosis toediening. 
Aangesien mikoplasmas die respiratoriese sisteem van volstruise teiken, moet die ondersoek na 'n 
mukosale entstof oorweeg word. In vergelyking met binnespierse toediening van ‘n entstof wat sal 
lei tot humorale immuniteit wat oorwegend verteenwoordig word deur IgG, sal mukosale 
toediening lei tot mukosale immuniteit wat verteenwoordig word deur IgA produksie. Vir die 
meting van IgA produksie benodig die ELISA sekondêre anti-IgA teenliggaampies. Alhoewel die 
teenliggampie normaalweg in geheel gebruik word vir die produksie van sekondêre 
teenliggaampies, is dit moontlik om slegs die gedeelte wat die swaarketting konstante area 
verteenwoordig te gebruik. Dit kan dan as ‘n rekombinante proteïen geproduseer word wat sal dien 
as 'n maklike reproduseerbare bron vir die produksie van sekondêre teenliggaampies. Die tweede 
doelwit van hierdie studie was dus om die baculovirus-insek ekspressiesisteem te evalueer vir die 
produksie van die volstruis IgA swaarketting konstante area (IgAH) proteïen aangesien die sisteem 
glikosilering van die proteïen toelaat. Die IgAH geen was ingevoeg in die pAB-6xHis

 
oordragplasmied en tesame met die ProFold

-ER1 baculovirus gebruik om Sf9 insekselle te 
infekteer vir die produksie van ProFold

-ER1_ IgAH deur middel van homoloë rekombinasie. Die 
IgAH proteïen was suksesvol uitgedruk soos bevestig deur HisProbe_HRP en voorheen 
geproduseerde konyn anti-volstruis IgA teenliggampies deur middel van 'n western-klad.
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%C amount of cross-linker 
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ABC   ATP-binding cassette 
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AIDS   acquired immunodeficiency syndrome 
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ATP   adenosine triphosphate 
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BSA bovine serum albumin 
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CAF central analytical facility 
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CMV   cytomegalovirus 
CTL   cytotoxic T lymphocyte  
CUT   carbohydrate uptake transporter 
dNTP deoxynucleotide triphosphate 
DTT dithiothreitol 
EDTA ethylene diamine tetra-acetic acid di-sodium salt 
ELISA  enzyme-linked immunosorbent assay 
EtBr ethidium bromide 
Fc fragment crystallisable region 
GALT  gut-associated lymphoid tissue 
GC green control 
GFP green-fluorescent protein 
GST glutathione S-transferase 
HMW  high-molecular weight  
HOAc acetic acid 
HRP  horseradish peroxidase 
ID intradermal 
IM intramuscular 
IDT integrated DNA technologies 
IFN-γ  interferon gamma 
Ig  immunoglobulin 
IgA immunoglobulin A 
IgAH immunoglubulin A heavy chain constant region 
IgD immunoglobulin D 
IgG immunoglobulin G 
IL  interleukin  
IPTG isopropyl β-D-1-thiogalactopyranoside 
IV  intravenous 
L liter 
LB Luria Bertani 
LPS   lipopolysaccharide 
LSD least significant difference 
m/v mass per volume ratio 
MALT   mucosa-associated lymphoid tissue 
MetOH methanol 
MG Mycoplasma gallisepticum 
MHC Ӏ  major histocompatibility complex class Ӏ 
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MHC ӀӀ major histocompatibility complex class ӀӀ 
Ms01 Mycoplasma struthionis sp. nov. str. Ms01 
Ms02 Mycoplasma sp. Ms02 
Ms03 Mycoplasma nasistruthionis sp. nov. str. Ms03 
NC no control 
NCBI national centre for biotechnology information 
NK   natural killer cells 
OB   occlusion body 
OD optical density 
ODV   occlusion derived virus 
OPD   o-phenylenediamine 
Opp   oligopeptide permease 
OppA oligopeptide ABC transporter substrate-binding domain 
OppB oligopeptide ABC transporter subunit, membrane component, B 
OppC oligopeptide ABC transporter subunit, membrane component, C 
OppD oligopeptide ABC transporter subunit, ATP-binding component, D 
OppF oligopeptide ABC transporter subunit, ATP-binding component, F 
ORF  open reading frame 
PAMP  pathogen-associated molecular pattern 
PBS phosphate buffer saline 
PBS-T phosphate buffer saline tween 
PCR   polymerase chain reaction 
pDNA plasmid deoxyribonucleic acid 
pNPP   p-nitrophenyl phosphate 
poly (A) polyadenylation 
PTP protein tyrosine phosphatase 
RE restriction enzyme 
rpm resolutions per minute 
rRNA   ribosomal ribonucleic acid 
RT room temperature 
SAP shrimp alkaline phosphatase 
SC   subcutaneous  
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
S-S  disulfide bond 
SV40 simian virus 40 
TB terrific broth 
TEMED tetramethylethylenediamine  
Th T helper cell 
TLR  Toll-like receptors 
TMB  3,3',5,5' -tetramethylbenzidine 
TPA tissue plasminogen activator 
UT untransfected 
UV ultra violet 
v/v volume per volume ratio 
VPN  veterinary procedural notice 
WASP  Wiscott-Aldrich syndrome protein  
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1. General introduction 
The ostrich industry in South Africa is the world leader with a 75% global market share. This 
industry dominates in the Klein Karoo region of the Western Cape as well as regions of the 
Southern Cape that are associated with dryer climates and winter rainfall. Oudtshoorn, in the Klein 
Karoo region, is known as the ostrich capital due to the amount of ostriches reared and slaughtered 
there. This industry generates 20 000 jobs in South Africa and export of ostrich products contributes 
R1.2 billion annually to the economy (DAFF, 2014). 
The three main products produced from ostriches include meat, leather and feathers. Ostrich meat is 
considered healthy and highly nutritive and there has been an increased demand for ostrich meat 
from especially the European Union as they are the biggest consumer of South African exported 
meat. As the demand for ostrich products, and specifically meat, increased over time, the rearing of 
ostriches became more intensive with the resulting use of feedlot systems also referred to as feeding 
camps. These intensive rearing systems create ideal conditions for the spread of pathogens with 
resulting disease outbreaks. One of the pathogens found to be problematic amongst feedlot ostriches 
is mycoplasmas (Botes et al., 2005; Poławska et al., 2011; DAFF 2014). Three ostrich-infecting 
Mycoplasma species were identified in South Africa by Botes et al. (2005) which were 
provisionally named Ms01, Ms02 and Ms03. In 2009 Langer isolated mycoplasmas from Namibian 
ostriches with 16S rRNA sequences that matched that of Ms01 and Ms03. Langer (2009) named 
Ms01 Mycoplasma struthionis sp. nov. as this strain was isolated from the lungs of the ostriches and 
Ms03 Mycoplasma nasistruthionis sp. nov. as this strain was isolated from the nasal cavity of the 
ostrich. The description by Langer (2009) has not yet been published and therefore not formally 
accepted. For the sake of simplicity the ostrich-infecting mycoplasmas will be referred to as Ms01, 
Ms02 and Ms03 in the rest of this thesis. 
In ostriches mycoplasmas are associated with upper respiratory tract infections which are mostly 
observed during seasonal changes and can be exacerbated due to stress and environmental 
conditions (Verwoerd 2000; Botes 2004). Ostrich-infecting mycoplasmas together with other 
pathogens can results in the loss of ostrich stocks, a reduced growth rate with resulting reduced 
production and downgrading of carcasses. Due to the impact of mycoplasma infections on ostrich 
production, strategies need to be developed to manage these organisms (Botes, 2004; Botes et al., 
2005; Verwoerd, 2000). Mycoplasma infections can be managed with good biosecurity practices, 
however, some ostriches might appear to be healthy although they are carriers of the organism. 
Medication such as antibiotics is used to treat existing infections but antibiotics do not eliminate the 
mycoplasmas. Antibiotics are also expensive and long periods of antibiotic treatment can result in 
Stellenbosch University  https://scholar.sun.ac.za
 2 
 
traces of antibiotic residues in the meat which makes the meat unsuitable for export (Kleven, 2008; 
Olivier, 2006; Stipkovits and Kempf, 1996). Hence, other approaches are needed to control 
mycoplasma infections such as vaccination. 
Several vaccines are commercially available for use against mycoplasma species in different animal 
species. These include vaccines such as Stellamune One (Pfizer Animal Health), Suvaxyn
®
 MH 
One (Zoetis) and Respisure
®
 (Zoetis). These formulations have been developed for different routes 
of administration and the route of administration does not necessarily correlate with the route of 
infection. For example Myco-Bac
®
 B (Texas Vet alb) is administered subcutaneously in the side of 
the neck but is for the prevention of respiratory disease in cattle. Other examples include Ingevac 
3FLEX (Boehringer) which aids in prevention of respiratory disease in pigs but is administered 
intramuscularly.  
Currently there is no registered vaccine available for use against mycoplasma infections in ostriches 
therefore the development of a vaccine that can be administered either intramuscularly, 
intradermally or mucosally should be investigated. The main types of vaccines that could be 
considered for development included live attenuated, inactivated whole cell, subunit vaccines and 
DNA vaccines. Live attenuated and inactivated whole cell vaccines, however, require cultivation of 
the organism in large quantities and subunit vaccines require an adjuvant. As ostrich-infecting 
mycoplasmas are difficult to cultivate and some subunit vaccines were shown to aggravate the 
symptoms of infections, these vaccines were eliminated as options. Attention was subsequently 
turned to DNA vaccines which have become more popular as they do not require the cultivation of 
the organism in large quantities. They are also inexpensive, regarded as easy to manufacture and 
safe. Similar to live attenuated vaccines they also have the ability to stimulate both humoral and 
cellular immunity (Bellamy and Freedman, 2005; Bosch and Frey, 2003; Ingolotti et al., 2010; 
Kumaragurubaran and Kaliaperumal, 2013).  
1.1 Evaluation of DNA vaccines 
In a previous study by Wium (2015) three DNA vaccines against Ms03 were developed and 
evaluated. The oppA gene, which codes for part of an ABC peptide transporter, was selected as the 
immunogenic gene and cloned into the pCI-neo, VR1020 and VR1012 vaccine plasmids. A field 
trial was conducted in which a single dose of all three vaccines was respectively administered 
intramuscularly to ostriches, but the trial had to be prematurely terminated due to an avian influenza 
outbreak. Despite this, preliminary results indicated that an immune response was elicited by both 
the pCI-neo_oppA and VR1020_oppA vaccines and therefore the use of DNA vaccines in ostriches 
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appears to be a viable approach. However, in a study done by De Wet (2015) on vaccination of 
ostriches against Ms01 infections, it was found that the dose as used by Wium (2015) was not 
necessarily sufficient. The first objective of this study was therefore to re-evaluate the ability of the 
pCI-neo_oppA and VR1020_oppA vaccines developed against Ms03 to elicit an anti-OppA 
antibody response in ostriches at different doses. To achieve this objective, the following aims were 
set: 
 To perform a vaccination trial in ostriches with the pCI-neo_oppA and VR1020_oppA DNA 
vaccines at three different doses including a booster vaccination.  
 To analyse the anti-OppA antibody response using the enzyme-linked immunosorbent assay 
(ELISA). 
 To monitor mycoplasma infections during the trial using PCR-analysis. 
1.2 Production of the IgA heavy chain constant region protein 
Given that mycoplasmas target the respiratory system of ostriches, the future development of a 
mucosal vaccine should also be considered. Compared to an intramuscular route of vaccination that 
results in the production of mainly IgG, a mucosally administered vaccine would result in the 
production of a different antibody class as the mucosal surfaces are protected by IgA antibodies. 
Therefore the ELISA developed to measure humoral antibodies against the OppA antigen of Ms03 
would have to be adapted to detect anti-OppA IgA antibodies. For this purpose, secondary anti-IgA 
antibodies would be required. Previous isolation of IgA from ostrich nasal samples for the 
production of secondary antibodies proved to be largely unsuccessful yielding low quantities of this 
protein. Instead of isolating the whole antibody, the protein representing the IgA heavy chain 
constant region (IgAH) can be produced in vitro and subsequently used for the production of 
secondary antibodies. The IgAH contains three glycosylation sites which plays a role in their 
function as well as in prevention from degradation. Therefore using a eukaryotic expression system 
capable of post-translational modifications would be preferable (Huang et al., 2012; Schroeder and 
Cavacini, 2010). The second objective of this study was therefore to evaluate the use of a 
baculovirus-insect expression system for the production of the IgAH protein. The aims set to achieve 
this objective were as follows: 
 To sub-clone the IgAH gene into the pAB-6xHis transfer vector. 
 To generate a recombinant baculovirus by means of homologous recombination. 
 To transfect an insect cell line and produce the IgAH protein. 
 To verify the expression of the IgAH protein. 
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1.3 Thesis layout 
A literature review relevant to the first and second objective of this study will be presented in 
Chapter 2 which includes an overview of mycoplasma metabolism, pathogenesis and control. 
Mycoplasmas specifically infecting the ostrich are discussed as well as management of these 
organisms using vaccines and the measurement of immune responses. The IgA antibody structure 
and baculovirus-insect expression system for production of proteins is also discussed in this chapter.  
Results obtained from the evaluation of two DNA vaccines during a vaccination trial are then 
presented in Chapter 3 followed by the results obtained from the production of the protein 
representing the IgAH in a baculovirus-insect expression system as described in Chapter 4.  
Finally the conclusions and future perspectives of this study are given in Chapter 5 followed by the 
reference list. At the end of this thesis are Addenda containing the results of the statistical analysis 
of the ELISA data as well as data used for the analysis (Addendum A), an alignment of the ostrich 
genome and the IgAH gene (Addendum B) and lastly an alignment of the IgAH secretory and 
transmembrane proteins with an indication of the domains (Addendum C). 
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2.  Literature Review 
2.1 Introduction 
The first objective of this study was to evaluate the immune response, elicited by two DNA 
vaccines against mycoplasma infections in ostriches. The literature review therefore includes a brief 
overview of the immune system as well as a discussion of different kinds of vaccines that can be 
used to elicit immune responses with a specific focus on DNA vaccines as was used in this study. 
An overview is then given of the enzyme-linked immunosorbent assay (ELISA) as measurement 
technique for the evaluation of vaccine induced immune responses. The second objective of this 
study was to produce a protein representing the constant region of the IgA antibody which would 
allow adapting the ELISA for the detection of mucosal immunity. An overview is therefore given of 
the structure of antibodies and specifically IgA followed by the baculovirus-insect expression 
system as a method for the production of immunoglobulin proteins. The literature review is 
concluded with a discussion on mycoplasmas, their pathogenicity, the control of ostrich-infecting 
mycoplasmas and DNA vaccine strategies previously developed in this laboratory. 
2.2 The immune system 
As background for later discussions on mycoplasma pathogenicity and specifically the mode of 
action of vaccines as a control measure against these organisms, it is important to understand how 
the immune system of a vertebrate host functions to provide protection against pathogens. To this 
end an overview of innate and adaptive immunity is given. 
2.2.1 Innate Immunity 
Innate immunity provides initial protection against infections. It was previously believed that innate 
immunity is nonspecific, weak and ineffective regarding its ability to protect against infections. It is 
now known that the innate immune system targets microbes specifically and is an effective early 
defence mechanism able to control and eliminate infections before the activation of the adaptive 
immunity (Abbas et al., 2014). 
For the innate immune system to function effectively it consists of components that have different 
but complimenting roles, including the prevention of microbes to enter the host as well as 
eliminating those that succeed to enter the host. The components responsible for these functions are 
epithelial barriers, phagocytes (neutrophils and monocytes/macrophages), dendritic cells, natural 
killer (NK) cells, cytokines and plasma proteins (including compliment system proteins) (Abbas et 
al., 2014).  
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The innate immune system becomes activated by recognising conserved features of the invading 
pathogen (Alberts et al., 2002). In order to indicate that these conserved features, mentioned above, 
are shared by microbes of the same type they are referred to as pathogen-associated molecular 
patterns (PAMPs). One example is bacterial lipopolysaccharides (LPS), also known as endotoxins, 
which are present in the cell wall of Gram-negative bacteria species but mammalian cells do not 
produce them. Similarly, bacteria contain surface glycoproteins with a terminal mannose residue 
which is absent in mammalian surface glycoproteins. Double-stranded RNA present in many 
viruses, as well as unmethylated CpG oligonucleotides, found in microbial DNA, are not 
found/abundant in mammalian cells and are therefore recognised by phagocytes (Abbas et al., 
2014).  
The innate immune system comprises of receptors that bind specifically to microbial molecules or 
PAMPs. A major class of these receptors is known as toll-like receptors (TLRs) which are able to 
recognise different microbial products such as nucleic acids or bacterial cell wall. Some TLRs are 
situated on the cell surface of the host cells and others are found in endosomes. Binding of TLRs 
with microbial products results in the expression of certain genes due to activation of transcription 
factors. The expressed genes encoding cytokines and enzymes aids activated phagocytes and 
dendritic cells to fulfil their function which is to terminate micro-organisms. Other receptors such as 
the cell surface receptor for N-formyl methionine and the mannose receptors to name a few, also 
form a part of the innate immune system (Abbas et al., 2014).  
2.2.2 Adaptive immunity 
Although the function of the innate immune system entails early defence against infections, it also 
provides secondary signals which lead to the activation of the adaptive immune response. 
Compared to innate immunity, adaptive immunity is known as the slower process of defence 
against infections but it mediates a more specific and thereby effective defence in comparison to the 
innate immune system (Abbas et al., 2014).  
The components of the adaptive immune system that will defend the host against microbes consist 
of lymphocytes. The lymphocytes can be sub-divided into B-lymphocytes (B-cells), NK cells and 
T-lymphocytes (T-cells). T-cells can further be activated into T-helper cells (Th) and cytotoxic T-
lymphocytes (CTL) (Abbas et al., 2014). 
In order for the adaptive immune system to be effective against infections, it has several properties 
including specificity, diversity, clonal and memory expansion. The functional significance of the 
specificity of the adaptive immune system is that a distinct antigen will be able to elicit a specific 
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response. However the functional significance of diversity is the ability of the adaptive immune 
system to elicit an immune response against a variety of antigens. For the adaptive immune system 
to keep up with the rapidly dividing pathogens or microbes, the activated lymphocytes must 
proliferate rapidly resulting in numerous clonal progeny cells. All of the cells are specific for the 
same antigen and this process is known as clonal expansion (Abbas et al., 2014). 
The adaptive immune response is initiated in compartments in which the T- and B-cells are matured 
and these compartments include the peripheral lymph nodes, the spleen and the mucosal lymphoid 
system. The lymph nodes and spleen responds to antigens that have entered the tissues and/or blood 
whereas the mucosal lymphoid system respond to pathogens that have breached the epithelial layer 
of mucosal surfaces (Abbas et al., 2014; Janeway et al., 2001). 
The adaptive immune system is able to recognise and differentiate between many antigens or 
portions of antigens and consists of two types, humoral and cellular immunity. The humoral 
immune response (mediated by B-cells) forms a very important part of the adaptive immune system 
as it is able to respond to different types of molecules, whereas the cellular immune response 
(mediated by T-cells) recognises and respond only to protein antigens. Each type of adaptive 
immunity is mediated by different cells and molecules for defence against microbes in the blood, 
and microbes inside infected cells. Protection is mediated by the humoral immune response also 
known as the production of antibodies. Protection against intracellular infections is mediated by 
cellular immunity or the cell-mediated response. For some diseases either a humoral or a cellular 
immune response would be sufficient for protection against a pathogen but for other diseases both 
humoral and cellular responses are required (Abbas et al., 2014; Gurunathan et al., 2000).  
The primary immune response is the first response elicited, after exposure to an antigen for the first 
time and naive B-cells or T-cells are then activated to give a primary immune response. A small 
part of the activated B-cells or T-cells do not differentiate into antibody secretion cells (plasma 
cells) or effector T-cells and become known as memory cells. These cells circulate in the blood and 
are found in various tissues and survive for months to years until the immune system is exposed to 
the same antigen again. A repeated encounter with the same antigen will result in a more rapid and 
larger immune response than the primary immune response and is facilitated by the memory cells. 
This is known as the secondary immune response (Abbas et al., 2014). The memory feature allows 
the immune system to react in a more effective manner against antigens that it encounters 
repeatedly. This is illustrated by the immune response pattern of B-cells as shown in Figure 2.1. 




Figure 2.1 Memory feature of the adaptive immune response results in a primary response with the first encounter 
of an antigen X and a more rapid secondary response for the second encounter of the same antigen (Abbas et al., 
2014). 
2.2.2.1 Humoral Immunity  
Humoral immunity is mediated by B-cell produced antibodies able to neutralise and eliminate 
invading pathogens. B-cells are activated by epitopes/antigenic determinants (the part of the antigen 
that the immune system is able to recognise) that bind to the B-cell antigen receptors (antibodies) 
and initiate an immune response (Abbas et al., 2014).  
Some B-cells differentiate into plasma cells which secrete antibodies containing the same antigen 
binding sites as those that originally recognised the antigen. Activated B-cells are able to secrete 
different classes of antibodies after differentiating into plasma cells, for example IgM, IgG, IgE etc. 
The different antibody classes secreted by the plasma cells each possess their own distinct 
functions. The humoral immune response is able to prevent infections by targeting microbes for 
phagocytosis, by neutrophils and macrophages and/or by coating the microbes with antibodies and 
thereby eliminating the microbes (Abbas et al., 2014).  
Globular protein epitopes are not able to bind to many antigen receptors and in order for a full B-
cell response to be elicited Th cells are required. The B-cells therefore have to phagocytose the 
protein, degrade and display the peptides bound to Major Histocompatibility Complex (MHC) class 
II molecules for the Th cells and its CD4
+
 co-receptor to recognise the globular proteins. Once the 
Th cells recognise the peptides presented by the B-cells, the Th cells expresses cytokines and cell 
surface proteins which activate the B-cells (Abbas et al., 2014).  
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2.2.2.2 Cellular Immunity 
Cellular immunity is responsible for the elimination of intracellular microbes which is mediated by 
T-cells. These intracellular microbes may be phagocyte ingested microbes or microbes that have 
infected non-phagocytic cells. In the case of ingested microbes the intracellular antigens will be 
processed by the cell and presented on the surface of the cell in combination with MHC II 
molecules and in the case of infected cells, processed antigen will be displayed in combination with 
MHC I molecules. T-cells have antigen receptors that mainly recognise processed antigens bound to 
MHC molecules on the surface of these antigen presenting cells (APCs) (Abbas et al., 2014; 
Luckheeram et al., 2012). 
Naive CD4
+
 Th cells and naive CD8
+
 CTLs are activated upon recognition of antigen peptides 
bound to MHC class II and I complexes respectively. Activation is initiated with the help of 
costimulator signals from antigens and cytokines (Abbas et al., 2014; Luckheeram et al., 2012; 
Murphy et al., 2012). 
Th cells promote antibody production as well as removal of antigen. As Th cells produce cytokines 
and cell surface molecules that are able to bind to receptors on B-cells and macrophages they 
promote the production of B-cell antibodies or activation of macrophages. Th cells also have the 
ability to activate neutrophils resulting in the elimination of microbes. The Th cells may 
differentiate into subdivisions known as Th-1, Th-2 and Th-17 cells. Each produces different 
cytokines which distinguishes the groups from one another. IFN-γ, produced by Th-1 cells, is a 
potent activator of macrophages and influences the production of antibody. These antibodies will 
further enhance phagocytosis of microbes, as the antibodies bind directly to phagocyte Fc receptors. 
Th-2 cells produce IL-4, IL-5 and IL3. The function of IL-4 includes differentiation of Th cells into 
Th-2 cells as well as stimulation of non-compliment activating IgG subclasses and IgE production 
where IgE combats parasitic worms. IL-5 supports growth and differentiation of activated B-cells 
and bone marrow derived granulocytes whereas IL-3 promotes the expansion of immature bone 
marrow progenitors of all blood types. Th-17 cells aids in the protection against bacterial and fungal 
infections as they secrete cytokines such as IL-17 and IL-22 which are responsible for recruiting 
neutrophils as well as monocytes to sites where antigens was recognised (Abbas et al., 2014; 
Gurunathan et al., 2000; Takatsu and Nakajima, 2008).  
Initiation of the activation of naive CD8
+
 CTL requires cross presentation of cytoplasmic antigens 
by dendritic cells (DCs) which is a somewhat unusual feature. Another unusual feature is that 
differentiation of naive CD8
+
 CTLs may require the accompanying activation of the CD4
+
 Th. The 
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function of CTLs is to remove infections by killing infected cells and therefore eliminating 
microbes that are concealed in the infected cells cytoplasm. By completely eliminating the infected 
cells the source of the infection is removed. CTLs that have been generated in the lymphoid organ 
may target the sites where the antigen or microbe is present by migrating into the blood. At sights of 
infection the differentiated CTL cells are activated, by the antigen present, and execute the wanted 
function of eliminating microbes (Abbas et al., 2014).  
2.2.2.3 The adaptive immune system in the mucosal lymphoid system 
The mucosal immune system has several functions including protection of the mucous membrane, 
by preventing invasion and colonisation of microbes, and preventing the uptake of antigens i.e. 
foreign proteins ingested from food and airborne matter amongst others (Holmgren and Czerkinsky, 
2005). Pathogens generally enter the host through a barrier, consisting of the external located 
epithelium and the underlying connective tissue, separating the internal environment from the 
external environment (Fellah et al., 2008). The surface layers of the eyes, respiratory, digestive and 
urogenital tracts are lined with epithelial cells. The epithelial layer together with the underlying 
tissue are known as the mucosa, mucosal membrane or the mucosal surface (Lundgren, 2004). 
These surfaces are protected by the innate and adaptive mucosal immune system against infections 
from the environment. 
The respiratory, gastrointestinal and genitourinary tracts are guarded immunologically by mucosa-
associated lymphoid tissues (MALT) which includes the gut-associated lymphoid tissue (GALT) 
and the bronchial-associated lymphoid tissues (BALT) (Fellah et al., 2008). MALT is a separate 
immunologic secretory system mediated by sub-epithelial clusters of lymphoid tissue. The MALT 
system immerses the mucosal surfaces with protective IgA antibodies produced by B-cells and 
thereby provide protection. Therefore the mucosal immune system is the main defense mechanism 
at the mucosal surface and protects these surfaces by means of secretory IgA through the mucosal 
immune system (Rabson et al., 2005). 
2.3 Vaccines 
In order to control infections and subsequent diseases the immune response needs to be stimulated. 
This can be done by means of vaccination as this process is the most effective way to control 
diseases, and uses non-pathogenic forms of microbes for the stimulation of the adaptive immune 
response (Abbas et al., 2014). Vaccines stimulate adaptive immunity allowing the host to fend off 
pathogens and thereby minimising diseases on farms which results in an increased productivity 
(Mäkelä, 2000; Marangon and Busani, 2006). 





century, Edward Jenner introduced the concept of vaccination when he was able to show 
that a previous exposure to cowpox prevented infection by smallpox as reviewed in Gurunathan et 
al. (2000). About 80 years elapsed before Louis Pasteur discovered that he could attenuate a 
bacterium for vaccine purposes. Killed or inactivated vaccines were developed by Daniel Salmon 
and Theobald Smith and used for vaccination against typhoid, cholera and plague (Plotkin and 
Plotkin, 2011). The germ theory was established by Pasteur, Koch, Ramon, and Mérieux and they 
developed the vaccines known as live attenuated, inactivated or killed pathogens, and inactivated 
toxins. These developments led to the first golden age of vaccines as these vaccines protected 
against a number of illnesses including rabies, tuberculosis in infants, diphtheria and many more 
(Delany et al., 2014). 
In the 20th century the main types of vaccines in use are live attenuated, inactivated whole-cell, 
toxoid, subunit and DNA vaccines. Live attenuated vaccines are prepared by passaging or culturing. 
The weakened pathogens are, however, still able to infect and replicate within their hosts as they 
contain bacteria or viruses with reduced virulence. These vaccines are able to elicit both humoral 
and cellular immunity and although they are able to produce long term immunity they impose a risk 
of reverting back to their pathogenic form. Culturing and inactivating some pathogens proved to be 
a tedious tasks and in some cases it is not possible (Bellamy and Freedman, 2005; Hasson et al., 
2015; Ingolotti et al., 2010; Kumaragurubaran and Kaliaperumal, 2013). 
Inactivated whole cell vaccines consist of micro-organisms that have been inactivated through 
physical (γ-rays) or chemical means. These inactivated vaccines are still able to evoke an immune 
response although they are not able to infect or replicate within the host. They therefore require 
multiple doses (boosters) or adjuvants in order for them to produce long-term immunity. This 
results in higher production costs and as these vaccines might require adjuvants they are more 
expensive to manufacture. They are also only able to elicit a humoral immune response. Inactivated 
whole cell vaccines do not hold any risk for reverting back to its pathogenic form unlike live 
attenuated vaccines (Bellamy and Freedman, 2005; Ingolotti et al., 2010; Meeusen et al., 2007). 
Subunit vaccines consist of antigenic proteins of pathogens including flagella or surface proteins. 
Manufacturing of these vaccines can be on large scale although they require repeated administration 
with adjuvants and are only able to induce a humoral immune response (Bellamy and Freedman, 
2005; Ingolotti et al., 2010). 
Toxoids are bacterial toxins that have been made non-toxic or are inactivated, but are still 
immunogenic. Although they are able to induce a humoral immune response they require boosters 
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and also have possible adverse side-effects. Manufacturing of these vaccines also holds obstacles 
regarding the detoxification process (Bellamy and Freedman, 2005; Ingolotti et al., 2010). 
DNA vaccines consist of a DNA sequence encoding the desired antigen that is molecularly cloned 
into a eukaryotic plasmid expression vector. These vaccines are non-live vaccines and therefore 
they do not hold the risk of reverting back to a pathogenic form. Manufacturing of DNA vaccines 
can be done on large scale with ease. DNA vaccines are also able to elicit both a cellular and 
humoral immune response, however, a drawback of DNA vaccines is the possible need for 
adjuvants due to reduced immunogenicity (Hasson et al., 2015; Kutzler and Weiner, 2008). A 
summary of the main types of poultry vaccines is given in Table 2.1. 
Table 2.1 Overview of the main type of vaccines used for poultry purposes. 
Type of vaccine Composition Immunity Induced Example 
Live attenuated 
vaccines 
Contain viruses or bacteria 
that have been made 
avirulent 




 IB Ma5 * 





organisms by means of 




(prevention of clinical signs of 
Mycoplasma gallisepticum in 
poultry) 
Subunit vaccines 





(prevention of coccidiosis in 
poultry) 
Toxoids 








containing the gene 
encoding the desired 
immunogen 





(Prevention of West Nile Virus 
infections in horses) 
* Available in South Africa.  
Compiled from Bellamy and Freedman (2005), Belli et al. (2009), Crouch et al. (2010), Kjærup et al. (2014), 
Kumarangurubaran and Kaliapernumal (2013), Pereira et al. (2014) and Ferguson-Noel and Williams (2015). 
 
2.3.1 DNA vaccines 
In the 1990's, the public's attention was turned to DNA vaccines as Tang and Johnston attempted to 
deliver human growth hormone, as gene therapy, into mice. DNA vaccines are known as the 
simplest vaccines as they consist of genes encoding the antigen rather than consisting of the antigen 
itself (Donnelly et al., 2005). It has been shown in the past decade and a half that this non-live 
vaccine approach is a simple way to induce an immune response, evoking a humoral and cellular 
immune response (Hasson et al., 2015; Kutzler and Weiner, 2008).  
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DNA vaccines are the simplest yet safest approach to use as they overcome safety concerns 
associated with live vaccines as well as the risks involved in the manufacturing of killed vaccines 
(Gurunathan et al., 2000; Kutzler and Weiner, 2008; Pereira et al., 2014). In order to be able to 
produce a vaccine the vaccine plasmid containing the immunogenic gene of interest needs to be 
amplified therefore the plasmid is transformed into bacteria. The bacteria are grown leading to 
amplification of the plasmid, followed by purification of the plasmid from the bacterial culture. The 
purified vaccine plasmid can then be inoculated into the animal where cells will take up the DNA 
and produce the antigenic protein (Gurunathan et al., 2000).  
Proteins that are synthesized in the cells after DNA vaccination have the ability to access pathways 
for presentation by both class Ӏ and ӀӀ MHC molecules. Similar to live-attenuated vaccines, DNA-
vaccines are able to induce both the humoral and cellular immune response but, unlike live-
attenuated vaccines, DNA vaccines only encode selected components of the pathogen and therefore 
there is no risk for reverting back to a pathogenic form and thereby infecting the host (Gurunathan 
et al., 2000). Although no DNA vaccines for human use have been licensed, there are a small 
number of licensed DNA vaccines for veterinary use as listed in Table 2.2  
Table 2.2 Licensed veterinary DNA vaccines. 
Product name Species Target 
Apex-IHN
®
 Salmon Infectious Haematopoietic necrosis virus (IHNV) 
LifeTide
®
- SW5 Swine Growth hormone releasing hormone (GHRH) 
Oncept

 Dog Melanoma 
West Nile-Innovator
®
 Horses West Nile Virus 
 Adapted from Pereira et al. (2014) 
2.3.2 Characteristics of DNA vaccines 
2.3.2.1 Characteristics of the expression vector 
DNA vaccine vectors combine prokaryotic and eukaryotic regions enabling the propagation of the DNA 
vaccine in bacterial cultures such as Escherichia coli as well as the expression of the gene of interest in 
the eukaryotic host (Williams, 2013). For a DNA vaccine to be functional it should contain the 
following:  
Firstly, transcriptional control elements for expression of the gene of interest in eukaryotic cells. For 
the production of the protein from the DNA vaccine, the plasmid should contain highly active 
transcriptional control elements. Most vaccine plasmids contain sequences from the immediate 
early region of the cytomegalovirus (CMV) as enhancer and promoter areas. The presence of CMV 
intron A in the upstream promoter sequence of the desired plasmid is effective for expression of 
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microbial cDNA's and would likely provide transcripts with signals allowing the transcripts to be 
processed and transported as eukaryotic mRNA (Gurunathan et al., 2000; Robinson and Torres, 
1997). 
Secondly, a polyadenylation sequence allowing for stabilisation of the mRNA transcripts. 
Polyadenylation, the addition of a poly (A) tail to mRNA transcripts, is of significant importance 
for nuclear export as well as translation of the mRNA transcript. A gene sequence from bovine 
growth hormone (BGH) is known as the most frequently used sequence for polyadenylation but 
simian virus 40 (SV 40) sequences can also be used (Gurunathan et al., 2000).  
Thirdly, an origin of replication for multiplication of the plasmid in bacterial cells. The origin of 
replication allows for multiplication and maintenance of plasmids in host cells and for stable 
plasmid production during bacterial growth. The goal of the origin of replication is the production 
of a substantial number of copy DNA plasmids as well as high purification yields in a short time 
(Pereira et al., 2014).  
Fourthly, a selectable marker usually a bacterial antibiotic resistance gene allowing for selection of 
the DNA vaccine during bacterial culture. Bacterial antibiotic resistance genes ensure stable 
production of the plasmid of interest and some of the most widely used antibiotic resistance genes 
are the kanamycin and ampicillin genes (Gurunathan et al., 2000; Pereira et al., 2014; Williams, 
2013). 
2.3.2.2 Characteristics of vaccine candidate genes 
A vaccine target should not contain homology with any protein of the host as the host can respond 
on this in two ways. Firstly, an autoimmune response can be induced in the host due to the vaccine 
which can result in autoimmune disease and secondly the host can be made tolerant to the vaccine 
hence no immune response would be induced (Flower and Perrie, 2013). 
The antigen should not be able to mutate rapidly (hypermutable) nor should it be involved in 
antigen variation. The epitope or antigenic determinant should not be masked and thereby prevent 
an effective immune response (Liu, 2011; Rueckert and Guzmàn, 2012). Neutralisation, by 
vaccination, of factors that enable the pathogen to access the host as well to survive in the host may 
offer protection. Therefore, genes that are essential for the viability of the pathogen will make a 
good vaccine target (Allan and Wren, 2003). 
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2.3.3 Mode of action of DNA vaccines 
The ability of a DNA vaccine to elicit an efficient immune response can be influenced by the 
concentration and by the type of APCs transfected. DNA vaccination is able to induce a B-cell 
response, Th responses as well as CTL responses. Depending on the route of vaccination, the 
injected DNA enters the nucleus of, for example, myocytes, keratinocytes or APCs. Genes encoded 
on the plasmid are transcribed and translated for the generation of the protein of interest (Donnelly 
et al., 2000; Gurunathan et al., 2000; Mäkelä, 2000). In order for a DNA vaccine to elicit an 
immune response the antigen encoded by the plasmid DNA is processed and transiently presented 
by at least three different mechanisms:. 
 Ӏ.  Direct transfection of myocytes, keratinocytes or any MHC class ӀӀ-negative cells: 
  injection of DNA into the muscle or skin of the organism will most probably result in 
  transfection of somatic cells. The somatic cells will present produced and processed 
  antigenic proteins via the MHC class I pathway to CTLs (Gurunathan et al. 2000). 
 ӀӀ. Direct transfection of professional APCs: due to intramuscular  injection, a small 
amount of APCs can be transfected which are able to present produced and processed 
antigenic proteins via both the MHC class I and II pathways to CTLs and Th 
respectively (Gurunathan et al., 2000). 
 ӀӀӀ. Cross-priming: antigenic proteins secreted by somatic and/or professional APCs 
transfected with plasmid DNA, that is then taken up by other professional APCs, 
processed and presented via both the MHC class I and II pathways to CTLs and Th 
respectively (Gurunathan et al., 2000). 
APCs transfected with the antigen migrate to the draining lymph nodes where they activate naïve T 
cells by presenting the antigen via both MHC class I and II molecules. Costimulatory signals are 
released and trigger an immune response including more CTLs and Th. In the lymph node the Th 
secrete cytokines and APCs secrete some of the antigen which activates the B-cells and induce the 
production of antibodies. The activated T- and B-cells can migrate to the tissues transfected with the 
vaccines and be reactivated where the CTLs are able to lyse the infected myocytes presenting 
antigens which result in increased release of antigens. Several factors, however, can influence the 
immune responses elicited by the DNA vaccine such as the route and method of administration and 
the dose of vaccine administered (Ingolotti et al., 2010; Kutzler and Weiner, 2008; McCluskie et al., 
1999). 
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2.3.4 Routes of administration and immunogenic response 
DNA vaccines may be administered in many ways such intramuscular (IM) injection, intradermal 
(ID) injection, subcutaneous (SC) injection, intravenous injection (IV) and intranasal (IN) delivery 
amongst others (McCluskie et al., 1999). The most popular routes are the IM and ID injection. 
Expression of the protein following ID and IM injection occurs in different cell types namely the 
keratinocytes and skeletal muscle (myocytes) respectively (Dunham, 2002). 
New age methods for delivering the DNA vaccines intradermally and intramuscularly include the 
use of a gene gun, electroporation and a needle-free method. With the use of a gene gun the skin is 
bombarded with DNA-coated gold beads by using compressed helium to accelerate the beads. As 
the DNA is delivered directly into the cell, only small amounts of DNA are necessary for the 
induction of an immune response (Doria-Rose and Haigwood, 2003; Dunham, 2002; Okuda et al., 
2014). Electroporation makes use of electrical impulses to produce pores in the cells, improving 
transfection. This method, however, has the disadvantage of prolonged exposure to high voltage 
electricity. Therefore animals will have to be sedated which will be impractical for large scale 
vaccination (Cole et al., 2015; Liu, 2011; Okuda et al., 2014; Saade and Petrovsky, 2012; Van 
Drunen Littel-van den Hurk et al., 2008). The needle-free method uses the CO2-powerd Biojector
®
 
device to spray the DNA vaccine through the skin for direct transfection of cells. This method did 
not show an increase of immune response in comparison to the use of the conventional needle 
approach on non-human primates and clinical trials using this device are still ongoing (Okuda et al., 
2014; Saade and Petrovsky, 2012)  
DNA delivery is, however, most commonly performed by the use of a hypodermic needle for both 
ID and IM delivery (Okuda et al., 2014). Typically a Th1 response will be elicited as a result of 
needle injection delivery as the DNA is delivered in the extracellular spaces of the cell. This 
promotes antibody production and therefore both cellular and humoral immunity is activated. Only 
the gene gun method is capable of a balanced Th1/Th2 response whereas both electroporation and 
the needle free method result in a Th2 response. As the needle injection results in both cellular and 
humoral immunity and is the most affordable it is the most popular method of administration. 
Factors that have an influence on delivery of DNA vaccines by means of needle injections include 
the needle type, muscle type injected and animal age (Okuda et al., 2014).  
2.3.5 Dose requirement 
Many factors have an impact on the dose required in order to elicit or induce an effective immune 
response and these include route of delivery as well as age of the animals amongst others. Different 
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doses administered to different animals are shown in Table 2.3. The dose administered to mice can 
be as low as 10-100 µg, where higher doses are required for larger animals and humans ranging 
from 500 to 2500 µg (Dunham, 2002; Gurunathan et al., 2000; Oshop et al., 2002). The total dose 
given to ducks and chickens, as seen in published studies, ranges from 0.5 to 1500 µg per bird 
administered over time. Only a few studies used DNA vaccine concentrations above 500 µg 
although in one published study a concentration of 10 mg was used per injection against infectious 
bursal disease in chickens (Meunier et al., 2016; Oshop et al., 2002).  
According to Dunham (2002) less DNA is required when using a gene gun due to the fact that the 
DNA is coated onto golden beads minimising degradation of the DNA. In mice it was shown that 
needle injections required 2-20 µg DNA in order to induce an immune response whereas with gene 
gun delivery only 1-3 µg DNA was required for an effective immune response (Dunham, 2002). 
DNA is also delivered directly into the cell compared to using a needle which will result in 
introduction of the DNA outside of the cells (Robinson and Torres, 1997). Although the use of the 
gene gun will result in the use of a smaller dose, multiple injections several times are required as 
only a small amount of DNA can be put on the gold beads. The stability of the DNA on the beads is 
also questionable and can complicate the results obtained by using this technique (Dunham, 2002; 
Liu, 2011). 
Not all the DNA injected into the animal will enter the cell; some is degraded before it enters the 
nucleus. About 90% of DNA never enters the cytoplasm. Of the remaining 10% DNA, less than 1% 
enters the nucleus (Babiuk et al., 2003). It was shown that after DNA inoculation of poultry (such as 
chickens and turkeys) that antigen was produced in small amounts in the picogram to nanogram 
range but was still able to induce an immune response (Meunier et al., 2016; Oshop et al., 2002). 
In some studies a dose related response could be observed, but in the case of poultry there was not a 
good response seen up until a booster vaccine was administered. It is not yet clear if this 
phenomenon is due to an immature immune system of the birds or if the time frame needs to be 
adjusted (Meunier et al., 2016; Oshop et al., 2002).   
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Table 2.3 Dose range and schedule of booster DNA administration to different animals. 
Animal Organism/disease Dose Booster Route Reference 
Mice Taxoplasma gondi 100 µg 
(Every 2 
weeks) x 2 
IM (Yuan et al., 2011) 
Mice H5N1 influenza virus 10 µg Week 2 IM (Luke et al., 2011) 









Week 1, 2 
and 5 




400 µg, 1000 µg-
10 000 µg 
(Every 
week) x 2 
IM (Hsieh et al., 2010) 
Turkey Chlamydophila psittaci 100 µg - 500 µg Week 2 IM (Verminnen et al., 2010) 
Turkey Turkey coronavirus 750 µg Week 2 IM (Chen et al. 2013) 
Ducks Duck plague virus 50 µg- 200 µg - 
IM/gene 
gun 
(Lian et al., 2011) 
Ducks Hepatitis B virus 400 µg 
Week 3 
and 7 
IM (Saade et al., 2008) 
Cattle 




weeks) x 2 
IM 
(Van Drunen Littel-Van 
Den Hurk et al., 2013) 
Cattle Mycobacterium bovis 1000 µg Week 3 IM (Skinner et al., 2003) 
Monkeys Alzheimer's disease 200 µg -2000 µg 
Weeks 2, 6 
and 26 
IM (Evans et al., 2014) 
Monkeys Ebola virus 1000 µg 
(Every 4 
weeks) x 2 





1500 µg -10 000 
µg 
(Every 4 
weeks) x 2 
IM (Schadeck et al., 2006) 
Dogs Trypanosoma cruzi 500 µg Week 2 IM 
(Arce-Fonseca et al., 
2013) 
Sheep Toxoplasma gondii 1000 µg Week 4 IM 
(Hiszczynska-Sawicka 
et al., 2011) 
Pigs Influenza A virus 200 µg - 1972 µg - 
Needle 
free 
(Borggren et al., 2016) 
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2.3.6 DNA vaccines: Advantages and concerns 
DNA vaccines can be manipulated to circumvent many safety issues and still retain specificity. 
DNA vaccines are not associated with problems regarding protein production such as improper 
folding of the protein of interest or high purification costs. There is also not the risk associated with 
live-attenuated vaccines since DNA vaccines are not able to spread or replicate and are not living, 
resulting in little risk of secondary infections or of reversion to an infecting form (Coban et al., 
2008; Kutzler and Weiner, 2008).  
Some concerns regarding the safety of DNA vaccines have however been raised and include the 
potential of the DNA vaccine to integrate into cellular DNA. This can have devastating results as 
for example instable chromosomes, mutagenesis and also malfunction of tumour suppressor genes. 
Integration, however, will occur at rates much lower than the spontaneous mutation frequency 
(Kumar et al., 2013; Kumaragurubaran and Kaliaperumal, 2013; Kutzler and Weiner, 2008). 
Another concern is the development of autoimmunity but early studies in both non-primates and 
humans showed that autoimmune disorders are unlikely (Hasson et al., 2015; Kutzler and Weiner, 
2008). 
Another concern regarding DNA vaccines is that they typically contain antibiotic resistance markers 
for selection and it is possible that these resistance genes can be horizontally transferred resulting in 
antibiotic resistant pathogenic bacteria. Kanamycin antibiotic resistance genes commonly used in 
DNA vaccine vectors, however, are not commonly used in the treatment of infections (Kutzler and 
Weiner, 2008; Vandermeulen et al., 2011). Although this is a concern, new antibiotic free selection 
systems have been developed and includes mechanisms such as complementation of auxotrophic 
complementing markers, RNA based selection markers and toxin-antitoxin-based strategies 
amongst others (Mignon et al., 2015; Vandermeulen et al., 2011). These systems, however, can be 
expensive as they require development of mutant host strains and defined media and therefore, if 
used in DNA vaccines, would result in an increase in production costs (Dong et al., 2010; Peubez et 
al., 2010). 
Other advantages of DNA vaccines includes their ability to encode multiple types of genes 
including viral and bacterial, as well as immunological and biological proteins and are therefore 
immensely flexible. They are also highly stable, and can be stored and transported with ease and are 
produced effortlessly on large scale (Kutzler & Weiner 2008; Ghanem et al. 2013; 
Kumaragurubaran & Kaliaperumal 2013). Furthermore, both arms of the adaptive immune system 
can be induced by DNA vaccines, and additionally the immune response can be directed to either 
the humoral or cellular immune response (Hasson et al., 2015; Khan, 2013). 
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2.3.7 Evaluation of antibody responses 
Humoral and mucosal immune responses to infection or vaccination can be measured by a variety 
of techniques including radioimmunoassay (RIA) and enzyme immunoassays. Enzyme 
immunoassays can be divided into two types known as heterogeneous and homogeneous enzyme 
immunoassays. Enzyme-linked immunosorbent assays (ELISA) are included in the heterogeneous 
type as they consist of both a solid and liquid phase whereas the homogeneous type has no solid 
phase. Since 1971, as termed by Engvall and Perlmann and by Weenmen and Schuurs (Clark et al., 
1986), ELISA has become standard use in the scientific world. ELISAs use enzyme amplification of 
antibody binding followed by conversion of colorimetric substrates to measure this. The ELISA 
technique was derived from the RIA, described by Berson and Yalow (Yalow and Berson, 1960). 
RIA however made use of radioactive substances and, as this can be a safety hazard, the technique 
was modified by replacing the radioisotopes with enzymes. The ELISA technique is very specific 
and easy to execute, sensitive as well as highly versatile requiring very little equipment and reagents 
are readily available (Hornbeck, 1991). To date there are different types of ELISAs including the 
sandwich, indirect and competitive ELISAs to name a few (Butler, 2000; Gan and Patel, 2013). For 
this study the focus will be on the indirect ELISA. 
This ELISA is often used in studies on infectious diseases and allows for the measurement of 
antibody levels. The first step of the indirect ELISA is to immobilise or adhere the antigen onto the 
solid phase which in this case is a pre-treated 96 well microtitre plate by means of passive 
adsorption (Gan and Patel, 2013; Voller et al., 1978). This is followed by the addition of a non-
reacting protein as that will block all areas of the well which was not coated with antigen and 
therefore prevent non-specific binding. This is followed by a wash step to remove the excess non-
reacting protein that did not bind to the wells. The primary antibody is then added to the wells and 
incubated in order for the primary antibodies to bind to the antigen. After incubation, excess 
unbound serum components are washed away, followed by the addition of an enzyme-conjugated 
secondary antibody (Burry, 2011; Gan and Patel, 2013). Depending on whether humoral or mucosal 
antibody levels are being measured this secondary antibody can either be anti-Ig, anti-IgG or anti-
IgA antibodies. Several detection and amplification methods for subsequent steps are available but 
in this study the biotin/avidin detection method was used, therefore biotin was covalently attached 
to the secondary antibodies by an N-hydroxysuccinimide ester of the biotin. The biotin-linked 
secondary antibody is incubated with the antigen-primary antibody complex in order for the biotin-
linked secondary antibody to adhere to the primary antibody. The unbound or excess biotin-linked 
secondary antibody is removed by a wash step after incubation. The wash steps that are performed 
between all steps will minimise the background of the ELISA results (Guesdon et al., 1979).  
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This is followed by the addition of avidin or streptavidin. Avidin or streptavidin has a high affinity 
for biotin and this ensures that the complex is very stable through pH changes, presence of 
chaotropes as well as multiple washings. Avidin has four binding sites per molecule and therefore 
four biotin moieties can bind to one molecule of avidin. However, all the avidin sites are not always 
occupied by biotin but the signal is increased as more biotin molecules bind to the avidin 
(Diamandis and Christpoloulos, 1991). As avidin is an egg-white glycoprotein which is highly 
alkaline this can result in non-specific binding. Therefore the use of a bacterial analogue 
streptavidin, isolated form Streptomyces avidinii, is preferred as it is a neutral non-glycosylated 
protein resulting in less non-specific binding (Bayer and Wilchek, 1990). The streptavidin is 
labelled with horse radish peroxidase (HRP) or alkaline phosphatase in order to detect the 
biotinylated secondary antibody by means of a colour reaction which is caused by the addition of a 
substrate. The colour change can be measured by means of a spectrophotometer and the colour 
reaction measured can be interpreted as being proportional to the amount of primary antibody 
present in the well (Gavrilova et al., 2014; Voller et al., 1978). 
Most ELISA assays contain marker enzymes such as β-galactosidase, alkaline phosphatase or horse 
radish peroxidase (HRP) and each has an appropriate substrate available for use in the ELISA. 
Some of the substrates include 2,2 - azino-bis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS), o-
phenylenediamine (OPD), 3,3',5,5' -tetramethylbenzidine (TMB), p-nitrophenyl phosphate (pNPP) 
and bisdiazobenzidine (BDB) amongst others. The appropriate substrates for the alkaline 
phosphatase enzyme includes OPD and pNPP resulting in an orange and yellow colour respectively. 
The appropriate substrates for HRP include TMB which results in a yellow colour, BDB resulting in 
a purple/reddish colour or ABTS which results in a green colour (Butler, 2000; Espina et al., 2004; 
Frey et al., 2000). In this study the ELISA marker enzyme used was HRP and ABTS was used as a 
substrate which resulted in a green product of which the absorbance can be measured at 405 nm 
(Butler, 2000) 
2.4 Secondary antibody production for detection of mucosal immunity 
Mucosal surfaces are mainly protected by means of secretory IgA through the mucosal immune 
system or mucosa-associated lymphoid tissues (MALT) (Rabson et al., 2005). Measurement of 
mucosal immunity implies that the amount of IgA produced is measured. Using a technique such as 
ELISA requires the production of secondary anti-IgA antibodies and therefore the isolation of IgA 
antibodies. Alternatively only a portion of the IgA antibody could be produced in vitro and used for 
the production of the secondary anti-IgA antibodies. To understand which part of the IgA antibody 
would be most suitable for this purpose, the structure of antibodies first needs to be discussed.  
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2.4.1 Antibody structure 
As shown in Figure 2.2 antibodies consists of two identical large polypeptide chains known as the 
heavy chains (H) as well as two identical small polypeptide chains known as the light chains (L). 
Each of the H and L chains contain a variable region (V) as well as a constant region (C) and the 
constant regions are the same in antibodies of the same class. The four chains are assembled to form 
a Y-shaped molecule as each of the light chains are attached to a heavy chain and the heavy chains 
are attached to each other by disulfide bonds. There are five types of heavy chains known as µ, α, δ, 
ε and γ which all differ in their constant region. In mammals the five classes are known as IgM, 
IgA, IgD, IgE and IgG, but only three classes are described in avian species namely IgM, IgA and 
IgY, which is the homologue of IgG in birds (Abbas et al., 2014; Huang et al., 2012; Zhao et al., 
2006). Immunoglobulin H chains consist of an N-terminal variable domain and 3-4 constant 
domains. All of the mammalian Ig types have three H chain constant region domains except for 
IgM and IgE which have four constant region domains whereas the IgA, IgM and IgY of birds have 
four constant region domains (Higgins and Warr, 1993; Kaetzel, 2014; Zhao et al., 2006)  
All of the H chains of the different classes of immunoglobulins can be produced in two forms 
namely the membrane-bound form or secreted form. The difference is that the membrane bound 
form has a hydrophobic transmembrane region which is coded for by two exons known as the 
membrane coding segment (Figure 2.3 indicated in yellow). These exons code for of roughly 25 
amino acid residues at the carboxy terminus of the H chain that anchor it to the B-cell surface. The 
secreted form lacks this domain and instead has a hydrophilic secretory tail (Figure 2.3 indicated in 
orange) that is coded for by a different exon known as the secretory-coding sequence. The two 
forms can only be produced by alternative RNA processing during the processing of the initial 
transcript. The primary transcript encoding the H chain gene has two potential polyadenylation (pA) 
sites indicated as pAm and pAs in Figure 2.3. Splicing between the 4th exon of the constant region 
and the secretory-coding sequence (indicated as SC in Figure 2.3) as well as at a second site 
downstream of the membrane coding segment results in the loss of the hydrophilic secretory tail 
and the transmembrane immunoglobulin is formed. The secreted form is produced if splicing occurs 
at the pAs site resulting in the membrane encoding segment being removed. This process of RNA 
splicing occurs in the same way for all classes of immunoglobulins (Janeway et al., 2001; Murphy 
et al., 2012). 




Figure 2.2 Illustration of an immunoglobulin molecule. C=constant region and V=variable region of the heavy 
and light chains respectively. Adapted from Murphy et al. 2012. 
 
Figure 2.3 Process of RNA splicing of immunoglobulin heavy chain genes to produce the transmembrane and 
secreted forms of immunoglobulins. MC= membrane coding sequence, SC= secretion-coding sequence, pAm= 
ployadenilation site resulting in the transmembrane form of the antibody, pAs= polyadenylation site resulting in 
the secretory form of the antibody (Murphy et al., 2012). 
2.4.2 IgA heavy chain structure 
The ostrich IgA H chain protein consists of four constant region domains (IgAH) that shares 44% 
DNA sequence similarity with chickens and 66% with ducks. The IgM and IgA genes are 
positioned in reverse orientation on duck, chicken and goose chromosomes. The IgAH genes of 
ducks, chickens, goose and ostriches have a close genetic relationship to one another, it is therefore 
assumed that the IgAH gene of the ostrich is also positioned in the reverse orientation (Guo et al., 
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Huang et al (2012) showed that the ostrich genome contains a single IgA H chain gene that consists 
of 4 exons that each code for a constant domain in the final protein product (Addendum B). The 
hydrophobic secretory tail is contained within the C-terminal end of the 4th domain and compared 
to other species the translated protein contains 10 conserved cysteine residues. The constant region 
also contains three N-linked glycosylation sites (N-165, N-221 and N-419) in 2, 3 and 4 with the 
third being situated in the canonical secretory tail. These are all conserved in birds (Huang et al., 
2012).  
2.4.3 Antibody region suitable for production of secondary antibodies 
The IgAH domains of the goose have similar antigenicity to natural IgA as suggested by western 
blot analysis (Guo et al., 2014; Huang et al., 2012) and since the goose IgAH is closely related to 
that of the ostrich the same would be expected for the ostrich IgAH. Furthermore, the antibody class 
is determined by the sequence and function of the heavy chain constant region which implies that 
this region within IgA can be used for the reproducible production of secondary anti-IgA antibodies 
(Huang et al., 2012; Karu et al., 1995). 
The IgAH protein can be produced in vitro and as the IgAH protein has three glycosylation sites it is 
important to use an expression system that will allow post-translational modifications such as 
glycosylation. The baculovirus-insect expression system is capable of post-translational 
modifications such as glycosylation and is able of producing a greater amount of proteins more 
rapidly compared to mammalian cell lines. Carayannopoloulos et al. (1994) showed that insect cells 
were able to assemble and secrete recombinant human IgA successfully in the baculovirus-insect 
expression system therefore this system can potentially be effective for the production of ostrich 
IgAH protein which in turn can be used for the production of secondary anti-ostrich IgAH antibodies 
(Carayannopoulos et al., 1994; Hasemann and Capra, 1990; Huang et al., 2012) 
2.5 The Baculovirus 
The Baculoviridae family is a large family of viruses capable of infecting arthropods (mainly 
insects), and contains a relatively large genome consisting of double stranded circular DNA. The 
genome of these viruses is packaged into rod-shaped nucleocapsids (Figure 2.4) and they replicate 
in the nucleus of the infected insect cell. Baculoviruses are used to control insect pests for example 
Cydia pomonella, on apple, the velvet bean caterpillar and the cotton bollworm to name a few 
(Jarvis, 2009; Van Oers, 2011).  
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2.5.1 The baculovirus-insect cell expression system 
The use of the baculovirus-insect cell expression system for production of recombinant proteins 
dates back to the 1980's when the first report regarding the virus as an expression vector was 
published. This system is known for providing high levels of production and eukaryotic protein 
processing capabilities. These two characteristics are usually associated with bacterial and 
mammalian systems respectively and make the virus suitable for foreign gene expression. It is 
regularly stated that a baculovirus-insect cell system has the ability to process a protein with 
eukaryotic modifications. Therefore high levels of recombinant protein with posttranslational 
modifications can be produced by means of a baculovirus vector in combination with insect cells or 
larvae. Although the insect cell possesses the ability of eukaryotic modifications, it is not equivalent 
to those of higher eukaryotes (Kost et al., 2005). 
The different genera of the family Baculoviridae are capable of infecting different orders of insect 
classes. The Alphabaculoviruses, as well as Betabaculoviruses, infect the Lepidoptera order 
whereas Gammabaculoviruses are specific for hymenopteran insects and Deltabaculoviruses infect 
dipteran insects. In the Alphabaculoviruses the GP64 protein is known as the budded virus (BV) 
envelope fusion protein which is essential for entrance of baculovirus particles into susceptible 
insect cells. The same function is however achieved by the non-homologous F protein in the 
Betabaculoviruses and Deltabaculoviruses. The Gammabaculovirus, however, does not contain a 
BV envelope fusion protein (Van Oers, 2011).  
Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) and, to a lesser extent, 
Bombyx mori NPV (BmNPV) are the two baculovirus species most extensively studied and utilised 
in biotechnology as vectors for production of recombinant proteins in insect cells (Jarvis, 2009; Van 
Oers, 2011). These two viruses form part of the Alphabaculovirus genus. The insects cells generally 
used for the baculovirus-insect expression system are known as lepidopteran derived insect cells 
which are easy growing cells that can easily be up scaled (Van Oers, 2011). 
2.5.2 Replication cycle of baculoviruses 
Baculoviruses have two different infective forms, also known as virions (Figure 2.4). The first 
virion is the occlusion derived virus (ODV) which is stable outside the insect host as it is embedded 
in an occlusion body (OB). The OB's are responsible for horizontal transmission as they enter the 
insect larvae gut by ingestion and release the ODV. The second virion is known as the budded virus 
(BV) which is responsible for vertical transmission as they are able to spread the infection from cell 
to cell within the host insect and is not occluded as in the case of the ODV (Rohrmann, 2013). The 
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BVs and the ODV differ in their morphological characteristics and are formed by the early and late 
phases of replication respectively (Figure 2.5), which resulted in the development of the 
baculovirus-insect expression system (Luque and O’Reilly, 1999).  
 
Figure 2.4 Two virion types of the baculovirus namely the BV and ODV occluded in OB's. MNPV= Multicapsid 
nucleopolyhedrovirus, SNPV= Singlecapsid nucleopolyhedrovirus (Larramendy and Soloneski, 2012). 
Studies suggest that the early and late phases are subdivided and the baculovirus therefore expresses 
genes in four phases during the infection process. This phenomenon is known as the replication 
cycle and the four phases of this cycle are referred to as the immediate early, early, late and very 
late phases (Figure 2.5) (van Oers 2011; Chen et al. 2013). During the immediate early phase the 
OB is ingested by the insect larvae followed by dissolution of the OB by the alkaline conditions of 
the midgut of the larvae whereby the virus is released and is now known as ODV (Rohrmann, 
2013). ODV infects the epithelial cells of the midgut through binding of the virus to receptors on 
the epithelial cells. These receptors mediate binding of the virus and virus envelope proteins, 
allowing fusion with the host cell membrane. The ODV enters the midgut epithelial cells by the 
enzymatic activity of some proteins present in the envelope allowing fusion with the cell 
(Rohrmann, 2013). 
According to Rohrmann (2013) the ODV envelope fuses with the membrane of the epithelial cell of 
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and through the nuclear pores. During the early phase the double stranded DNA (dsDNA) of the 
nucleocapsids is replicated. The late phase entails exiting of the nucleocapsids from the nuclear 
membrane. Envelope proteins are required for virus budding and allow the replicated nucleocapsids 
to bud from the plasma membrane which is then known as the BV. The BV is responsible for 
systemic infection of neighboring and other susceptible cells in the insect. During the very late 
phase polyhedrin protein production starts which is responsible for the formation of the matrix of 
OBs and which protect the virions from harsh environmental conditions outside the insect. The 
release of BV is terminated during this phase and nucleocapsids accumulate in the nucleus of the 
midgut epithelial cell. The singlecapsid nucleopolyhedrovirus (SNPV) or multicapsid 
nucleopolyhedrovirus (MNPV) will obtain an envelope from the nucleus of the infected epithelial 
midgut cells and be known as ODV. The produced polyhedrin accumulates in the nucleus and at 
some point forms a crystallized structure around the ODV which is then known as OBs and released 
from the larvae (Rohrmann, 2013; Van Oers, 2011).  
Polyhedra are large particles, consisting of BV embedded within a protective paracrystalline array, 
that appear in the nuclei of infected insect cells. A single virus-encoded protein known as 
polyhedrin is responsible for the paracrystalline array structure of the OB's. The very late phase, 
however, includes the production of both polyhedrin and a 10 kDa protein (P10) in high 
concentrations (van Oers 2011; Chen et al. 2013). The function of P10 however is not yet fully 
understood but plays a role towards the end of infection by releasing the OBs from the cell nucleus 
(van Oers 2011; Chen et al. 2013). 
Viral cathepsin-like protease and chitinase enzymes are responsible for liquefying the larvae and in 
this process OBs are released from the cell (Clem and Passarelli, 2013; Juliant et al., 2013). Infected 
larvae become hyperactive and have an increase in their locomotory activity due to the baculovirus 
as it is able to modify the behavior of its host. This abnormal behavior is known as 
'Wipfelkrankheit' or 'tree top disease' and is brought about by the expression of the protein tyrosine 
phophatase. By modifying the host behavior the baculovirus ensures the spread of OBs over large 
areas of plants as larvae will move to the top of plants before they liquefy. The next larvae will 
ingest the OBs while ingesting the plant and be infected (Clem and Passarelli, 2013; Van Houte et 
al., 2012). 




Figure 2.5 Replication cycle of the Baculovirus consisting of four phases: The immediate-early phase- 
where the OB is ingested and released ODV are transported to the nucleus of the larvae midgut epithelial 
cells. The early phase- Replication of baculovirus DNA in the nucleus of the larvae midgut epithelial cell. 
The late phase- Release of the budded virus resulting in secondary infection of the larvae cells. The very late 
phase- where polyhedrin is produced for the formation of OBs and OB release (Al-Rubeai, 2015). 
 
2.6 The development of the baculovirus as expression vector 
For cell culture purposes the BV is required since it is responsible for cell to cell infection. Since 
OBs are responsible for horizontal transmission, they are not required in a cell culture system and 
therefore polyhedrin production is also not necessary in vitro. Hence the polyhedrin gene can be 
replaced with foreign DNA or a gene of interest. The baculovirus contains strong promoters in order 
to produce large amounts of polyhedrin. If the polyhedrin gene is replaced by another gene of 
interest for expression, the viruses would not be able to form occlusion bodies as the formation of 
the occlusion body matrix is dependent on polyhedrin. Instead, the gene of interest will be 
expressed in high levels due to the control of the powerful polyhedrin promoter (Luque and 
O’Reilly, 1999). 
The lack of polyhedrin production will cause vertical transmission to continue since the viruses 
containing a gene of interest are still able to form BV's and can be cultured. The approach of 
replacing the polyhedrin gene with the gene of interest has been modified over time, for example, 
by using other promoters, producing occlusion-positive recombinant viruses as well as the 
expression of more than one foreign gene simultaneously (Luque and O’Reilly, 1999).  
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2.6.1 Baculovirus transfer plasmid design 
As the bacoluvirus vector itself has a relatively large genome it is frequently not possible to insert a 
foreign gene into the baculovirus genome by means of direct cloning. Therefore, homologous 
recombination between the viral genome and a transfer plasmid, containing the gene of interest, is 
used in an approach to produce recombinant viral progenies (Van Oers, 2011).  
A general method used to achieve homologous recombination includes the construction of a 
"transfer" plasmid as well as the process of co-transfection. Recombinant baculovirus transfer 
plasmids are constructed to contain the polyhedrin promoter and to be able to express chimeric 
genes as they would also contain the foreign gene of interest. The constructed plasmid should 
contain the gene of interest flanked by up- and downstream sequences from the polyhedrin region 
of the baculovirus genome in order for homologous recombination to occur (Figure 2.6). The 
recombinant baculovirus vector is then generated by co-transfecting the cells with the transfer 
plasmid and genomic baculovirus DNA (Figure 2.7) (Jarvis, 2009).  
 
Figure 2.6. Transfer plasmid containing cDNA encoding for the protein of interest, flanked by polyhedrin 
sequences (Jarvis, 2009). 
 
Figure 2.7. Generation of a recombinant baculovirus by means of homologous recombination (Jarvis, 2009). 
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2.6.2 Modifications to the baculovirus vector 
Recombinant baculovirus DNA molecules are produced in co-transfected insect cells as a result of 
homologous recombination. In order for the polyhedrin gene to be eliminated and the foreign gene 
to be inserted in the baculovirus genome a double cross over recombination event is necessary. This 
event however does not occur often with a frequency of about 0.1% (Jarvis, 2009). 
As only 0.1% of the produced viruses will be recombinant, separation of recombinant viruses from 
the majority of parental viral progenies is necessary and can be achieved by baculoviral plaque 
assays. The produced viruses could be distinguished from one another as parental viral progeny 
produced polyhedrin positive plaques whereas the recombinant viral progeny produce polyhedrin 
negative plaques since the recombinant viral progeny does not contain the polyhedrin gene. Hence 
separation of parental and recombinant viral progenies, by an investigator, could be achieved by 
using a visual screen. The investigator, however, should have a trained eye and many investigators 
fail to separate the plaques (Jarvis, 2009; Van Oers, 2011). Around 1990 it became clear that the 
system needs improvement to be able to isolate recombinant viral progeny. Modifications were 
developed that entailed two categories: modifications of the transfer plasmid and modifications to 
the parental baculovirus genome to create a baculovirus vector.  
Modification of the transfer plasmid was done to simplify the recombinant expression and 
purification. These modifications included incorporation of secretory signal peptide sequences and 
purification tags, replacing the polyhedrin promoter with baculovirus promoters that vary as well as 
promoters responsible for simultaneous drive of expression of more than one recombinant protein 
(Jarvis, 2009). The purpose of modifications to the parental baculovirus genome was to isolate 
recombinant baculoviruses and to increase the recombination efficiency of the baculovirus. 
The incorporation of the lacZ gene into the transfer plasmid which encodes β-galactosidase, was 
used to refine the technique used to purify recombinant viruses as it was recognisable by visual 
screening of plaque assays. This technique was however not infallible as it could not identify double 
homologous crossovers nor single homologous crossovers, which are recurrent. Single homologous 
crossover recombination results in viral recombinant genomes which contain the transfer plasmid as 
a whole as well as the bacterial replicon, at some loci (Jarvis, 2009; Van Oers, 2011). 
Increasing homologous recombination efficiency was of the essence as the natural process resulted 
in less than 1% success. This was also a time consuming process hence modifications were made 
which resulted in the first baculovirus vector with a linearisable DNA genome. Introducing a 
Bsu36I site into the baculovirus genome by means of a novel sequence allowed for linearisation of 
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the genome at that specific site by means of Bsu36I. This approach resulted in more than 30% 
recombinant viral progenies. An important feature of this linear baculovirus vector was that it was 
not able to replicate. In order to improve the homologous recombination the E. coli lacZ gene was 
introduced into the genome up- and downstream of the viral genes. The lacZ gene contributed 
another Bsu36I site together with the other two Bsu36I sites introduced by the novel sequence in the 
polyhedrin site. This allowed triple digestion of the baculoviral genome and in this process the 
orf1629 gene is lost. A wiscott-Aldrich syndrome protein (WASP), phosphoprotein PP78/83, is 
encoded by the orf1629 gene. This protein is responsible for the nuclear actin filament formation 
during baculovirus infection. Hence the orf1629 gene is an essential gene required for replication of 
the virus in insect cells. The orf1629 gene is restored upon recombination and results in 90% 
recombinant baculovirus production. This is as a result of the deletion of the orf1629 gene from 
linearised baculoviral genomes used, thus parental baculovirus vector would not be able to replicate 
on its own (Jarvis, 2009; Van Oers, 2011). 
2.6.3 Advantages of the baculovirus-insect cell expression system 
An advantageous feature of the baculovirus includes its narrow host range. The baculovirus is 
generally restricted to infect only specific species of invertebrates and as this narrow range only 
includes insects, it would be safe for vertebrates, plants and humans (Jarvis, 2009; Szewczyk et al., 
2009). The baculovirus-insect expression system holds eukaryotic protein processing abilities 
including phosphorylation, N- and O-glycosylation, correct signal peptide cleavage and proteolytic 
processing amongst others. Proper folding of the protein as well as S-S bond formation can be 
accomplished by the baculovirus-insect expression system whereas this is not possible in the 
reducing environment of the E. coli cytoplasma. In contrast prokaryotic expression systems are able 
to produce high levels of recombinant proteins but are not capable of posttranslational 
modifications (Demain and Vaishnav, 2009; Jarvis, 2009). The baculovirus-insect expression 
system can be easily up scaled and as the virus will use the polyhedrin promoter in order to express 
the foreign protein, high levels of the foreign protein will be expressed. There is also no limit on the 
size of the protein of interest and multiple genes can be expressed simultaneously (Demain and 
Vaishnav, 2009). 
2.6.4 Disadvantages of the baculovirus-insect cell expression system 
It is known that promised results concerning recombinant protein production may differ from the 
results gained when actually producing recombinant proteins. Producing the recombinant protein as 
well as the solubility levels achieved is dependent on the protein which is being studied. This is an 
indication that although the baculovirus-insect expression system should theoretically be able to 
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produce high levels of the foreign protein as well as a soluble protein, it is not always that simple 
(Jarvis, 2009; Van Oers, 2011). Although the baculovirus-insect expression system has eukaryotic 
processing abilities as they infect lepidopteran insects, which is the host for baculovirus vectors, 
these processing abilities are different from those of higher eukaryotes. Another consideration to 
take into account is that the baculovirus infections of the host cell can have a unfavorable effect on 
the host protein processing capabilities (Jarvis, 2009) 
2.7 Choice of insect cells, baculovirus vector and transfer plasmid 
2.7.1 Characteristics of insect cells as host for the baculovirus 
For the production of baculovirus, virus-like particles and recombinant proteins to name a few, over 
400 cell lines derived from 100 insect species have been used as hosts. Insect cells have a diameter 
of 10 to 20 µm and can be spherical or fibroblast-like in shape. Lepidoptera insect cells are the most 
commonly used in the baculovirus-insect expression system and were primarily selected for 
production of biopesticides. Today engineered insect cells are able to mimic mammalian 
glycosylation patterns and produce high yields of recombinant proteins (Contreras-Gómez et al., 
2014). 
Three host cell lines are the most popular and frequently used for recombinant protein production. 
These include the Sf21 and Sf9 (a clonal isolate of the Sf21 cells) cell lines which were derived 
from the pupal ovarian tissue of the fall army worm Spodoptera frugipedra. The third host cell line 
is the BTI-Tn-5B1-4 or High-Five

 cell line derived from adult ovarian tissue of the cabbage looper 
Trichoplusia ni (Contreras-Gómez et al., 2014). Cell lines that are not used frequently include the 
Bm5 and Tn368 cell lines. These cell lines are able to produce large amounts of recombinant 
protein but do not grow well in suspension culture and are therefore not popular. Sf9, Sf21 and 
High-Five

 cells on the other hand, do well in adherent cultures as well as suspension cultures 
(Contreras-Gómez et al., 2014). High-Five

 cells are able to produce higher yields of recombinant 
proteins than Sf9 cells, they have rapid doubling time and allow quick adaptation to suspension 
culture. Although High-Five

 insect cells are able to express proteins up to 25-fold higher than Sf9 
cells the level of expression of a protein mostly depends on the protein being expressed (Contreras-
Gómez et al., 2014). Sf9 and Sf21 cells however are preferred for the propagation of virus stocks as 
they are able to produce high-titre viral stocks as a result of higher transfection efficiency (Frenzel 
et al., 2013). 
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2.7.2 Characteristics of the baculovirus vector and transfer plasmid 
Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is able to infect many insect 
cells and as a result numerous expression vectors based on this baculovirus have been developed. 
Other baculovirus vectors derived from Bombyx mori nucleopolyhedrovirus (BmNPV) and 
Trichoplusia ni single nucleopolyhedrovirus (TnSNPV) are available but the AcMNPV is the most 
popular and widely used baculovirus vector for the expression of recombinant proteins in insect 
cells (Contreras-Gómez et al., 2014). 
Different baculovirus vectors are available and recommended for different types of proteins such as 
cytoplasmic proteins, transmembrane proteins, cystein-rich proteins and glycosylated proteins. As 
immunoglobulins are glycoproteins the focus will be on the vectors recommended for glycoprotein 
expression. Generally, functional secreted proteins such as glycoproteins as well as membrane-
bound proteins are expressed at lower levels in comparison to nonsecreted cytoplasmic proteins. As 
mentioned in section 2.5.2 the baculovirus encodes for viral cathepsin-like protease and chitinase 
enzymes which can compromise glycoprotein export machinery as chitinase accumulates in the ER 
(Van Oers et al., 2015). Increased expression levels of some glycoproteins can be accomplished by 
adding various DNA elements to baculovirus vectors. One of the elements known to increase 
production of glycoproteins is chaperones which aid in folding of the protein. Although insect cells 
synthesize endoplasmic reticulum (ER) molecular chaperones it is only at levels required for insect 
cell functions and as the target protein will be produced at much higher levels the chaperones 
produced by the insect cells are not sufficient to facilitate folding of the protein of interest. Some 
target proteins are therefore misfolded and accumulate as inclusion bodies or are degraded (Vembar 
and Brodsky, 2008). Hence, protein production can be improved by co-transfection of the insect 
cells with a baculovirus vector expressing not only the protein of interest but also chaperone 
proteins (Contreras-Gómez et al., 2014).  
A variety of transfer plasmids are compatible with the different baculovirus vectors for different 
purification requirements. These include expression of a target protein with a GST, His or GFP tag 
to name a few. The multiple cloning site (MCS) region of each transfer plasmid is flanked by 
baculovirus derived sequences which include the strong polyhedrin promoter upstream of the MCS 
region and a polyadenylation and essential baculovirus orf 1629 gene also present in the baculovirus 
vector. This allows for homologous recombination resulting in a circular baculovirus vector 
containing the gene of interest. The transfer plasmids contain an antibiotic resistance gene as well as 
a bacterial origin of replication for propagation of the plasmid in E. coli (AB Vector, 2014).  




2.8.1 Metabolism of mycoplasmas 
Mycoplasmas are a group of bacteria and members of the prokaryotic class known as the 
Mollicutes. They are known for their reduced genome size and also as the smallest self-replicating 
organisms. Characteristics of mycoplasmas which make them unique include the lack of a cell wall, 
low GC content and a minimal set of organelles. As a result of their small genome these organisms 
do not contain an extensive range of metabolic activities (Henrich et al., 1999; Razin, 1978; Razin 
et al., 1998). 
Mycoplasmas are divided into fermentative and nonfermentative organisms based on their 
carbohydrate metabolizing abilities. Fermentative mycoplasmas gain energy by the use of the 
pyruvate dehydrogenase pathway by producing acids from carbohydrates. Non-fermentative 
mycoplasmas, however, gain energy by ATP, ornithine, CO2 and ammonia production by means of 
the arginine dihydrolase pathway. A complete tricarboxylic acid cycle is absent in mycoplasmas 
and they have no quinones or cytochromes and therefore they cannot use oxidative phosphorylation 
as an ATP- generating mechanism. As a result, low ATP yields and a substantial amount of 
metabolic end products are produced. Metabolic activities of the mycoplasma are, however, 
primarily associated with energy generation rather than provision of substrates for synthetic 
pathways. They consequently do not have the ability to synthesize products such as fatty acids, 
cholesterol, some amino acids, purines and pyrimidines. Consequently, they are obligate parasites 
as they depend on a host for these products (Henrich et al., 1999; Razin, 1978; Razin et al., 1998). 
To acquire these essential molecules from their host, mycoplasmas use different types of transport 
systems such as the phosphoenolpyruvate-dependent sugar phosphotransferase transport systems 
(PTS) for transporting sugars and ABC transporters for transporting amongst other, peptides and 
proteins (Adamu et al., 2013; Henrich et al., 1999; Razin et al., 1998). Of these, the ABC 
transporters are the most prominent within mycoplasma genomes and the interest in this transporter 
has increased (Garmory and Titball, 2004; Nicolás et al., 2007). 
2.8.2 ABC transporters in mycoplasmas 
ATP-binding cassette transporters, more commonly known as ABC transporters, make up one of 
the largest protein families in mycoplasmas. These transporters are known for the coupling of 
adenosine triphosphate (ATP) hydrolisation to the movement of molecules across the membrane. 
ABC transporters are widespread and evolutionary related in different species, however they have 
different functions and roles (Beis, 2015; Garmory and Titball, 2004). By disrupting ABC 
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transporter function Garmory and Titball (2004) could demonstrate that these transporters played a 
role in bacterial virulence. Adding to this is the location of these transporters (in the membrane) as 
well as the surface exposure of some of the proteins which increase the probability of 
immunogenicity (Garmory and Titball, 2004). It was concluded that ABC transporter proteins may 
be satisfactory targets for the development of antimicrobials and antibacterial vaccines (Garmory 
and Titball, 2004; Nicolás et al., 2007). 
These transporters were originally characterised as nutrient uptake systems although it is now clear 
that they consist of two groups namely the importers and the exporters. Exporters are found in all 
eukaryotic and prokaryotic organisms and are responsible for the export of proteases, hemolysin 
and polysaccharides out of the cell whereas the importers are found only in archea, prokaryotes and 
plants. The importers mediate uptake of molecules such as sugar, inorganic ions and oligopeptides 
(Beis, 2015; Davidson and Maloney, 2007; Eitinger et al., 2011; Henrich et al., 1999; Higgins, 
2001).  
Genome sequencing of both Mycoplasma pneumoniae and Mycoplasma genitalium resulted in the 
discovery of an ABC transporter in the group of importers which is responsible for the import of 
oligopeptides. This importer is also known as the oligopeptide permease (Opp) ABC transporter 
(Henrich et al., 1999; Wium et al., 2015). The OppABCDF system of mycoplasmas consists of five 
core domains in which each of the domains is encoded by a single gene which is polycistronically 
organised within an operon. The domains consist of the homologous integral membrane proteins, 
OppB and OppC; the homologous nucleotide-binding proteins, OppD and OppF found in the 
cytoplasm and lastly, the extracellular substrate-binding domain OppA which is a lipoprotein 
anchored to the membrane (Berntsson et al., 2009; Henrich et al., 1999; Hopfe et al., 2011). Gram-
negative bacteria contain periplasmic substrate-binding proteins whereas Gram-positive bacteria 
contain substrate-binding proteins anchored to the cell membrane (Berntsson et al., 2009; Nicolás et 
al., 2007). A pore is formed by the homologous integral membrane proteins as both proteins, OppB 
and OppC, cross the membrane six times with 12 transmembrane segments in total. This was 
predicted from the sequences of these domains as well as the requirement of the 12 transmembrane 
segments for substrate transport through the membrane (Henrich et al., 1999). The OppD and OppF 
domains bind ATP and hydrolyse the ATP which fuels the transport of the substrate through the 
membrane whereas OppA is responsible for the binding of the substrate which results in the import 
of oligopeptides into the cell (Berntsson et al., 2009; Wium et al., 2015). 
As the OppA protein has the function of binding substrates it is regarded as an essential protein and 
is well recognised in bacteria. The OppA protein in mycoplasmas is expected to be essential for 
Stellenbosch University  https://scholar.sun.ac.za
 36 
 
survival as these organisms are not able to produce oligopeptides. Staats et al. (2007) found that 
only two out of eleven Mollicutes genomes which were available at the time contained the oppA 
gene. It was therefore questioned if the OppA protein is essential for survival of mycoplasmas. The 
genomes of 39 mycoplasmas were studied by Wium et al. (2015) to determine whether these 
mycoplasmas do contain the oppA gene and therefore their possible significance for survival. It was 
illustrated that all mycoplasmas which contained annotated OppABCDF operons (not including 
hemoplasmas) do contain an oppA gene which suggests the importance of the OppA protein as part 
of the Opp transport in mycoplasmas (Wium et al., 2015). Therefore the OppA protein can be 
considered as a possible target for vaccines and antimicrobials against mycoplasmas. 
2.8.3 Pathogenicity of mycoplasmas 
2.8.3.1 Adhesion of the mycoplasma to its host 
Infection of a host cell is established by the adherence of the mycoplasma to the host tissue. With 
this being the first step to colonisation it is regarded as a major virulence factor. Adherence and 
colonisation of a host holds nutritional advantages such as a higher concentration of nutrients and 
the availability and utilisation of fatty acids and cholesterol of the host membrane. Mycoplasmas 
are dependent on their host for nutritional substances therefore they usually adhere to and colonise 
epithelial linings of respiratory and urogenital tracts of infected animals and can be considered 
surface parasites. The attachment of the mycoplasmas to the host cells will not be disrupted by 
ciliated epithelium or urine as they attach firmly to the host cell (Bradbury, 2005; Kleven, 1998; 
Razin, 1978; Thompson et al., 2011). Mycoplasmas can also adhere to a variety of other surfaces 
including erythrocytes, tracheal epithelium, spermatozoa as well as surfaces such as glass and 
plastic but are particularly known for their adhesion and colonisation of epithelial linings (Razin, 
1978).  
Fimbriae and pili are structures used in a large number of bacteria for adherence to the host cell. 
Mycoplasmas, however, lack these structures and therefore externally exposed membrane bound 
components, mediate binding to the host cell and are collectively known as adhesins (Hopfe et al., 
2011; Le Roux and Hoosen, 2010; Razin et al., 1998). M. pneumoniae and M. genitalium have the 
most defined and studied adhesins (Razin et al., 1998). The major adhesin proteins P1 of M. 
pneumoniae and MgPa of M. genitalium play a crucial role in cytoadhesion, are similar in structure, 
function in host attachment, and are exposed membrane proteins (Le Roux and Hoosen, 2010; 
Razin et al., 1998). 
A variety of mycoplasmas have unique features such as a terminal organelle, also known as the tip 
organelle which enables them to adhere to the host cell in order to colonise and obtain nutrients. 
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The adhesins are concentrated in the tip organelle which also contains accessory proteins 
(Chaundhry et al., 2007; Seto et al., 2001). Both M. pneumoniae and M. genitalium contain these tip 
organelles. The tip organelle of M. pneumoniae consists of P1 and P30 proteins which provide 
polarity to the cytoaherence event whereas the tip structure in M. genitalium contains MgPa and 
P32 proteins (Browning et al., 2011; Rottem, 2003). For M. pneumoniae the process of adhesion 
does not rely on the adhesin proteins alone but it also includes the accessory proteins HMW1, 
HMW2, HMW3, A, B and C. The accessory proteins involved in adhesion of M. genitalium include 
MG312, MG317 and MG320. The accessory proteins together with cytoskeletal elements are 
responsible for the assistance in lateral movement and the location/distribution of the adhesin 
molecules at the tip organelle. The cytoskeleton-like structure has multiple functions which include 
adjusting cell shape, gliding motility and localisation of adhesins and are therefore of significant 
importance (Razin et al., 1998).  
The tip organelle is not found in all mycoplasma species. Homologous structures are only found in 
the mycoplasmas which are in the same phylogenetic group as M. pneumoniae and M. gallisepticum 
(Browning et al., 2011). The mycoplasmas which are not in the same phylogenetic group depend on 
unrelated proteins and lipoproteins for adhesion to the host cell. Species such as M. hominis lack the 
tip organelle and are dependent on their surface lipoproteins which play a role in cytoadherence 
such as the variable-adherence-associated (Vaa) or P50 protein as well as the OppA protein (Brown 
et al., 2014; Browning et al., 2011; Henrich et al., 1999). 
2.8.3.2 Invasion of the host cell 
It is seen in numerous bacteria that when there is contact between the bacterial pathogen and the 
host cell, bacterial internalisation is made easier as rearrangements in the host cytoskeleton are 
triggered. As mycoplasmas only contain a cell membrane and no cell wall, direct contact is made 
with the host cell which could facilitate invasion of the host cell (Rottem, 2003). 
It was believed for a considerable time that mycoplasmas do not invade the host cell but rather stay 
attached to epithelial cells. However, some mycoplasmas have evolved the ability to enter non-
phagocytic cells of the host and this forms an important part of their pathogenicity (Rottem, 2003). 
The mycoplasmas able to invade their host cells have a unique advantage as they will be able to 
resist the host defenses, which will enable them to establish chronic and in some cases systemic 
infections (Rosengarten et al., 2000). One of the mycoplasma species able to invade their host cells 
is known as M. penetrans which was isolated from a patient with acquired immunodeficiency 
syndrome (AIDS). Winner et al. (2000) showed that mycoplasma invasion is not restricted to 
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human pathogens such as M. penetrans, M. fermentans, M. pneumoniae and M. genitalium because 
these properties could also be seen in M. gallisepticum, an avian pathogen. 
The mechanism by which the mycoplasma is able to invade the host cell is not fully understood 
although it was proposed that the mycoplasmas generate 'uptake signals'. The signals would then 
cause assembly of cytoskeletal structures which include actin filaments, tubulin and α-actin in the 
host cell (Rottem and Naot, 1998). The invasion mechanisms of mycoplasmas are similarly to the 
clathrin-coated pits mechanism of endocytosis observed in Chlamydia trachomatis. In the case of 
M. genitalium, after it has entered the cell it seems to be situated in membrane-bound vacuoles close 
to the host cell nucleus (Le Roux and Hoosen, 2010). 
2.8.3.3 Evasion of the host's immune system 
Some mycoplasmas survive and persist without being affected by the host immune system by 
locating themselves intracellularly. As survival of mycoplasmas entails avoiding the immune 
system but still remaining in contact with the host cell, these organisms developed mechanisms 
allowing them to circumvent recognition by the immune system (Bradbury, 2005; Le Roux and 
Hoosen, 2010). The host usually targets the Mollicute's surface, as the epitopes recognised by the 
host immune system are the membrane proteins expressed on the surface of the Mollicutes. In order 
to survive they change their surface antigenic repertoire to avoid detection by the hosts immune 
system (Le Roux and Hoosen, 2010; Rottem, 2003). 
Molecular mimicry and phenotypic plasticity are two of the most studied mechanisms which enable 
the mycoplasmas to avoid recognition by the host's immune system. Sequence or structural 
similarities of antigenic determinants or self antigens that are found in both mycoplasmas and the 
host cell are known as molecular mimicry (Cusick et al., 2012; Rottem, 2003). Mycoplasmas are 
also able to change the variation of one genotype's nucleotide sequence by DNA arrangement which 
leads to the production of more than one alternative form of the phenotype. This phenomenon is 
known as phenotypic plasticity and can change the morphology, response to environmental 
conditions and the physiology of a trait of the mycoplasma (Bradbury, 2005; Le Roux and Hoosen, 
2010).  
Bacterial pathogens have a survival strategy whereby they gain or lose surface components at a high 
frequency. This method is known as antigenic variation and is the common way to achieve 
phenotypic plasticity. Some mycoplasmas possess multigene families encoding cell surface 
lipoproteins, playing an important role in the generation of antigenic variation and switching. This 
Stellenbosch University  https://scholar.sun.ac.za
 39 
 
allows the mycoplasma to evade the host's immune system (Bradbury, 2005; Le Roux and Hoosen, 
2010). 
2.8.4 Managing mycoplasma infections 
2.8.4.1 Prevention 
In poultry, mycoplasmas can be transmitted from generation to generation, which is known as 
vertical transmission. Some progress has been made regarding the elimination of this vertical 
transmission by dipping eggs in antibiotic solutions or heating the eggs to 46 ºC for 12-14 h. A 
combination of egg dipping and injection with antibiotics can also be used as preventative method 
(Kleven, 2008; Nascimento et al., 2005; Swayne et al., 2013). 
In previous studies it has been shown that mycoplasmas are able to survive up to 6 days on human 
hair and skin. They can also survive on materials such as cotton and rubber (Christensen et al., 
1994). As the mycoplasmas are able to survive in the environment on different materials, they can 
be transmitted indirectly via wild birds, drinking water, breeding materials on clothes, footwear or 
contaminated equipment (Marois et al., 2000; Scholtz, 2014). 
To detect mycoplasma infections in the early stages would be advantageous as this could prevent 
spread of infections to other flocks and therefore flocks need to be monitored consistently. 
However, it should be kept in mind that diagnosis can sometimes result in false negative detection 
of mycoplasma infections as mycoplasmas are able to conceal themselves in affected tissues. 
Another preventative measure is an effective biosecurity program which entails following certain 
methods in order to prevent infections or spread of infections. Small geographical areas, however, 
then contain a greater number of poultry resulting in a higher risk for exposure to infections. 
Therefore it is crucial that all personal on the farm follow the procedures to insure that there is no 
lapses in the program which can lead to infection outbreaks (Kleven, 2008; Nascimento et al., 
2005). 
2.8.4.2 Medication 
Poultry mycoplasmas can be treated with antimicrobials or antibiotics which will decrease 
manifestations as well as the risk of vertical transmission. However, antibiotics that target the cell 
wall of microbes will not have an effect on mycoplasmas as they lack a cell wall. Therefore 
mycoplasmas are resistant to antibiotics like penicillins or cephalosporins but they are sensitive to 
antibiotics such as macrolides and tetracyclines which inhibits protein synthesis and 
fluoroquinolones which inhibits DNA synthesis (Kleven, 2008). 
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Enrofloxacin and tiamulin are the preferred drugs to use against M. synoviae and M. gallisepticum 
infections in chickens and turkeys. Commercially available enrofloxin is a fluoroquinolone with 
antimicrobial activity against most pathogens such as Gram-negative bacteria and Mycoplasma spp. 
Tiamulin known as a pleuromitilin antibiotic has been used routinely against M. gallisepticum 
infections in poultry such as chickens and turkeys. These drugs accumulate in high concentrations 
in mucosal membranes of the respiratory and reproductive tracts where the mycoplasmas are 
usually found (De Lucas et al., 2013; Li et al., 2010; Nascimento et al., 2005; Stipkovits and 
Kempf, 1996).  
A factor to consider in the treatment of mycoplasma infections is that secondary bacterial infections 
can also occur in conjunction with mycoplasma infections. Therefore antibiotics that will target 
both the secondary infection and the mycoplasma infection need to be selected (Stipkovits and 
Kempf, 1996). Introduction of antibiotics to birds can be accomplished through their drinking 
water, feed or injection. However, the use of antibiotics as well as an immune response can have an 
influence on diagnosis of mycoplasma infections as they are able to evade or conceal themselves in 
affected tissue. Thereby they protect themselves from the host immune system and antibiotic 
treatments. Residing intracellularly, encourages the establishment of latent infections resulting in 
ineffective drug therapies (Liu et al., 2007; Nascimento et al., 2005; Razin et al., 1998). 
Although antibiotic medication can reduce vertical transmission and clinical signs it cannot 
eliminate infection from a flock. As a result, the antibiotic treatment has to be repeated but this 
could lead to the development of antibiotic resistance (Stipkovits and Kempf, 1996). Using 
antibiotics in food producing animals can lead to accumulation of these residues in meat and milk 
amongst others. The antibiotic residues can lead to numerous problems in humans such as transfer 
of antibiotic resistance and immunopathological effects to name a few (Darwish et al., 2013). 
Although it is useful in prevention of economic losses, antibiotics are therefore not viewed to be a 
long-term solution (Kleven, 2008; Stipkovits and Kempf, 1996). 
2.8.4.3 Vaccines 
The use of veterinary vaccines instead of antibiotics and drugs for the treatment or prevention of 
diseases holds many advantages and has become regular in farmed animals. It is also more cost 
effective and antibiotic resistance is avoided (Sharma and Hinds, 2012). A few factors should, 
however, be taken into consideration such as administration of the vaccine, the type of vaccine as 
well as costs of the vaccine and vaccination process. Although vaccines provide a good solution for 
the control of diseases, good biosecurity and management practices should still be a priority and 
vaccination should not be regarded as a replacement (Kleven, 2008; Marangon and Busani, 2006).  
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A few live attenuated vaccines against M. gallisepticum (MG) in chickens have been developed 
including the F strain, 6/85 and ts-11, with only 6/85 and ts-11 being commercially available in 
South Africa (Armour et al., 2013; Kleven, 2008). However, currently there are no vaccines 
available against mycoplasma infections in ostriches. 
2.8.5 Ostrich-infecting mycoplasmas 
Mycoplasmas that infect ostriches are associated with a respiratory disease syndrome where they 
infect the upper respiratory tract of ostriches leading to inflammation in the eye (conjunctivitis), 
nose (rhinitis) and air sack (airsacculitis) (Botes et al., 2005; Huchzermeyer, 2002). Clinical signs of 
this syndrome include swollen sinuses, eye infections, watery discharge from the nose and rattle 
sounds in the throat. This is observed mostly during cold and dusty conditions in feedlot ostriches 
and predominantly during seasonal changes. Mycoplasma infections can however be increased due 
to stress, environmental conditions and other opportunistic infections caused by pathogens such as 
E. coli and Pasteuralla species to name a few (Botes et al., 2005). The result of this respiratory 
syndrome is a loss in production, downgrading of carcasses and reduced growth rate (Botes, 2004; 
Botes et al., 2005; Verwoerd, 2000).  
Botes et al. (2005) isolated three ostrich-infecting mycoplasma species referred to as Ms01, Ms02 
and Ms03. Langer (2009) isolated Ms01 and Ms03 from Namibian ostriches and described them as 
non-motile, non-helical and fried egg forming colonies. The cells of both are able to be filtered 
through a 0.22 µm filter and they both require serum and cholesterol for growth (Langer, 2009). 
The three ostrich-infecting mycoplasma species Ms01, Ms02 and Ms03 were found to be quite 
different from each other and phylogenetically fall into two mycoplasma groupings. This was 
shown by the analysis of the 16S rRNA gene sequences which revealed that Ms01 grouped in a 
different clade to Ms02 and Ms03 but all form part of the hominis group as can be seen in Figure 
2.8 (Botes et al., 2005; Wium et al., 2015). 




Figure 2.8 Phylogeny of mycoplasma species based on 16S rRNA sequences. All three ostrich-infecting 
mycoplasmas (indicated by the arrows) fall within the hominis group (Adapted from Wium et al. 2015). 
2.8.5.1 Control of ostrich-infecting mycoplasmas 
Intense rearing of ostrich chicks has resulted in increased population densities and concomitant 
stress which results in a greater risk of mycoplasma infections. Medication or antibiotics typically 
used against mycoplasma infections in ostriches are Doxycycline, Tylosin and Oxytetracycline 
amongst others. As antibiotics are not able to eradicate the mycoplasmas but only reduce or contain 
them, some ostriches will not have symptoms associated with mycoplasma infections but will be a 
carrier of the infection. Symptoms of mycoplasma infections can be identified early by inspecting 
ostriches in the morning for clinical signs of the disease and taking note of disapproved ostrich 
numbers at abattoirs due to infections. Ostriches that show clinical symptoms as mentioned in 
section 2.8.5 should be removed from the flock. Monitoring and early identification of mycoplasma 
infections can determine the type and time period of treatment (Olivier, 2006). Due to the 
ineffectiveness of medication, infections should be managed and controlled within commercial 
ostrich farms by means of biosecurity systems (Olivier, 2006). 
Biosecurity systems include the reduction of factors causing stress, regular cleaning of water 
troughs, monitoring of feed intake and weight gain as well as shelter from wind, dust and rain for all 
ostriches. Vehicles, implements and protective clothing should be disinfected when arriving at 
ostrich farms as well as when departing, in order to keep the production areas sanitary as the 
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pathogens can stay viable in soil for long periods. Another preventative measure is the use of 
footbaths although this can also become a possible infection site therefore the footbaths needs to be 
disinfected regularly (Kleven, 2008; Mather and Marshall, 2011). 
Maintaining biosecurity systems has become more difficult to implement as rearing of ostriches 
became intensive (Kleven, 2008; Mather and Marshall, 2011). The Veterinary Procedural Notice 
(VPN) VNP/04/2012-01 (Revision 6.0) 2012 provides biosecurity measures for ostrich production 
in South Africa. These regulations were implemented after the first outbreak of avian influenza in 
2004 and all ostrich farms must adhere to these regulations to avoid any form of disease outbreaks. 
Although these measures were put in place to prevent avian influenza outbreaks they can also be of 
use to prevent spread of mycoplasma infections. As mycoplasmas are opportunistic pathogens, 
preventing spread of other pathogens might also prevent mycoplasma infections. Included in the 
VPN is that all water sources accessible to ostriches should be fenced off to prevent or minimise 
contact between the ostriches and wild birds. No pigs or other poultry may be kept on ostrich farms 
and water troughs should be disinfected regularly. A factor to consider is that biosecurity will only 
work with well trained and committed personnel (Scholtz, 2014). 
As medication or antibiotic treatment against mycoplasma infections in ostriches is expensive and 
does not eradicate the mycoplasmas, alternative methods for controlling of mycoplasma infections 
by vaccination were investigated in previous studies. Pretorius (2009) found that the commercially 
available vaccines MS-Bac and MG-Bac against Mycoplasma synoviae and Mycoplasma 
gallesepticum respectively which infect chickens had no effect on the ostrich-infecting 
mycoplasmas. Currently there are no vaccines available against the ostrich-infecting mycoplasmas 
and successful cultivation of mycoplasmas is problematic (Botes et al., 2005). The development of 
DNA vaccines will circumvent the cultivation problem and can therefore provide a possible 
alternative to the development of vaccines against mycoplasma infections in ostriches. 
2.8.6 Development of DNA vaccines against ostrich-infecting mycoplasmas 
Selection of DNA vaccine vectors 
The VR1020 and pCI-neo vectors were selected in a previous study for use in DNA vaccine trials 
against Ms03 in ostriches (Wium, 2015). The vectors were chosen as they were used for DNA 
vaccine studies in poultry such as chickens, ducks and turkeys (Lee et al., 2003; McCutchan et al., 
2004; Meunier et al., 2016). The pCI-neo vector is a mammalian expression vector that contains a 
human enhancer/promoter region, and a CMV eukaryotic promoter, for the expression of cloned 
DNA inserts in mammalian cells. pCI-neo also contains the late SV40 polyadenylation sequence 
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which has been shown to be efficient for polyadenylation and a ampicillin resistance gene for 
selection during plasmid production (Promega Corporation, 2009).  
The VR1020 vector also contains the CMV eukaryotic promoter for expression, but instead contains 
a Bovine growth hormone (BGH) polyadenylation and the kanamycin resistant gene for selection 
(Coban et al., 2005). An upstream signal sequence known as the tissue plasminogen activator (TPA) 
is included in the VR1020 vector and this sequence is able to improve expression in mammalian 
cells and assist in the secretion of the expressed protein (Lobo et al., 1999). 
Characteristics and selection of oppA as vaccine candidate gene 
The OppA protein has also been evaluated as antigen in the Moraxella catarrhalis and Yersinia 
pestis species as vaccine antigen (Chaudhuri and Ramachandran, 2014; Yang et al., 2011). Agüero 
et al. (2015) showed that the OppA protein of M. gallisepticum is an excellent vaccine candidate as 
it exhibited immunogenicity.  
In M. hominis the oligopeptide transport protein was found to contain a substrate binding domain 
referred to as OppA. The OppA is an extracellular lipoprotein anchored to the cell membrane and in 
the case of M. hominis was found to be involved in host attachment. The OppA protein has several 
characteristics which makes it a suitable candidate for use in a vaccine. Firstly, being located 
extracellularly implies that the OppA protein will be exposed to the immune system of the host and 
can therefore be regarded as a virulence factor (Henrich et al., 1999; Hopfe et al., 2011; Wium et 
al., 2015). Sedondly, the ABC importers and thus OppA proteins, are not found in eukaryotes but 
only in prokaryotes, archaea and bacteria (Berntsson et al., 2010; Rice et al., 2014). Therefore, 
homologous genes should not be present in the ostrich genome. Thirdly, since mycoplasmas need to 
acquire nutrients from their host the Opp transporter plays an essential role in their survival. Wium 
et al. (2015) found that with the exception of hemoplasmas, all mycoplasma Opp operons, evaluated 
in their study, contain an OppA and therefore it most probably has an essential role as a part of the 
Opp transporter in Mycoplasma species. As all three ostrich infecting mycoplasmas also contain an 
OppA, it can possibly be used as a vaccine candidate for prevention of mycoplasma infections in 
ostriches.  
In previous studies the oppA gene of Ms01 and Ms03 was inserted into the DNA vaccine vectors 
pCI-neo, VR1020 and VR1012 for evaluation in vaccine trials (De Wet, 2015; Van Tonder, 2013; 
Wium, 2015). In the study done by Wium (2015) the vaccines containing the oppA gene of Ms03 
were administered in a single dose (100 µg/ml). The trial was however terminated after 3 weeks as 
a result of an avian influenza outbreak. Results up until week 3 showed that both the pCI-neo and 
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VR1020 vaccines were able to elicit an immune response. As the trial was not concluded these two 
vaccines were re-evaluated in this study of which the result are presented in the next chapter. 
In the study by Van Tonder (2013) administering the DNA vaccines orally using a bacterial carrier 
was also evaluated. For this purpose secondary rabbit anti-ostrich IgA antibodies were used which 
was produced using intact IgA protein. Part of the antibody can, however, be produced 
recombinantly as an alternative for the production of these antibodies. This would ensure a 
reproducible source for the production of secondary anti-IgA antibodies. Results on the production 
of such a protein using a Baculovirus-insect expression system is subsequently presented in Chapter 
4. 
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3. Vaccination Trial 
3.1  Introduction 
The demand for ostrich products such as meat, leather and feathers has resulted in more intensive 
rearing strategies which in turn create an environment for the spread of pathogens and thus diseases. 
Mycoplasma infections are associated with respiratory disease in feedlot ostriches and result in 
reduced production. To date, three species were found to be involved namely Ms01, Ms02 and 
Ms03 (Botes et al. 2005). The ostrich industry contributes substantially to the South African 
economy and to ensure conservation of this industry, disease management is of utmost importance.  
In an attempt to address Ms03 infections, a DNA vaccine was developed as part of a previous study. 
The oppA gene of Ms03 was chosen as vaccine antigen and cloned into the VR1020, VR1012 and 
pCI-neo plasmids (Wium 2015). These vaccines were administrated to ostriches at a single dose 
(100 µg/ml) to determine if an anti-OppA antibody response could be elicited. As a result of an 
avian influenza outbreak in the region, the trial was terminated after 3 weeks resulting in only a 
single vaccination being administered and collection of blood samples at week 0 and 3 only. The 
results, however, showed that both VR1020_oppA and pCI-neo_oppA were able to elicit an immune 
response over the 3 week period, but no response was observed for VR1012_oppA. The objective of 
this study was therefore to re-evaluate the ability of the pCI-neo_oppA and VR1020_oppA vaccines 
developed against Ms03 to elicit an anti-OppA antibody response in ostriches. To this end ostriches 
were vaccinated with the pCI-neo_oppA and VR1020_oppA DNA vaccines, but using three 
different doses and also including a booster vaccination after 6 weeks. Serum was collected from 
trial birds over a period of 9 weeks and analysed for anti-OppA antibodies using an enzyme-linked 
immunosorbent assay (ELISA). During the course of the trial all ostriches were weighed and 
monitored using PCR-analysis in order to establish if the ostriches were infected with mycoplasmas. 
3.2 Materials and Methods 
3.2.1 Ethical clearance 
In order to conduct the trial it was necessary to obtain ethical clearance. The Stellenbosch 
University Animal Ethics Committee (SU-ACUM 13-00019) granted ethical clearance for the trial 
to be conducted. Ethical permission was also obtained from the Department of Agriculture, Forestry 
and Fisheries (Reference: 12/11/1/1/3) in terms of Section 20 of the Animal Disease Act 1984 (Act 
No 35 of 1984). Included in the ethical clearance was that the research should be compliant with the 
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Meat Safety Act (Act No 40 of 2000) for allowance of the animals to enter the human food chain 
after slaughter.  
3.2.2 Preparation of DNA vaccines 
The VR1020 and pCI-neo vectors containing the Ms03 oppA gene were previously transformed into 
E. coli JM109 competent cells by Wium (2015) and cultures stored at -80ºC. These were used to 
prepare overnight cultures (O/N) in a Falcon
®
 tube (14 ml) by inoculating 5 ml 2xYT-medium (16 g 
tryptone, 10 g yeast extract and 5 g NaCl) with 10 µl of freezer stock for VR1020_oppA and pCI-
neo_oppA respectively. The VR1020_oppA O/N cultures also contained 10 µl kanamycin (25 
mg/ml) whereas the pCI-neo_oppA O/N cultures contained 5 µl ampicillin (100 mg/ml). The O/N 
cultures were grown for 16-18 h at 37°C on an orbital shaker (200 rpm). Starter cultures were 
prepared for both plasmids in a 50 ml Erlenmeyer flask by adding 20 µl kanamycin (25 mg/ml) for 
VR1020 and 10 µl ampicillin (100 mg/ml) for pCI-neo, to 10 ml of 2xYT medium and inoculating 
it with 1 ml of each O/N culture respectively. The starter cultures were incubated at 37°C on an 
orbital shaker at 200 rpm for 8 h. The starter cultures were then each added to a 2 L Erlenmeyer 
flask containing 200 ml 2xYT medium with 400 µl kanamycin (25 mg/ml) and 200 µl ampicillin 
(100 mg/ml) for VR1020 and pCI-neo respectively. The cultures were incubated for 16 h at 37°C on 
an orbital shaker (150 rpm). This was followed by the isolation of the plasmids using an endotoxin-
free plasmid DNA purification kit (NucleoBond
®
 Xtra Midi Plus EF, Macherey-Nagel, Germany) 
according to manufactures instructions. The yields of the two isolated plasmids were determined 
using a Nanodrop
®
 ND 1000 spectrophotometer (Novell
®
, USA). The integrity of both the plasmids 
were determined by electrophoresis by loading 5 µl of purified plasmid on a 1% (w/v) agarose gel 
consisting of SeaKem
®
 LE Agarose (Lonza, Switzerland) dissolved in 1x TAE buffer (40 mM Tris-
aminomethane; 1 mM EDTA, pH 8; 20 mM glacial acetic acid) containing 0.5 µg/ml ethidium 
bromide (EtBr) for visualisation under UV-light. The agarose gel was electrophoresed in 1x TAE 
buffer and depending on the size of the gel, 80 Volts (V) were used for a 3 cm x 10 cm gel, 90 V for 
a 7 cm x 10 cm gel and 110 V for a 10 cm x 15 cm gel. 
For visual confirmation that both plasmids contained the oppA gene and were in the supercoiled 
formation, the plasmids were digested with restriction enzymes. The pCI-neo_oppA plasmid was 





), 2 µl 10x buffer G, 0.2 µl bovine serum albumin (BSA) (10 
mg/ml), 1 µl pCI-neo_oppA (1 µg/µl) and 0.5 µl AccI. This mixture was incubated at 37°C for 2 h 
followed by a deactivation step at 80ºC for 5 min. AccI has only one cut site in the plasmid 
following the insert. The VR1020_oppA was digested with BamHI Fast-digest (Fermentas, USA) in 
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a mixture with a final volume of 20 µl which contained 16.5 µl Milli-Q
®
, 2 µl 10x FastDigest 
buffer, 0.5 µl VR1020_oppA  plasmid (1 µg/µl) and 1 µl BamHI Fast-digest. The mixture was 
incubated at 37°C for 5 min followed by a deactivation step at 65°C for 10 min. The BamHI has a 
cut site on the plasmid on either side of the insert. The digested products were then analysed by 
loading 5 µl of the digested product on a 1% (w/v) agarose gel containing 0.5 µg/µl EtBr in order to 
visualise the digested products under UV-light. The agarose gel was electrophoresed as previously 
described. 
The two isolated DNA vaccines were diluted to the desired concentration of 100 µg/ml, 600 µg/ml 
and 1200 µg/ml with sterile PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.5 
mM KH2PO4, pH 7.2) in a class II biological safety cabinet (ESCO, Singapore). The dilutions were 
made a day before use in 100 ml serum bottles which were sealed with 20 mm rubber silicone 
stoppers (Sigma-Aldrich) and covered by a 20 mm aluminum seal with a tear away center cap 
(Sigma-Aldrich). 
3.2.3 Animals used for vaccination trial 
Ostriches hatch with an immature immune system and as a result rearing of day-old ostrich chicks 
to an age of 3 to 4 months is a critical phase. During this time high mortalities occur and they are 
also prone to airway infections (Scholtz, 2014). The trial was initiated in Fraserburg using ± 3 
month old ostriches which were reared in Fraserburg (Northern Cape Province) as a precautionary 
measure to limit pathogen exposure. They were then moved to Oudtshoorn (Western Cape 
Province) once reaching a weight of 40 kg (± 4 months of age). At the start of the trial each of the 
ostriches received a tag (Allflex Livestock Identification Tags or Infotag Eartags/Oorplaatjies) 
under their wing, containing a unique number in order to specifically identify each ostrich in the 
trial.  
The ostriches had access to water ad lib at all times and were kept in open air camps in Fraserburg 
and Oudtshoorn. Birds were handled by trained and experienced farm personnel at all times. Trial 
birds were not kept separate in Fraserburg, and in Oudtshoorn and the ostriches forming part of the 
trial were grouped with other ostriches of the same weight and age that had arrived from 
Fraserburg. 
3.2.4 Vaccination trial design 
For the vaccination trial 140 ostriches were divided into a pCI-neo_oppA group, a VR1020_ oppA 
group and a control group. As shown in Table 3.1 the pCI-neo_oppA and VR1020_ oppA groups 
Stellenbosch University  https://scholar.sun.ac.za
 49 
 
each had 60 ostriches whereas the control group contained 20 ostriches. Each of the groups of 60 
were further divided into 3 subgroups containing 20 ostriches each that received the pCI-neo_oppA 
and VR1020_ oppA vaccines at the respective doses of 100, 600 and 1200 µg/ml whereas the 
control group did not receive any vaccine. The vaccine doses were administered in a single 1 ml 
volume by IM injection in the upper thigh of the ostriches at week 0 and a booster administered at 
week 6 (Table 3.1).  
Blood samples (4 ml) were drawn from the jugular vein by using 18Gx1/2" needles (Vacuette
®
, 
Austria) and collected in Vacuette
®
 Z serum sep clot activator tubes at week 0, 3, 6 and 9. 
Centrifugation at low speed for 10 min was used in order to separate the serum before transferring 
to 1.5 ml Eppendorf tubes and storing at -20°C. The ostriches were kept in Fraserburg from week 0 
to 3 and in Oudtshoorn from week 6 to 9. 
After arrival of the ostriches in Oudtshoorn one week prior to the week 6 sampling and the 
administration of a booster vaccine, the birds were kept in quarantine for 29 days and random 
testing was done for avian influenza. This is standard practice as required by avian influenza control 
measures. In order to simulate challenge conditions, the birds were then moved to feedlots with 
other ostriches where they received 2.5 kg of feed per ostrich per day. To further create ideal 
conditions for possible mycoplasma infections to occur the trial was conducted in late autumn, early 
winter (March 2015 to June 2015) since mycoplasma infections are known to be a problem during 
seasonal changes such as autumn and spring. 
3.2.5 Weight recording during trial 
During the trial period the ostriches were weighed at week 0, 6 and 9 (Table 3.1).This was done to 
evaluate the influence of the vaccine on the weight gain of the ostriches as well as to monitor the 
overall well-being of the ostriches. During week 3 there was no scale available and the weight 
therefore not recorded.  
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Table 3.1 Vaccination trial groups with administration route, schedule and dose used. 


















0    
20 
3   - - 
6    
9   - 
600 
0    
20 
3   - - 
6    
9   - 
1200 
0    
20 
3   - - 
6    
9   - 
VR1020_oppA 
100 
0    
20 
3   - - 
6    
9   - 
600 
0    
20 
3   - - 
6    
9   - 
1200 
0    
20 
3   - - 
6    






3   - 
6   
9   
Total   140 
* Vaccine dose administered in final volume of 1 ml 
# Vaccines administered intramuscularly  
♦ Ostriches were in Fraserburg during week 0 to 3 and in Oudtshoorn during week 6 and 9.  
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3.2.6 Trachea swab sample analysis by PCR 
Swab samples were taken during week 0, 3, 6 and 9 from the trachea of the ostriches (Table 3.1). 
Dry sterile swabs with a plastic applicator and a soft rayon swab tip were used (Copan, Italia). The 
swabs were inert and non-toxic to micro-organisms as well as the ostriches. Prior to PCR analysis 
each swab was rinsed in 200 µl sterile PBS buffer, contained in a 1.5 ml Eppendorf tube. These 
samples were then used for PCR analysis in order to determine the presence of mycoplasma 
infections. The samples were first tested by using a generic primer pair specific for the Mycoplasma 
genus. The samples that tested positive were further evaluated using species-specific primer pairs 
for the three ostrich-infecting mycoplasma species namely Ms01, Ms02 and Ms03. The sequences 
of the primer pairs used are shown in Table 3.2. All primers were designed by Botes (2004) and 
already available in the laboratory. 
Each PCR reaction contained 9.95 µl Milli-Q
®
 water, 2 µl 10x reaction buffer, 2.4 µl MgCl2 (25 
mM), 0.8 µl dNTP mix (5 mM) (Kapa Biosystems, RSA), 0.4 µl of each primer depending on the 
target (20 pmol/µl), 0.05 µl of 5 U/µl Super-Therm polymerase (JMR Holdings, USA) and 4 µl of 
the trachea sample. A Verti 96 well thermal cycler (Applied Biosystems) was used for amplification 
with the following conditions: 30 cycles of 94ºC (30 sec), 55ºC (15 sec), 68ºC (1 min) and a single 
cycle of 6 min at 68ºC before cooling to 15ºC. The reaction mixtures and thermal cycler conditions 
were the same for all primer sets. The PCR products were analysed on a 1% agarose gel containing 
0.5 µg/ml EtBr for visualisation of the PCR products under UV light. Electrophoresis conditions 
were as previously described. 
All samples that tested positive with the generic primer pair but negative with the species-specific 
primer pair were sequenced. The reaction mixtures contained 5 µl sequencing buffer (400 mM Tris-
base (pH 9), 10 mM MgCl2∙6H2O), 1 µl of 16R1514 reverse primer or GPO3F forward primer, 1.5 
µl of the trachea swab sample and 2 µl BigDye
®
 Terminator mix (v3.1, Applied Biosystems, USA) 
and 0.5 µl Milli-Q
®
 water to a final volume of 10 µl. The PCR conditions were as follow: 35 cycles 
of 96ºC (10 sec), 52ºC (30 sec), 60ºC (4 min) and a final step of 60ºC (10 min). The products were 
analysed by the Central Analytical Facility (CAF) DNA sequencing unit of the University of 
Stellenbosch by means of an ABI® 3100 Genetic Analyser (Applied Biosystems, USA). The 
sequences were subsequently analysed further with the Basic Alignment Search Tool (BLAST) by 
searching for similar sequences in the 16S ribosomal RNA sequence (Bacteria and Archaea) 
database of the National Center of Biotechnology Information (NCBI).  
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primer   
16R1541 
(R) 
5'-GGTTGGATCACCTCCTT -3' 780 
 # (F) = forward primer 
 * (R) = reverse primer 
 (Botes, 2004) 
 
3.2.7 Preparation for analysis of serum samples 
To analyse the serum samples of the ostriches taken during the trial, the ELISA technique 
developed by Wium (2015) was used. This, however, required the preparation of the Ms03 OppA 
proteins as antigen. Section 3.2.7.2 to section 3.2.7.3 describes the production and isolation of this 
protein. The ELISA was also re-optimised (section 3.2.7.4) to confirm that the parameters as used 
by Wium (2015) were optimal. 
3.2.7.1 Producing the expression plasmid containing the oppA gene 
Preparation for expression of the OppA protein 
In previous studies the required Ms03 oppA gene was cloned into a pGEX-4T-1 vector (GE 
Healthcare, United Kingdom) (Wium 2015). The pGEX-4T-1 vector allows for expression of 
proteins with a Glutathione S-transferase (GST) tag which can be isolated by means of affinity 
chromatography with a Glutathione-Agarose column. The pGEX-4T-1_oppA was transformed into 
E. coli BL21(DE3)pLysS cells (Promega, USA) and freezer stocks made by adding 500 µl 80% 
glycerol to 500 µl of the E. coli cells containing the plasmid with the gene of interest and stored at -
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80ºC. Freezer stocks were also made of the pGEX-4T-1 vector without any insert that was 
transformed into E. coli BL21(DE3)pLysS cells (Promega, USA). This was used as a control during 
protein expression studies. 
Luria Bertani (LB) (10 g/L Bacto-Tryptone, 5 g/L yeast extract, 5 g/L NaCl, pH 7) bacteriological 
agar plates (15 g/L) containing ampicillin (100 mg/ml) was casted and allowed to set. An 
inoculation loop was used to collect some of the thawed freezer stock of both the pGEX-4T-1_oppA 
as well as the pGEX-4T-1 plasmid containing no gene which was each streaked out on a LB agar 
plate and incubated at 37ºC for 16-18 h. 
Colony PCR 
Colony PCR was performed as by Wium (2015) to analyse colonies which formed on the agar 
plates in reactions containing 1 µl 10x reaction buffer, 0.4 µl dNTP's (5 mM), 0.6 µl MgCl2 (25 
mM), 0.5 µl pGEX_F (20 pmol/µl), 0.5 µl T7_R (20 pmol/µl), 0.1 µl Super-Therm polymerase (5 
U/µl) and 6.9 µl Milli-Q
®
. Primer sequences are shown in Table 3.3. The primers used in this 
reaction were already available in the laboratory for use, therefore it was not necessary to have the 
primers synthesised. Selected colonies on the agar plates were picked with a sterile tooth pick and 
mixed into the reaction mixture in 0.2 µl thin wall PCR tubes respectively before the amplification 
reaction was started. This was done with an initial step of 94ºC (5 min) followed by 25 cycles 
consisting of a denaturing step at 94ºC (30 sec), annealing step at 55ºC (30 sec) and 
elongation/extension step at 72ºC (30 sec). The reaction ended with a single 72ºC (7 min) step and 
cooling to 15ºC. The PCR products were analysed on a 1% agarose gel containing EtBr (0.5 µg/ml) 
for visualisation under UV light. The agarose gel was electrophoresed as previously described. 
O/N cultures were made from the colonies that tested positive by scraping them from the plates 
using a sterile toothpick which was added to a Falcon
®
 tube containing 5 ml LB medium and 5 µl 
ampicillin (100 mg/ml) followed by incubation at 37ºC for 16-18 h on an orbital shaker (200 rpm). 
Freezer stocks were subsequently made by adding 500 µl of the O/N culture to 500 µl 80% glycerol 
in a 1.5 ml Eppendorf tube and this was then used to start the expression process. 
Table 3.3 Primers used for colony PCR 
Primer 
name 
Sequence Comment Reference 
T7_R 5'-GCTGTAATTTGGGCATTTTCTTG-3' 
Internal oppA primer, binds 
at position 592-615 
Wium (2015) 
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3.2.7.2 Expression of the OppA protein 
An O/N culture was made by adding 4.75 ml Terrific-Broth (TB) medium (12 g/L Bacto-Tryptone, 
24 g/L Bacto yeast extract, 4 ml/L of 2 M glycerol) supplemented with 100 ml/L phosphate buffer 
(1 M KH2PO4, 1 M K2HPO4), to a 14 ml Falcon
®
 tube. To this 250 µl glucose (20% m/v), 5 µl 
chloramphenicol (34 mg/ml), 5 µl ampicillin (100 mg/ml) and 25 µl freezer stock (pGEX-4T-
1_oppA in E. coli BL 21 cells) was added. The same was done for the control except that only the 
pGEX-4T-1 plasmid without any insert was used. Both cultures were incubated at 37ºC for 16 h on 
an orbital shaker (200 rpm). 
An expression culture for the pGEX-4T-1_oppA was made by adding 95 ml TB-medium, 5 ml 
glucose (20% (m/v)), 100 µl ampicillin (100 mg/ml), 100 µl chloramphenicol (34 mg/ml) and 2 ml 
of the O/N culture to a 1 L Erlenmeyer flask. The expression culture for the pGEX-4T-1 control 
was made by adding 15 ml TB medium, 15 µl ampicillin (100 mg/ml), 15 µl chloramphenicol, 1.5 
ml glucose (20% (m/v)) and 200 µl of the O/N culture containing only the pGEX-4T-1 plasmid to a 
50 ml Erlenmeyer flask. The expression cultures were incubated at 37ºC on an orbital shaker at 200 





spectrophotometer. Expression was induced by adding IPTG to a final concentration of 0.4 mM to 
the culture containing the pGEX-4T-1_oppA plasmid as well as the control culture. The expression 
cultures were incubated at 37ºC for a further 6 h while on an orbital shaker (200 rpm). Samples (1 
ml) were taken from both the pGEX-4T-1_oppA and pGEX-4T-1 expression cultures at the start of 
induction and then every 2 h up until 6 h after induction. 
After the 6 h incubation period the remaining culture was harvested by centrifugation at 10 000 x g 
at 4ºC for 10 min (Beckman Coulter Avanti
®
 J-E). The supernatant was discarded and the pellets of 
the culture containing the pGEX-4T-1_oppA as well as the pGEX4T-1 plasmid each resuspended in 
1xTen50 buffer (100 µl per 1 ml of culture) (10 mM Tris-HCl, 1 mM EDTA, 50 mM Nacl, 0.1% 
Triton X-100, 0.2 M dithiothreitol (DTT) and 10% (v/v) glycerol) containing a protease inhibitor (1 
tablet per 10 ml extraction solution of cOmplete ULTRA Tablets, Mini, EASYpack tablet, Roche). 
The samples were subsequently analysed by means of SDS-PAGE.  
SDS-PAGE analysis of expressed OppA proteins 
An acrylamide gel was caste that consisted of a stacking gel and an 8% resolving gel. The 4.5% 
stacking gel contained 4.25 ml stacking buffer (0.125 M Tris-base, 0.1% (m/v) SDS, pH 6.8), 0.75 
ml stacking monomer (30% T, 2.7% C dissolved in stacking buffer), 15 µl N,N,N',N'-
Tetramethylethylenediamine (TEMED) and 30 µl ammonium persulfate (0.2 mg/µl). The resolving 
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gel contained 9.6 ml resolving buffer (0.375 M Tris-base, 0.1% (m/v) SDS, pH 8.0), 2.4 ml 
resolving monomer (30% T, 2.7% C dissolved in resolving buffer), 30 µl TEMED and 36 µl 
ammonium persulfate (0.2 mg/µl). 
The expression samples were prepared for electrophoresis by adding 12 µl bromophenol blue (0.1% 
(m/v) bromophenol blue in 0.1 M NaOH) and 30 µl reducing treatment buffer (0.125 M Tris-base, 
4% (m/v) SDS, 20% (v/v) glycerol and 10% (v/v) 2-mercaptoethanol, pH 6.8) to 30 µl of the 
resuspended pellet. The mixture was boiled for 3 min followed by incubation on ice up until the 
samples were loaded. The SDS-PAGE gel apparatus was set up containing the acrylamide gel and 
was filled with electrode buffer (25 mM Tris-base, 192 mM glycine, 0.1% SDS, pH 8.3). After 25 
µl of each sample was loaded on the acrylamide gel it was electrophoresed for 2 h at a constant 25 
mA. The resolving gel was subsequently stained for 1 h at 37ºC in Coomasie staining solution 
(0.125% Coomasie Brilliant Blue R250, 50% (v/v) MetOH and 10% (v/v) HOAc) under agitation in 
a hybridization oven/shaker (USA). The excess stain was then removed and the gel incubated in 
destain 1 (50% (v/v) MetOH and 10% HOAc) for 1 h at 37ºC under agitation in the hybridization 
oven/shaker followed by removal of destain 1 and incubation in destain 2 (5% (v/v) MetOH and 7% 
HOAc) at RT O/N under agitation at 25 rpm on a GyroTwister (Labnet, USA).  
3.2.7.3 Isolation of the expressed OppA protein 
The Ms03 OppA-GST protein was isolated from the resuspended E. coli cell pellet (Section 3.2.7.3) 
by means of a Glutathione-Agarose column (Sigma, USA). The lyophilized powder was swelled in 
Milli-Q
®
 water (200 ml/g) for 30 min at RT and left O/N at 4ºC for 100% swelling of the powder to 
occur. The column (10.5 mm in height and 2.5 mm in width) was packed with the swelled slurry, 
avoiding the formation of bubbles, which added up to a volume of 10 ml. The column was 
equilibrated by washing it with 10 volumes (100 ml) of equilibration buffer (10 mM PBS and 150 
mM NaCl, pH 7.4) in order to remove the lactose present in the lyophilized product. The column 
was then left O/N at 4ºC on 20 ml of the equilibration buffer. 
The sample (8 ml) containing the Ms03 OppA-GST protein was prepared by 3 freeze-thawing 
cycles (20 min at 37ºC followed by 10 min at -80ºC) and 5 cycles of 2 sec sonication followed by 2 
min on ice. The samples were then pulled through a 25Gx5/8" needle (Avacare, China) into a 1 ml 
Injekt-F syringe (BBraun, Germany) 3 times. The same procedure was then followed using a 
23Gx1/4" needle (Nipro, Belgium) also for 3 repeats. The sample was then centrifuged (Labnet 
Prism

 R Refrigerated Microcentrifuge) at 10 000 x g for 10 min (4ºC) in order to obtain a clear 
supernatant which was loaded onto the column under gravity flow at 4ºC. The clear supernatant was 
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allowed to run through the column 5 times followed by a 1 h - 2.5 h incubation on the column in an 
attempt to increase binding of OppA-GST proteins and therefore the yield of the isolated protein. 
The clear supernatant was subsequently eluted from the column followed by the first wash step 
using 5 volumes (50 ml) PBS-T (PBS, pH 7.2 with 1% (v/v) TritonX-100) containing a protease 
inhibitor (3 tablets per 50 ml) (cOmplete ULTRA Tablets, Mini, EASYpack, Roche). A second 
wash step was done with 5 volumes (50 ml) of PBS (pH 7.2) also containing a protease inhibitor (3 
tablets per 50 ml). The bound Ms03 OppA-GST proteins were then eluted from the column with 3 
volumes (30 ml) of elution buffer (10 mM reduced L-Glutathione and 50 mM Tris-HCl, pH 9.5) 
containing two cOmplete ULTRA Tablets. Twenty samples of 1 ml each were collected in 1.5 ml 
Eppendorf tubes. The column was subsequently cleaned by 5 volumes (50 ml) of cleansing buffer 1 
(0.1 M boric acid and 0.5 M NaCl) followed by 5 volumes (50 ml) of Milli-Q
®
 water. This was 
followed by 5 volumes of cleansing buffer 2 (0.1 M sodium acetate and 0.5 M NaCl) and finally the 
column was stored at 4ºC in 2 volumes (20 ml) of storage buffer (2 M NaCl with 0.2% Thimerosal). 
The concentration of the isolated protein was determined by means of the Bradford assay. A 
standard curve was used in order to determine the concentration of the eluted samples. The curve 
consisted of an increasing protein concentration of 0, 0.25, 0.5, 0.75, 1.00, 1.25 and 1.5 mg/ml of 
bovine serum albumin (BSA) made up with the elution buffer containing protease inhibitor tablets.  
The Bradford assay was done in a 96-well polystyrene microtitre plate (Greiner Bio-one, Germany) 
by loading 5 µl per well of each sample and standard followed by the addition of 250 µl Bradford 
reagent (0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) etanol and 8.5% (v/v) phosphoric 
acid) to the same well (all samples were done in triplicate). The plate was incubated for 2 min at 
room temperature (RT) and absorbance was measured at 620 nm using a Multiskan 
Spectrophotometer plate reader (Labsystems, Finland). The samples containing the Ms03 OppA 
protein as indicated by the Bradford assay were subsequently analysed by SDS-PAGE as previously 
described. 
3.2.7.4 Optimisation of the ELISA for analysis of serum samples collected during the vaccination 
trial 
Biotinylation of secondary rabbit anti-ostrich antibodies for use in ELISA analysis 
Rabbit anti-ostrich immunoglobulin (Ig) antibodies were previously produced and provided by Dr. 
A. Botes, Department of Biochemistry, University of Stellenbosch. These antibodies were isolated 
from the rabbit serum by mixing 0.5 ml rabbit anti-ostrich Ig serum with 1 ml PBS followed by the 
addition of 1.5 ml saturated ammonium sulfate ((NH4)2SO4; 1 kg/L). The mixture was incubated at 
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 J-E centrifuge. The supernatant was discarded and the pellet dissolved in 1 ml 
PBS (pH 7.2) followed by the addition of 1 ml saturated (NH4)2SO4. The mixture was incubated for 
20 min at 4ºC and centrifuged at 15 000 x g at 4ºC for 20 min. Again the supernatant was discarded 
and the pellet redissolved in 0.5 ml PBS. The dissolved pellet was dialysed in a cellulose dialysis 
tube (average flat width: 10 mm; average diameter: 6 mm) (Sigma-Aldrich, Germany) O/N at 4ºC 
against an excess of carbonate buffer (0.1 M NaHCO3, pH 8.3), with a single buffer change after 5 
hours. After O/N dialysis the concentration of the antibodies in the dialysate was measured by 
means of the Nanodrop
®
 ND 1000 spectrophotometer (Novell
®
, USA) at 280 nm followed by 
dilution of the sample to 5 mg/ml Ig in carbonate buffer (0.1 M NaHCO3, pH 8.3).  
The Ig was biotinylated by adding 600 µl of biotinylation reagent (2 mg/ml biotinamidohexanoic 
acid N-hydroxysuccinimide ester dissolved in dimethylformamide) dropwise to 2.4 ml Ig (5 mg/ml) 
in a pear-shaped flask and stirring the mixture slowly for 2 h at RT. The mixture was dialysed in a 
cellulose dialysis tube (average flat width: 25 mm; average diameter: 16 mm) (Sigma-Aldrich, 
Germany), O/N at 4ºC against an excess of PBS with a single buffer change after 5 h. Following 
O/N dialysis, glycerol was added to the biotinylated antibodies in a 1:1 ratio and stored at -20ºC.  
Determining coating concentration and serum dilution factor 
Maxisorp plates (96 well Nunc with certificate, Denmark) were used for ELISA analysis of the 
serum samples collected during the vaccine trial. For this purpose the optimal coating concentration 
of the wells with antigen (Ms03 OppA-GST protein) needed to be determined. Six rows were 
coated with different concentrations of Ms03 OppA-GST protein diluted in carbonate buffer (50 
mM NaHCO3, pH 9.6). Row A and B was coated with 1 µg/ml, C and D with 5 µg/ml and rows E 
and F with 10 µg/ml (Figure 3.1). The coated plate was incubated for 18 h at 4ºC to allow for 
binding of the antigen to the plate surface.  
The coating antigen was decanted followed by the addition of 200 µl casein buffer (10 mM Tris-
HCl, 154 mM NaCl, 0.5% casein and 0.02% Thimerosal, pH 7.6) to all wells to block non-specific 
binding. The plate was incubated at 37ºC for only 1 h instead of 2 h as done by Wium (2015). The 
casein buffer was then decanted and the plate washed 5x with PBS-Tween (PBS buffer, pH 7.2 
containing 0.1% (v/v) Tween
®
 20) and 3x with Milli-Q
® 
water, compared to the 8x PBS-Tween 
wash used by Wium (2015).  
A week 0 and week 3 serum sample from ostrich 207 (pCI-neo_oppA 1200 µg/ml group) and from 
266 (VR1020_oppA 1200 µg/ml group), was used for optimising the serum dilution factor to be 
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used during ELISA analysis. These sera were diluted (1:20) in casein-Tween (casein buffer, pH 7.6 
containing 0.1% (v/v) Tween
®
20) and 200 µl of these dilutions added to the wells in column 2 and 
8 respectively (Figure 3.1). To the rest of the columns 100 µl/well of casein-Tween was added. A 
serial dilution was made by transferring 100 µl of the serum sample from column 2 into column 3, 
mixing, and repeating the transfer up until column 6 ending with a dilution factor of 1:320. The 
same serial dilution was repeated from column 8-12. The final 100 µl taken from column 6 and 12 
was discarded. Column 1 and 8 acted as blank and therefore only received 100 µl/well casein-
Tween. The plate was incubated at 37ºC for 1 h, the serum dilutions decanted and the plate washed 
5x in PBS-Tween and 3x using Milli-Q
® 
water. 
After selecting a coating concentration the serial dilution was repeated as before except that a single 
coating concentration was used for all wells and the serial dilution started at 1:40 and ended at 
1:640. A week 0 and week 9 serum sample from ostrich 261 (VR1020_oppA 1200 µg/ml subgroup) 
was used for the serial dilution. This was done to determine the highest dilution factor where a 
difference is still visible between two samples in order to not over- or underestimate results 
observed. Increasing the washing steps to 10x with PBS-Tween followed by a 3x wash with Milli-
Q
® 
water was also evaluated. 
 
Figure 3.1 Plate layout used for optimising the ELISA coating concentration and serum dilutions. The 1 µg/ml, 5 
µg/ml and 10 µg/ml refer to the coating concentrations. Indicated in the orange blocks are the rows which 
received 200 µl of the 1:20 diluted serum. The black arrows indicate the serial dilution with the transfer of 100 µl 
from the first column to the next. The red arrows indicate the discarding of the final 100 µl serum sample at the 
end of the serial dilution. W0 = Week 0 and W3 = Week 3. 
 
Biotinylated antibody (rabbit anti-ostrich Ig) was diluted 1:100 in casein-Tween and 100 µl of this 
dilution added to each well followed by 1 h incubation at 37 ºC. The plate was washed 5 or 10 times 
with PBS-Tween as well as 3 times with Milli-Q
®











200 µl 100 µl 100 µl 100 µl
100 µl
200 µl 100 µl 100 µl 100 µl
100 µl
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conjugate (Invitrogen) (2 ml streptavidin HRP, 3 ml 0.5% casein buffer, 40 ml glycerol) was diluted 
(1:100) in casein-Tween and 100 µl of this dilution added to each well followed by a 1 h incubation 
at 37ºC. A wash step was performed again as before followed by the addition of 100 µl substrate 
(0.5 mg/ml 2,2′-Azino-bis 3-ethylbenzothiazoline-6-sulfonic acid (ABTS) and 0.5 µl/ml H2O2 in 0.1 
M citrate buffer, pH 5) to each well. The plate was subsequently incubated for 30 min at 37ºC and 
the absorbance of the wells measured at 405 nm by using a Multikan Spectrophotometer plate 
reader (Labsystems, Finland). The coating concentration was plotted graphically against the serial 
dilution to analyse the results. 
3.2.8 ELISA analysis of ostrich serum samples 
All serum samples collected from the ostriches during the vaccination trial from week 0-9 were 
analysed in triplicate following the procedure described in section 3.2.7.4 except that all wells were 
coated with 10 µg/ml OppA-GST protein and two serum dilutions used for analysis namely 1:100 
and 1:500. Plates were washed 5 times with PBS-Tween and 3 times with Milli-Q
® 
between all 
incubation steps. Absorbance values measured during ELISA analysis represent antibody levels and 
are referred to as titre values. 
All of the plates contained the same plate control sample (ostrich number 217) from the pCI-
neo_oppA 1200 µg/ml subgroup, which was randomly selected, in order to monitor plate to plate 
variation. In order to evaluate the specificity of the ELISA a no-coat column (column 12) was 
included in one of the ELISA plates using a sample that gave a high titre value using the described 
ELISA. The no-coat column was coated with 100 µl/well carbonate buffer (50 mM NaHCO3, pH 
9.6) but contained no protein. Except for the column containing no protein, all the steps following 
coating were the same as described before and serum samples applied to the no coat column were 
diluted 1:100.  
3.2.1 Statistical analysis of trial data  
Statistical analysis for the ELISA results obtained by diluting the serum 1:100 and 1:500 as well as 
weight data recorded during the trial was done by using the General Linear Model (GLM) 
procedure by means of the Agrobase Generation II
®
 (Agronomix Software Inc.) software. The 
analysis of variance (ANOVA) and least significant difference (LSD) was calculated and a 
significance level of P<0.05 was chosen for analysis. The only ostriches that were not included in 
the ELISA analysis and subsequent statistical analysis were those who lost a tag or those with more 
than two data sampling points (week 0, 3, 6 and 9) missing due to serum samples not being 
collected. The data used for the statistical analysis are given in Addendum A. 




3.3.1 Preparation of DNA vaccines 
Both the pCI-neo_oppA as well as the VR1020_oppA plasmids were isolated successfully with final 
concentrations of 89300.32 µg (11 preps) and 89300.68 µg (10 preps) respectively which was 
sufficient for vaccination at week 0 and week 6. On a 1% agarose gel (Figure 3.2) the majority of 
both the plasmids were identified as supercoiled as indicated by a band at 7000 bp for the 
undigested pCI-neo_oppA isolated plasmid (Figure 3.2 A) and a band at 8000 bp for the undigested 
VR1020_oppA isolated plasmid (Figure 3.2 B). A small percentage of the undigested pCI-
neo_oppA and VR1020_oppA plasmids were nicked. The restriction enzyme digestion also 
confirmed the presence of the Ms03 oppA gene in both plasmids. The pCI-neo_oppA digestion with 
AccI resulted in a single band between 8000 bp and 10 000 bp on the agarose gel representing the 
pCI-neo plasmid (5472 bp) together with the oppA gene (3867 bp) in a linear form (Figure 3.2. A). 
Digestion of the VR1020_oppA with BamHI resulted in two bands, the first band representing the 
linear plasmid (5044 bp) and the second band, representing the Ms03 oppA gene (3867 bp) (Figure 
3.2 C). 
3.3.2 Vaccination trial 
3.3.3 Weight recording during trial 
The average weight of the different groups as recorded during the vaccination trial is shown in 
Table 3.4. The weight gain/loss of the different groups was all in the same range from one time 
point to the next as there was no statistically significant difference between the groups over the 9 
week period (pCI-neo_oppA P = 0.9564; VR1020_oppA P = 0.5290) . The only exception was the 
VR1020_oppA 600 µg/ml subgroup which, based on the LSD (1.8101) value for the weight change, 
had a statistically significant lower average weight at week 9 compared to the control group 
(Addendum A). The control group and the vaccinated groups gained weight from week 0 to week 6 
but from week 6 up until week 9 there was an average weight loss of 0.05 kg amongst all groups. 
Similar to the period of week 0 to week 6, weight gains was expected from week 6 to week 9 as the 
ostriches were in a seemingly good condition at week 6, had no mycoplasma infections and were on 
a standard feeding schedule formulated to favour weight gain. Problems were however experienced 
with the availability of the normal pelleted feed between the week 6 and 9 time points and birds 
were therefore given feed in a mashed form. Due to the change in feed the ostriches stopped eating 
and needed to be pastured after spending only 1 week in the feedlot. They were pastured for the 
remainder of the trial receiving only 1 kg of extra feed per bird per day. 




Figure 3.2 A 1% agarose gel showing the integrity of the DNA vaccine plasmids, pCI-neo_oppA (A) and 
VR1020_oppA (B and C) after plasmid isolation. 
(A): MM: GeneRuler

 (Fermentas); Lane 1-7: Isolated pCI-neo_oppA plasmid digested with the AccI   
restriction enzyme; Lane 9-14: Isolated pCI-neo_oppA plasmids undigested. 
(B): MM: GeneRuler

 (Fermentas); Lane 1-7: Isolated VR1020_oppA plasmids undigested digested. 
(C): MM: GeneRuler

 (Fermentas); Lane 1-7: Isolated VR1020_oppA digested with the BamHI restriction 
enzyme. 
Table 3.4 The average weight of each trial group as recorded during the vaccination trial. 
 
Average Weight (kg) 

















100 µg/ml 26.53 43.23 44.87 
600 µg/ml 25.95 42.72 43.74 
1200 µg/ml 26.75 45.8 45.39 
VR1020 
  
100 µg/ml 27.53 47.88 47.24 
600 µg/ml 26.23 42.56 41.08 
1200 µg/ml 25.95 44.5 42.85 
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3.3.4 Trachea swab sample analysis by PCR 
The results of the PCR analysis of the swab samples are shown in Table 3.5 A for the pCI-
neo_oppA vaccine groups and Table 3.5 B for the VR1020_oppA vaccine groups. The control group 
shown in Table 3.5 A and B refer to the same group. No mycoplasma infections could be detected 
by PCR for any of the groups in week 0 and week 3 during which time the ostriches were in 
Fraserburg. After moving the ostriches to Oudtshoorn also no infections could be detected by PCR 
at week 6, but at this point the ostriches have only been in Oudtshoorn for one week and still in 
quarantine. At week 9, however, there was an increase in PCR detected infections. At week 9 the 
ostriches were already out of quarantine for 8 days and were therefore exposed to the rest of the 
farm environment and therefore an increase in infections could be expected. 
For the pCI-neo_oppA vaccine groups the highest percentage of infections was due to Ms02 at 
7.27% of the total infections followed by Ms03 with 3.63% of the total infection and Ms01 with 
total infections of 1.81% (Table 3.5 A). As for the VR1020_oppA vaccine groups the highest 
percentage of infections was again due to Ms02 infections with 10.52% of the total infections 
followed by Ms03 infections which were 5.26% and lastly Ms01 with the lowest infection rate of 
3.50% (Table 3.5 B). Overall the pCI-neo_oppA vaccination groups had fewer infections due to the 
ostrich-infecting mycoplasma species than the VR1020_oppA vaccination groups, with only the 
VR1020_oppA 1200 µg/ml subgroup and the control group having no infections. Multiple 
infections were present in some birds. The pCI-neo_oppA 1200 µg/ml subgroup contained one 
ostrich and VR1020_oppA 600 µg/ml subgroup contained four ostriches infected by more than one 
of the ostrich-infecting mycoplasmas. 
Not all infections detected at week 9 were as a result of mycoplasma infections as determined by 
BLAST analysis (Table 3.6 and Table 3.7). Some of the trachea samples tested positive for 
mycoplasma when using the genus specific primers but when testing for the ostrich-infecting 
mycoplasmas, results were negative. Therefore these samples were sequenced and BLAST analysis 
performed to confirm if the infections were indeed due to mycoplasmas (Table 3.6). Results 
revealed no mycoplasma infections but instead Gram-negative bacteria of the family 
Entrobacteriaceae were found, which included Cronobacter zurichensis, Pantoea agglomerans and 
Citrobacter murliniae (Table 3.7). Some of the members of this family are present in the gut of 
many animals without causing harmful effects (Linton and Hinton, 1988). The only exception was 
that of the Gram-positive plant associated bacterium that can also be found in soil namely 
Curtobacterium plantarum which is a member of the Microbacteriaceae family (Table 3.7). It is 
therefore not impossible that these bacteria could be found in some samples. Ostriches could have 
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encountered both of these by either pecking the soil or other birds faeces. It should be noted that 
these bacteria would by no means represent all the bacteria that the trial ostriches were exposed to 
but only the ones that were present and had cross reactivity with the Mycoplasma genus specific 
primers. 
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Table 3.5 Ms01, Ms02 and Ms03 infections as detected by PCR analysis during the course of the vaccination trial for the (A) pCI-neo_oppA and (B) VR1020_oppA 
vaccinated groups. 
A Experimental groups 
Percentage infections at each 
sample point 
 
B Experimental groups 





   
µg/ml* 
Week 
0 3 6 9 
 












100 - - - - 
600 - - - - 
 





1200 - - - - 
 
1200 - - - - 














100 - - - 
2/19 
(10.53%) 




600 - - - 
4/18 
(22.22%) 




1200 - - - - 
Control 
 
- - - - 
 









100 - - - 
1/19 
(5.26%) 
600 - - - - 
 
600 - - - 
2/18 
(11.11%) 













- - - - 
 * Vaccine concentration administered 
 # Total number of birds in group at end of trial  
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Table 3.6 Bacteria other than the three ostrich-infecting mycoplasmas detected when using mycoplasma genus 
primers. 
Experimental groups 
Total infections at each sample point not due to ostrich infecting 
mycoplasmas 
Vaccine Dose Week 0 Week 3 Week 6 Week 9 
pCI-neo_oppA 
100 µg/ml - - - 2/19 (10.53%) 
600 µg/ml - - - 1/17 (5.88%) 
1200 µg/ml - - - - 
VR1020_oppA 
100 µg/ml - - - - 
600 µg/ml - - - 1/18 (5.56%) 
1200 µg/ml - - - 3/20 (15.00%) 
Control - 1/20 (5.00%) - - 1/17 (5.88%) 
 







E-value Identity Accession number 
Citrobacter murliniae 961 98% 0 97% NR028688.1 
Cronobacter zurichensis 1230 93% 0 97% NR104924.1 
Curtobacterium plantarum 1230 97% 0 97% NR104943.1 
Pantoea agglomerans 1206 91% 0 99% NR114111.1 
Pantoea agglomerans 612 99% 4e
-
175 95% NR114735.1 
 
3.3.5 Preparation for analysis of serum samples  
3.3.5.1 Expression and Isolation of OppA proteins 
Producing the expression plasmid containing the oppA gene 
A number of colonies resulting from the transformation of pGEX-4T-1_oppA into E. coli 
BL21(DE3)pLysS cells were selected for analysis by colony PCR and all contained the pGEX-4T-
1_oppA plasmid as shown in Figure 3.3 (lane 3-11) with a band at about 600 bp. The pGEX_F 
primer together with the T7_R primer results in a PCR product of 592 bp as the T7_R primer binds 
at position 592-615 inside the oppA gene whereas the pGEX_F binds to the pGEX-4T-1 vector. 




Figure 3.3 Colony PCR results of colonies containing pGEX-4T-1_oppA on a 1% agarose gel. MM: GeneRuler

 
(Fermentas), Lane 1: Negative control, PCR containing no DNA only Milli-Q
®
, Lane 2: Positive control 
containing isolated pGEX-4T-1_oppA plasmid, Lane 3-11: PCR products of colonies tested. 
 
Expression of the OppA protein and SDS-PAGE analysis 
Ms03 OppA proteins were successfully expressed as confirmed by SDS-PAGE analysis (Figure 
3.4). The expressed fusion protein consisting of an OppA protein (145 kDa) and a GST tag (26 
kDa) resulted in a band of 171 kDa as indicated by the red block in Figure 3.4. No expression was 
observed in the control (lane 1 and 4) at 0 h and 6 h due to the fact that the control contained a 
plasmid without the oppA gene. The samples containing the pGEX-4T-1_OppA plasmid also 
showed no expression at 0 h (lane 2-3) but the Ms03 OppA-GST protein was expressed at 6 h (lane 
5-6). 
 
Figure 3.4 8% SDS-PAGE analysis of the OppA-GST protein expressed in E. coli BL21(DE3)pLysS cells. MM: 
PageRuler

 Unstained protein ladder (Thermo Scientific). Lane 1: Expression of control at 0 h. Lane 2-3: 
Expression of Ms03 OppA-GST at 0 h. Lane 4: Expression of control at 6 h. Lane 5-6: Expression of Ms03 
OppA-GST at 6 h. 
 
3.3.5.2 Isolation of the expressed OppA protein 
The Ms03 OppA-GST protein was successfully isolated by means of a Glutathione-Agarose column 









MM 1         2         3       4          5        6     
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detected by Bradford analysis of the 20 samples collected during the isolation process. The purified 
Ms03 OppA-GST protein starts eluting at sample 5 and the highest concentration of purified eluted 
Ms03 OppA fusion protein is reached at sample 9, 10 and 11 with concentrations of 0.673 mg/ml, 
0.650 mg/ml and 0.708 mg/ml respectively. The highest concentration that was reached based on 
Bradford analysis could be increased from 0.554 mg/ml to 0.947 mg/ml protein by increasing the 
incubation time of the sample on the column from 1h to 2 h and 30 min. 
After initial isolation of the Ms03 OppA-GST protein, SDS-PAGE analysis showed that the GST 
tag was cleaved from the Ms03 OppA protein during isolation. To prevent this from happening and 
ensuring efficient isolation of the protein with the Glutathione-agarose column, a protease inhibitor 
was added to the lysis buffer and all the buffers used during the isolation process to ensure that the 
protein remained in its fusion state. No protease inhibitor was, however, added to the equilibrium 
buffer as almost all of the equilibrium buffer was eluted before the addition of the sample 
containing the OppA-GST protein. 
SDS-PAGE analysis confirmed that the protein that was isolated with the Glutathione-Agarose 
column was indeed the Ms03 OppA-GST protein as indicated by the protein bands at 170 kDa in 
lanes 6-9 (Figure 3.6, red block). In Figure 3.6, Lane 2 shows that the supernatant which was loaded 
on the column contained the Ms03 OppA-GST protein as well as other proteins. Lane 3 indicated 
that most of the Ms03 OppA-GST proteins were able to bind to the column and in lane 4 and 5 it is 
shown that most of the proteins not containing a GST tag were eluted by the wash steps. There were 
still some unwanted proteins after isolation (lanes 6-9), although the largest amount of protein 
isolated was the Ms03 OppA-GST protein as this is the most prominent band in these lanes. 
 
Figure 3.5 Elution profile illustrating the concentration of protein (mg/ml) per sample eluted during isolation of 
the Ms03 OppA-GST protein, as determined by Bradford analysis. The elution profile indicates that sample 9, 10 




































Figure 3.6 8% SDS-PAGE gel analysis of the isolated OppA-GST proteins isolated using a glutathione-agarose 
column. MM: Color Prestained Protein Standard, Broad Range (BioLabs
®
 Inc., New England). Lane 1: Cells 
harvested after 6 h of expression. Lane 2: Supernatant before loading on column. Lane 3: Flow through after 
incubation period on column. Lane 4: After wash 1. Lane 5: After wash 2. Lane 6-9: Eluted OppA-GST proteins 
as indicated in red block (171 kDa). 
 
3.3.5.3 Optimisation of ELISA for analysis of serum samples collected during the vaccination trial 
Figure 3.7 A and B shows the absorbance values obtained for the VR1020_oppA and pCI-neo_oppA 
serum samples respectively when serial dilutions ranging from 1:20 to 1:320 of different coating 
concentrations were used. For both A and B of Figure 3.7 the 1 and 10 µg/ml coating concentrations 
showed a difference in absorbance values between the week 0 and 3 serum samples. A serum 
dilution between 1:80 and 1:160 in combination with both the 1 and 10 µg/ml coating concentration 
resulted in a low absorbance value for the week 0 serum, but still allowed a high signal to 
background ratio to be achieved for the corresponding week 3 sera. Although both the 1 and 10 
µg/ml coating concentrations allowed differences in absorbance values, the 10 µg/ml coating 
concentration was chosen for further analysis as this was also the coating concentration used in the 
previous study by Wium (2015). For simplicity, a dilution factor of 1:100 (indicated at the black 
vertical line) was chosen for further ELISA analysis. 
Serum samples that are diluted with a too low dilution factor can cause overestimation of binding as 
the antibodies will bind non-specifically or with low binding efficiency, whereas a too high dilution 
factor can cause an underestimation of the binding as there is not enough antibody (due to the 
dilution) to result in an effective signal (Tate and Ward, 2004). The serial dilution was therefore 
repeated using a range from 1:40 to 1:640 and results shown in Figure 3.8 A. For simplicity the 
1:500 dilution (indicated at the black vertical line) was chosen for further ELISA analysis as a 
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171 kDa
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serum samples collected during the trial from week 0 to week 9 were subsequently analysed using a 
1:100 and 1:500 dilution factor.  
 
Figure 3.7 Plots of absorbance values of ELISA determinations of different serum dilutions and different coating 
concentrations. (A) Optimisation of the ELISA technique with different coating concentrations of the OppA-GST 
protein. Week 0 and week 3 serum of the bird 266 in the VR1020_oppA 1200 µg/ml subgroup was used in order 
to perform the optimisation of the ELISA technique (I): Coating concentration of 1 µg/ml. (II): Coating 
concentration of 5 µg/ml. (III): Coating concentration of 10 µg/ml. The 1:100 dilution is indicated by the vertical 
black line. (B) Optimisation of the ELISA technique with different coating concentrations of the OppA-GST 
protein. Week 0 and week 3 serum of the bird 207 in the pCI-neo_oppA 1200 µg/ml subgroup was used in order to 
perform the optimisation of the ELISA technique (I): Coating concentration of 1 µg/ml. (II): Coating 
concentration of 5 µg/ml. (III): Coating concentration of 10 µg/ml. The 1:100 dilution is indicated by the vertical 
black line. 
 
Compared to the results obtained by Wium (2015) there was no appreciable difference observed in 
background due to the decrease from 2 h to 1 h at 37ºC, for the block step.  
Residual Tween can interfere with the enzymatic activity of peroxidase conjugates (Gibbs, 2001) 
and therefore plates were washed 5x with PBS-Tween followed by a 3x Milli-Q
®
 wash in order to 
determine if the background could be reduced as compared to washing the plate 8x with only PBS-
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of the week 0 and week 3 serum used in combination with a serial dilution of 1:20 to 1:320 with this 
modified washing technique. 
Using a week 0 and week 9 serum in combination with a 1:40 to 1:640 serial dilution the 5x PBS-
Tween wash followed by the 3x Milli-Q
® 
water wash was compared to a 10x PBS-Tween wash 
followed by the 3x Milli-Q
® 
water wash (Figure 3.8 A and B) 
Increasing the wash steps to 10x PBS-Tween resulted a in higher ELISA absorbance titre value for 
the week 9 serum at almost all of the dilution factors compared to the 5x PBS-Tween wash. For 
both wash steps the titre values were in the same range for the week 0 serum. The increase in PBS-
Tween wash steps, however, increased the blank column values and thus background form 0.102-
0.116 to 0.113-0.131. The 5x PBS-Tween wash step followed by the 3x Milli-Q
®
 wash was 
subsequently used for further ELISA analysis.  
3.3.5.4 Biotinylation of rabbit anti-ostrich antibodies 
The rabbit anti-ostrich antibody was successfully biotinylated since it allowed for interaction of 
biotin with the streptavidin HRP with a resulting colour reaction seen after addition of the substrate 
to each of the wells (Figure 3.9). This procedure has also been used in numerous ELISA approaches 
in this laboratory and performed very similarly.  
 
Figure 3.8 Graphical representation of the serial dilution from 1:40 to 1:640 of the week 0 and 9 serum of ostrich 
261 in the VR1020_oppA 1200 µg/ml subgroup by means of the ELISA technique with a single coating 
concentration of 10 µg/ml. (A) plate washed 5x with PBS-Tween followed by 3x water wash. (B) Plate washed 
10x with PBS-Tween followed by 3x water wash. The vertical black line indicates the 1:500 dilution that was 
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Figure 3.9 96 well Maxisorb plate showing the colour reaction of two serum samples from the VR1020 1200 
µg/ml subgroup (sample 1: ostrich 265 and sample 2: 266) with the use of the biotinylated antibody in the ELISA 
technique. B: Blank row receiving no serum, W0: Serum sample taken at week 0, W3: Serum sample taken at 
week 3, W6: Serum sample taken at week 6, W9: Serum sample taken at week 9. The plate was coated with 10 
µg/ml Ms03 OppA protein and all serum samples were diluted 1:100 in casein-Tween. 
 
3.3.6 ELISA analysis of ostrich serum samples 
The range of the titre values for the plate control samples for both serum dilutions are shown in 
Table 3.8. The plate control sample (pCI-neo_oppA 1200 µg/ml subgroup, ostrich 217) was chosen 
randomly and was one of the samples with a high titre value at week 0 compared to other samples 
in the same subgroup. The titre values obtained for the plate control sample were consistently 
within the same range. Although aliquots were made of the plate control sample they were still 
exposed to freeze/thaw cycles which might have had an influence on the variation of the range. As a 
result of plate control variation form plate to plate, some variation would be expected between all 
plates analysed. The no-coat column (1:100 serum dilution) also indicated that there was no non-
specific binding as the titre values were in the same range as the blank (0.130-0.238). 
Table 3.8 Range of titre values for both serum dilutions for week 0, 3, 6 and 9 of the plate control sample. 
Serum dilution 
Range 
Week 0 Week 3 Week 6 Week 9 
1:100 0.754-1.251 0.603-0.983 0.512-1.194 1.140-1.830 
1:500 0.131-0.245 0.071-0.158 0.159-0.233 0.209-0.333 
Four ostriches were excluded from the trial and subsequent ELISA analysis. Three of these were 
from the control group where one was accidently injected with the pCI-neo_oppA (1200 µg/ml) 
vaccine, and the other two together with the fourth ostrich from the VR1020_oppA 600 µg/ml 
subgroup that lost their tags during the trial. Figure 3.10 and Figure 3.11 represents the average 
anti-OppA antibody response as produced in response to the pCI-neo_oppA and the VR1020_oppA 
vaccines respectively as determined by the ELISA when using a dilution factor of 1:100 for the 
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serum whereas Figure 3.12 and Figure 3.13  represents the average anti-OppA antibody response 
when using a dilution factor of 1:500 for the serum. 
As shown by the results in Figure 3.10, Figure 3.11, Figure 3.12 and Figure 3.13 the control group, 
which received no vaccine, had an overall average titre in the same range from week 0-6. At week 9 
however, there is a slight increase in the average titre. The serum samples from the control group 
for the 1:100 dilution and 1:500 dilution were not all analysed on the same plate and also not with 
the same batch of isolated OppA proteins. Instead the serum samples from week 0-9 of each ostrich 
were analysed together on the same plate and therefore at the same time point and using the same 
batch of coating antigen. The increase in absorbance values from week 6 to week 9 for the control 
group can therefore not be ascribed to handling error alone. 
ANOVA analysis of the pCI-neo_oppA vaccination results (1:100 serum dilution, Figure 3.10) 
indicated a significant treatment x time interaction for the data as a whole with P = 0.0462. By 
using the calculated LSD value (0.2235) a pair wise comparison was done between the immune 
responses of each of the vaccinated subgroups and the control group to determine if there was a 
statistical significant difference between doses. This revealed that there was no statistical significant 
difference between the control group and any of the vaccinated subgroups at week 0, week 3 or 
week 6. At week 9, however, the antibody response produced by the 100 and 600 µg/ml doses 
differed significantly from the control. There was no statistical significant difference between the 
control and the 1200 µg/ml dose at any of the time points and at week 9 there was no statistical 
difference between the different doses when using a 1:100 serum dilution.  
ANOVA analysis of the VR1020_oppA vaccination results (1:100 serum dilution, Figure 3.11) 
indicated a significant treatment x time interaction for the data as a whole with a P < 0.05. The LSD 
value (0.2796) calculated was also used for pair wise comparison between the immune responses of 
each of the vaccinated subgroups and the control group to determine if there was any statistical 
significant differences between doses. No statistical significant difference was observed between 
the control group and any of the vaccinated subgroups at week 0, week 3 or week 6. Compared to 
the pCI-neo_oppA vaccine the antibody response produced by all of the subgroups differed 
significantly from the control group, however, the significant difference again could only be 
observed at week 9. A significant difference was also observed between the 100 and 600 µg/ml, 600 
and 1200 µg/ml as well as the 100 and 1200 µg/ml doses at week 9. 




Figure 3.10 Average titre values as determined by means of the ELISA technique illustrating the anti-oppA 
antibody response against the pCI-neo_oppA vaccine injected into ostriches during the field trial. The results were 
obtained by with a 1:100 dilution of the serum samples. The black arrows indicate the time points at which the 
ostriches were vaccinated. 
 
Figure 3.11 Average titre values determined by means of the ELISA technique illustrating the anti-OppA 
antibody response against the VR1020_oppA vaccine injected into ostriches during the field trial. The results were 
obtained with a 1:100 dilution of the serum samples. The black arrows indicate the time points at which the 
ostriches were vaccinated. 
The statistical significance of the ELISA results for the pCI-neo_oppA vaccination group (1:500 
serum dilution, Figure 3.12) was determined as before and indicated there was no significant 
treatment x time interaction for the data as a whole with P = 0.2774. These results differ from that 
obtained with the 1:100 serum dilution where a significant treatment x time interaction was 
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group and any of the vaccinated subgroups at week 0, week 3 or week 6. When using a 1:500 
dilution only the pCI-neo_oppA 100 and 1200 µg/ml doses differed significantly from the control, 
however, the significant difference could only be observed at week 9. These results once again 
differed from the 1:100 dilution results where the 100 µg/ml and 600 µg/ml doses produced a 
significant difference when compared to the control at week 9. 
Similar to the 1:100 results an ANOVA analysis of the 1:500 serum dilution VR1020_oppA 
vaccination (Figure 3.13) results indicated a significant treatment x time interaction for the data as a 
whole with P < 0.05. As before, the LSD value (0.2120) indicated no statistical significant 
difference between the control group and vaccinated subgroups at week 0, week 3 and week 6. 
Once again, similar to the 1:100 dilution factor the antibody response produced by the 
VR1020_oppA 100, 600 and 1200 µg/ml doses differed significantly from the control and only at 
week 9. Different from the 1:100 dilution factor there was no significant difference between the 600 
and 1200 µg/ml doses but as for the 1:100, there was a significant difference between both the 100 
and 600 µg/ml as well as the 100 and 1200 µg/ml doses.   




Figure 3.12 Average titre values determined by means of the ELISA technique illustrating the anti-oppA antibody 
response against the pCI-neo_oppA vaccine injected into ostriches during the field trial. The results were obtained 




Figure 3.13 Average titre values determined by means of the ELISA technique illustrating the anti-oppA antibody 
response against the VR1020_oppA vaccine injected into ostriches during the field trial. The results were obtained 
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Ostriches hatch with an immature immune system making them more susceptible to especially 
respiratory infections such as those caused by mycoplasmas (Scholtz, 2014). The mortality of 
chicks up to the age of three months can be as high as 50% (Cloete et al., 2001). Due to the large 
number of ostrich farms in the Oudtshoorn district, infections are common on these farms and as a 
result day old ostrich chicks are moved to distant areas such as Fraserburg until they reach an age of 
about 3-4 months. As there are fewer ostrich farms in Fraserburg compared to Oudtshoorn, spread 
of infections from farm to farm is limited. The vaccination trial described here was therefore started 
in Fraserburg with 3 month old ostriches at the end of autumn. Ostriches were kept at Fraserburg 
during the week 0 and week 3 sampling points and only moved to Oudtshoorn one week prior to the 
week 6 sampling point. During the first sampling point (week 0) ostriches that formed part of the 
trial needed to be tagged for identification purposes. In a previous study by De Wet (2015) the 
ostriches were tagged in the neck which attracted the attention of other ostriches. They subsequently 
pecked at each other's tags resulting in the loss of tags and because these birds were untraceable the 
number of trial birds was decreased over time. In this study, the ostriches were therefore tagged 
underneath their wings which resulted in fewer tags being lost. 
In the vaccination trial, the pCI-neo_oppA and VR1020_oppA vaccines were administered to the 
ostriches in three different doses at week 0 and a booster at week 6. All of the vaccine plasmids 
were administered in supercoiled form as it has been shown that this conformation results in higher 
transfection rates into mammalian cells and is less susceptible to intracellular degradation than other 
plasmid conformations (Maucksch et al., 2009; Ghanem, Healey, & Adly, 2013).  
The anti-OppA antibody responses against both the pCI-neo_oppA and VR1020_oppA vaccines 
were evaluated by means of an ELISA. The dilution factor used for sera can cause either over- or 
underestimation of results due to a too low or too high dilution. Two different dilution factors were 
therefore used namely 1:100 and 1:500 and the results statistically analysed. Overall the outcome of 
the ELISA results were not different when using the 1:100 or 1:500 dilution factor except for the 
pCI-neo_oppA 600 (1:100 dilution) and 1200 µg/ml (1:500 dilution) doses which showed a 
significant difference from the control group at the different serum dilutions. Although both serum 
dilutions resulted in a high coefficient of variance, this is expected as none of the animals will have 
the same reaction to the vaccine and this reaction can also not be controlled. The coefficient of 
variance, however, increased dramatically from analyses with the 1:100 dilution (pCI-neo: 51.74%; 
VR1020: 53.82%) to analyses with the 1:500 dilution (pCI-neo: 86.11%; VR1020: 133.10%) and 
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therefore the statistical significance is decreased. Hence, the 1:100 dilution factor will preferably be 
used in future studies and only these results will be discussed. 
The 1:100 dilution indicated that the 100 and 600 µg/ml doses of the pCI-neo_oppA vaccine was 
able to produce an anti-OppA immune response (P = 0.0462) but only after administering a booster 
vaccination. All of the VR1020_oppA doses that were administered to the ostriches resulted in 
significantly higher average titre values than that of the control but similar to the pCI-neo vaccine 
only after a booster vaccine was administered. This indicates the necessity of a booster vaccination. 
The 600 µg/ml dose produced a higher average titre than the 1200 µg/ml dose and the difference 
between these two doses was statistically significant. This implies that 600 µg/ml is the preferred 
dose for the specific age and weight of the ostriches that were vaccinated. Sample collection, 
however, was only done up until week 9 and a different result may have been obtained with more 
sample points beyond week 9. Although the 100 µg/ml dose resulted in the lowest average titre 
values it was also able to elicit a statistically significant anti-OppA immune response at week 9. 
Therefore, given more time, the 100 µg/ml dose might be sufficient for eliciting an anti-OppA 
antibody response. 
After IM injection of a DNA vaccine the plasmids are taken up by the muscle cells near the 
injection site. Although the mechanism of plasmid uptake into the muscle cells is not yet clear it is 
speculated that this process is facilitated by T tubules which are only found in skeletal and cardiac 
muscle cells (Dupuis et al., 2000; Kutzler and Weiner, 2008; Saade and Petrovsky, 2012). 
Following the uptake of the DNA vaccine by the muscle cells the plasmid enters the cell nucleus by 
means of the host cellular machinery and is expressed (Kutzler and Weiner, 2008). Expressed 
antigen will trigger the activation of a primary immune response which results in antibody 
production against the antigen, and is mediated by both B- and T-cells (Janeway et al., 2001). When 
comparing the antibody response elicited by the pCI-neo_oppA vaccine to that of the 
VR1020_oppA vaccine, the VR1020_oppA vaccine had higher average titre values indicating a 
greater antibody response. This might be due to the fact that the VR1020 plasmid contains a tPa 
signal sequence upstream from the oppA gene. This sequence assists with expression, export of the 
protein and immunogenicity as shown by Malin et al. (2000). As the pCI-neo plasmid does not 
contain a tPa signal like the VR1020 plasmid, it is possible that synthesised proteins were not 
transported out of the cell and therefore not presented well enough for an immune response to be 
elicited during that time. Another possibility is that it the transport of the protein out of the cell 
takes longer and therefore needs more time to be sufficiently exposed to the immune system. 
Therefore the choice of plasmid in DNA vaccines can have an influence on the immune response as 
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seen with the VR1020_oppA vaccine when compared to the pCI-neo_oppA vaccine's ability to elicit 
an anti-OppA immune response. 
There were no significant differences between antibody levels of the vaccinated subgroups and the 
control group from week 0 to week 6. Hence, no primary antibody response was elicited by any of 
the vaccine doses. A general trend was, observed for the VR1020_oppA 600 and 1200 µg/ml doses 
where average titre values increased from week 0 to week 3 followed by a decrease from week 3 to 
week 6. If a first vaccination is able to elicit a primary immune response with the formation of 
memory B cells the production of a secondary immune response (after administration of a booster) 
can generally be observed. This is due to the fact that the host will be able to recognize the same 
antigen faster and with greater magnitude than the primary immune response (Reynolds et al., 
2015). In a study done by Blignaut et al. (2000) an immune response to an inactivated vaccine in 
ostriches was only seen by day 14 with a maximum response at about 21 days. As in the case of 
both the DNA vaccines no increase in immune response was seen at week 3 for any of the 
vaccinated groups. It might be that not enough time was allowed for the production of the OppA 
protein before the administration of a booster. The inactivated vaccine as in the case of the study by 
Blignaut et al. (2000) can immediately start to activate the immune system as the antigen is already 
present. In the case of a DNA vaccine it possibly takes the antigen longer to reach the immune 
system as it still has to be expressed or it might have been expressed at levels that are too low to 
elicit an anti-OppA response during that time. As there is possibly a delay in the time that it takes 
for the antigen to be presented to the immune system it might explain why only a secondary 
immune response is observed and together with the booster results in an anti-OppA immune 
response for both the vaccines. 
As ostriches are susceptible to mycoplasma infections during seasonal changes, the health of the 
ostriches was monitored during the course of the trial (late autumn, early winter) which included 
weight measurement at week 0, 6 and 9 as well as swab sample collection and analysis of those by 
means of PCR at week 0, 3, 6 and 9. Comparing the average weight change of the vaccinated 
groups and control group over the course of the trial revealed that the birds gained weight up until 
week 6 but their weight gain decreased from week 6 to week 9 with some birds even losing weight. 
Given that this trend was also observed for the control group ostriches, the weight loss cannot be 
ascribed to either of the vaccines. After the ostriches were moved into the feedlot system problems 
were experienced in the supply of pelleted feed and they were given feed in a mashed form. 
Ostriches in feedlot systems tend not to consume feeds that they are not used to (Brand and Gous, 
2006) and the sudden introduction of the other feed resulted in them not eating with a subsequent 
lack of weight gain. It is also unlikely that the weight loss was due to the transport of the ostriches 
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since the weight loss only started to occur after two weeks in Oudtshoorn and coincided with feed 
problems.  
The PCR results revealed that none of the trial birds had infections from week 0 to 6 which might 
be ascribed to the fact that the ostriches were in Fraserburg from week 0 to week 3 where less 
infections were expected and they were still in quarantine at the week 6 sampling point in 
Oudtshoorn. The ostriches also only arrived in Oudtshoorn one week prior to the week 6 sampling 
point and therefore it is possible that the birds were not yet exposed to mycoplasmas. After the 29 
day quarantine the ostriches were moved out into a feedlot system for one week and pastured for the 
remainder of the trial. Exposure of ostriches to the rest of the farming environment resulted in low 
levels of mycoplasma infections which were detected by PCR analysis at week 9 with Ms03 and 
Ms01 infections being lower in comparison with Ms02. Mycoplasma infections are common on 
Oudtshoorn ostrich farms and especially prominent during seasonal changes. The trial was 
conducted during late autumn, early winter and therefore an increased exposure to mycoplasma 
infections was expected. Having feed problems in addition to this and birds not eating, further 
increased their susceptibility to mycoplasma infections. As their immune system was already under 
pressure as a result of the vaccination, the challenge conditions created by the feedlot system, 
weather and the feed problem possibly all had an effect on the number of infections seen during 
week 9.  
During the course of the trial some of the samples that tested positive were not actually due to 
mycoplasmas. This indicated that the general primers have some cross reactivity and that the genus 
specific primers need to be re-designed. 
In order to determine the ability of the vaccines to protect the ostriches against Ms03 infections they 
should be challenged with the pathogen. Enough time should, however, be allowed for the vaccines 
to elicit a primary and secondary anti-OppA antibody response before they are challenged with the 
pathogen. Collop (2011) showed that anti-Ms03 OppA antibodies have a low level of cross 
reactivity with the OppA protein of Ms01 but none with the OppA protein of Ms02. Therefore the 
vaccines used for this study might be able to provide limited protection against Ms01 infections but 
no protection against Ms02 infections will be provided.  
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4. Production of IgAH proteins by means of the Baculovirus-insect 
expression system  
4.1 Introduction 
Mycoplasma infections in ostriches could be controlled by using a vaccine but currently there is no 
commercially available vaccine against ostrich infecting mycoplasmas. Two DNA vaccines against 
ostrich-infecting mycoplasmas were developed by Wium (2015) and in the previous chapter we 
were able to induce an immune response using these vaccines. The DNA vaccines were however 
administered intramuscularly and as Botes et al. (2005) found that mycoplasmas target the mucosal 
surfaces in ostriches, the possibility of administering the same DNA vaccine mucosally should be 
investigated. 
A mucosal vaccine is administered to a mucosal surface mucosally (oral, eyes, nose) and should 
result in the production of IgA antibodies (Hobson et al., 2003). The ELISA technique can be used 
to measure an immune response elicited by a mucosal vaccine but requires secondary anti-IgA 
antibodies. Currently secondary antibodies against ostrich IgA is not commercially available and 
the production of such antibodies would require the isolation of ostrich IgA. Isolation of IgA from 
ostrich nasal samples is problematic and results in low yields (Botes, 2004). The process of IgA 
isolation from the ostrich can be avoided by producing the protein in vitro. For the purpose of 
producing secretory antibodies the entire protein is, however, not required but only the IgA heavy 
chain constant region (IgAH) of the ostrich. 
Immunoglobulins are known as glycoproteins containing glycosylated sites which can influence 
their function and plays a role in protection against proteolytic degradation. These modifications 
can have a structural and functional effect on the protein and have an influence on its 
immunogenicity. Ostrich IgAH contains three N-linked glycosylation sites and it is therefore 
important that an in vitro expression system can provide post-translational modifications such as 
glycosylation for applications in which the native protein is required (Huang et al., 2012; Schroeder 
and Cavacini, 2010; Zhong and Wright, 2013). The most popular expression system used to 
produce such post-translational modified proteins is the baculovirus-insect cell expression system. 
The yield produced by this expression system is larger than those of mammalian cell lines and this 
expression system is also capable of post translational modifications similar to those of higher 
eukaryotes. Therefore the baculovirus-insect cell expression system holds an advantage over 
bacterial expression systems as these systems do not have post translational modification 
capabilities (Verma et al., 1998).  
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The Sf9 insect cell line is commonly used for production of the recombinant baculovirus as it 
allows both small and large scale protein production, and can be used for virus propagation prior to 
transfection. Several baculovirus vectors are commercially available depending on the protein to be 
expressed. The ProFold

-ER1 baculovirus is specifically recommended for glycoproteins as well as 
secreted proteins since it encodes for the molecular chaperones calreticulin and protein disulfide 
isomerase (PDI). Both of these chaperones ultimately facilitate folding of the protein of interest in 
the endoplasmic reticulum (ER). Calreticulin is a lectin chaperone able to interact with 
glycoproteins whereas PDI participates in disulfide bond formation and can also fold proteins 
independently of disulfide bonds. Overexpession of PDI is also able to improve the longevity of the 
infected insect cells by about 24 h compared to cells infected with control viruses that do not 
contain PDI, as well as improve yields of secreted proteins. (Dalton and Barton, 2014; Taylor et al., 
2004; Turano et al., 2002). The ProFold

-ER1 baculovirus vector also contains the gene encoding 
Aequorea victoria green-fluorescent protein (GFP) which allows for visualising cells infected with 
the recombinant baculovirus. All of these genes are expressed during the very late stage of infection 
at about the same time as the target protein and are situated away from the polyhedrin site to avoid 
interference of strong promoters. Therefore expression of the gene of interest is not compromised 
by the expression of the PDI, Calreticulin or GFP (AB Vector, 2014). 
For insertion of the IgAH gene into a baculovirus vector a transfer plasmid is used and several 
different plasmids are commercially available. The pAB-6xHis

 transfer plasmid used in this study 
is compatible with the ProFold

-ER1 baculovirus vector and allows expression of proteins with an 
N-terminal 6xHis tag. It also contains a thrombin site for the removal of the tag after isolation of the 
protein of interest if desired. Also present in the transfer plasmid is a gene encoding ampicillin 
resistance, a bacterial origin of replication and the MCS with unique RE sites which is flanked by a 
strong polyhedrin promoter as well as the essential baculovirus orf 1629 gene which allows 
insertion of the gene to be expressed into the baculovirus vector by homologous recombination.  
The objective for this study was to evaluate the use of a baculovirus-insect expression system for 
the production of the ostrich IgAH protein. To this end the IgAH gene was sub-cloned into the pAB-
6xHis

 transfer plasmid and used to co-transfect Sf9 insect cells with the linearised viral ProFold

-
ER1 baculovirus vector for the generation of ProFold

-ER1_IgAH recombinant baculovirus. Sf9 
cells were transfected with the ProFold

-ER1_IgAH baculovirus for the production of the IgAH 
protein. The aim was then to verify the produced IgAH protein using the SDS-PAGE and western 
blot techniques. 
Stellenbosch University  https://scholar.sun.ac.za
 82 
 
4.2 Materials and Methods 
4.2.1 Sub-cloning of the IgAH gene into the pAB-6xHis

 baculovirus transfer vector 
4.2.1.1 Primer Design 
Primers were designed by using the computer program Primer Designer (version 1.0.1, Scientific 
and Educational Software) and synthesized by Integrated DNA Technologies (IDT). The primers 
were designed according to the ostrich IgAH DNA sequence obtained from the National Centre for 
Biotechnology Information (NCBI) nucleotide database (Accession number: JN709445.1). The 
forward primer (Figure 4.1) was designed to bind from base pair (bp) 1 to 18 (position 1 = start of 
sequence) and the reverse primer from bp 1277 to 1298 (end of sequence). For subsequent cloning 
into the transfer plasmid suitable restriction endonuclease (RE) sites were added to each of the 
primers. The forward primer contained the EcoRI RE recognition site whereas the reverse primer 
contained the NotI RE recognition site. Five random base pairs were added to the 5' end of each 
primer to allow for efficient cutting of the RE.  
 
Figure 4.1 The primers designed for the amplification of the IgAH gene. Forward Primer (IgA F(EcoRI)): A- 
Five added bases, B- EcoRI RE recognition site, C- Primer. Reverse Primer (IgA R(NotI)): A- Five added bases, 
B- NotI recognition site, C- Primer.  
4.2.1.2 Amplification and isolation of the IgAH gene 
The IgAH gene cloned into a pGEX-4T-1 expression vector was obtained from co-workers at 
Onderstepoort (Pretoria). The gene represented the mRNA sequence of the IgAH which consists of 
four domains including the secretory coding segment (Addendum C). The vector containing the 
IgAH gene was multiplied by making an O/N culture as described in section 3.2.2, with the use of 
LB media, and incubating the culture at 37ºC for 16-18 h on an orbital shaker (200 rpm). The 
pGEX-4T-1_IgAH was isolated from the E. coli culture by means of the Invisorb
®
 Spin Plasmid 
Mini Two kit (Invitek, Berlin). The plasmid was isolated according to the manufacturer's 
















65ºC. The concentration of the isolated pGEX-4T-1_IgAH plasmid was determined by 
means of the Nanodrop
®
 ND 1000 spectrophotometer (Novell
®
, USA). 
The gene was PCR amplified from the vector with the use of the designed primers in order to obtain 
the gene containing the RE recognition sites. For amplification, the optimal annealing temperature 
of the designed primers was firstly determined by using different annealing temperatures of 66ºC, 
64ºC, 62ºC, 60ºC, 58ºC and 56ºC. The IgAH gene was then PCR amplified form the pGEX-4T-1 
plasmid using the following reaction conditions: 5 µl 5x Fidelity buffer, 0.75 µl dNTP's (10 mM), 
0.75 µl IgA_F(EcoRI) forward primer (10 µM), 0.75 µl IgA_R(NotI) reverse primer (10 µM), 1 µl 
plasmid DNA (130.9 ng/µl diluted 1:20 in Milli-Q
® 
water), 0.5 µl KAPAHifi DNA polymerase (1 
U/µl) (Roche, RSA) and Milli-Q
® 
water to a final volume of 25 µl. The parameters of the Veriti

 96 
Well Thermal Cycler (Applied Biosystems) used were as follow, an initial step of 5 min (95°C), 
followed by 25 cycles of 20 sec (98°C), 15 sec (66°C), 40 sec (72°C) with a final step (single cycle) 
for 5 min (72°C) followed by cooling to 15°C. The PCR products were analysed on a 1% agarose 
gel containing EtBr (0.5 µg/ml) for visualisation of the products under UV light. Depending on the 
size of the agarose gel used, PCR products were electrophoresed in 1x TAE buffer at 80 Volts (V) 
for a 3 cm x 10 cm gel, 90 V for a 7 cm x 10 cm gel and110 V for a 10 cm x 15 cm gel. 
In order to produce a larger yield of the IgAH gene for RE-digestion and subsequent cloning the 
PCR reaction was scaled up to a final volume of 100 µl using the same PCR parameters as before. 
Due to non-specific binding of the primers the PCR product had to be excised and cleaned from the 
agarose gel. The total volume of PCR product was therefore loaded on to a 0.5% agarose gel 
containing EtBr (0.5 µg/ml) and electrophoresed (120 V). The IgAH gene with a size of 
approximately 1300 bp was excised from the gel and purified using the GFX PCR DNA and Gel 
Band Purification Kit (GE Healthcare, Sweden) as per manufacturer's instructions except for the 
elution step where Milli-Q
®
 was used to elute the product. The concentration of the purified product 
was determined using a Nanodrop
®
 ND 1000 spectrophotometer (Novell
®
, USA) and the product 
analysed on a 1% agarose gel containing 0.5 µg/ml EtBr for visualisation in order to determine if 
the purification step was able to remove all non-specific PCR products. The agarose gel was 
electrophoresed as previously described. 
4.2.1.3 Restriction enzyme digestion of the pAB-6xHis transfer plasmid and IgAH gene 
The pAB-6xHis

 transfer plasmid (AB vector, USA) was kindly provided by Prof. Pieter Swart 
(Department of Biochemistry, Stellenbosch University) in E. coli JM109 cells (Promega, USA). An 
O/N culture was made as in section 3.2.2 of the E. coli JM109 cells containing the pAB-6xHis

 
transfer plasmid in order to increase the plasmid concentration. The plasmid was isolated and the 
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concentration determined by means of the Nanodrop
®
 ND 1000 spectrophotometer (Novell
®
, USA). 
This was followed by a double digestion of the isolated pAB-6xHis
 
transfer plasmid using the 
EcoRI and NotI RE's. The reaction contained 2 µl 10x FastDigest buffer (Fermentas), 11.6 µl 
plasmid DNA (pDNA) (86.4 ng/µl), 1 µl NotI , 1 µl EcoRI and 4.4 µl Milli-Q
® 
water adding up to a 
total volume of 20 µl. The reaction mixture was incubated at 37ºC for 13 min followed by a 5 min 
heat inactivating step at 80ºC. Purification of the reaction mixture was done by means of the DNA 
Clean & Concentrator

-5 Kit (Zymo Research, USA) according to the manufactures instructions. 
This was followed by dephosphorylation of the digested plasmid product by means of shrimp 
alkaline phosphatase (SAP, Promega) in a reaction containing 3 µl 10x Reaction buffer for SAP, 1 
µl SAP (1 U/µl), 5.7 µl digested plasmid (after cleanup) and 20.3 µl Milli-Q
® 
water. The reaction 
mixture was incubated for 15 min at 37ºC. 
The isolated PCR product of the IgAH gene was also double digested with the BamHI and NotI RE 
in a reaction mixture containing 4 µl 10x FastDigest buffer (Fermentas), 3.4 µl IgAH gel purified 
PCR product (145.2 ng/µl), 1 µl BamHI, 1 µl NotI and 30.6 µl Milli-Q
® 
water. The reaction mixture 
was incubated at 37 ºC for 13 min and heat inactivated at 80ºC for 5 min followed by purification 
with the DNA Clean & Concentrator

-5 Kit (Zymo Research, USA) as per manufactures 
instructions. 
4.2.1.4 Ligation of the IgAH gene and the pAB-6xHis

 transfer plasmid and transformation into E. 
coli JM109 cells 
The IgAH gene was ligated into the pAB-6xHis

 transfer plasmid using a vector to insert ratio of 1:1 
and 1:3. The 1:1 reaction contained 4.1 µl pDNA (24.6 ng/µl), 0.3 µl insert DNA (42 ng/µl), 1 µl 
10x Ligase buffer, 1 µl T4 DNA ligase (Promega) and 3.6 µl Milli-Q
®
 water. The 1:3 reaction 
contained 4.4 µl pDNA (22.6 ng/µl), 0.9 µl insert DNA (42 ng/µl), 1 µl 10x Ligase buffer, 1 µl T4 
DNA ligase and 2.7 µl Milli-Q
® 
water. The reactions were incubated at 4ºC O/N.  
Each of the ligated plasmid products were transformed into E. coli JM109 (Promega, USA) 
competent cells as follows: the JM109 cells were removed from the -80ºC freezer and allowed to 
thaw on ice. The cells were mixed and 50 µl pipetted into chilled 14 ml Falcon
®
 tubes followed by 
the addition of 5 µl of either the 1:1 or 1:3 ligation products. The contents of the tubes were gently 
mixed by flicking the tube and incubated on ice for 20 min. Subsequently, a 42ºC water bath was 
used in order to heat shock the cells for 45 sec followed by 2 min incubation on ice. LB medium 
(950 µl; 10 g/L Bacto-Tryptone, 5 g/L yeast extract, 5 g/L NaCl, pH7) was added to the Falcon
®
 
tubes containing the transformation product and incubated at 37ºC for 1 h 30 min on a orbital shaker 
(200 rpm). The incubated cells were plated on LB plates containing agarose (15 g/L) as well as 1 
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µl/ml ampicillin (100 mg/ml), by spreading 100 µl of the transformation product on a plate for each 
of the 1:1 and 1:3 reactions respectively. The rest of the transformation product was concentrated by 
means of centrifugation at 10 000 x g for 10 min and 600 µl of the supernatant discarded. The 
pellets were resuspended in the remaining supernatant and 50 µl and 100 µl of concentrated 
samples spread on a plate respectively. This was repeated for the 1:1 and 1:3 transformation 
products. All the agar plates were incubated for 16-18 h at 37ºC. Colonies which formed on the agar 
plates were analysed by means of colony PCR as previously described with the only exception 
being the pAB-6xHis

 primers pHF and mR (Table 4.1) which was used instead of the pGEX_F 
and T7_R primers.  
O/N cultures were made from the colonies that contained the plasmid with insert as confirmed by 
the colony PCR. This was done by scraping the colony from the plate by means of a sterile 
toothpick and adding it to 5 ml of LB medium in a Falcon
®
 tube containing 5 µl ampicillin (100 
mg/ml) followed by incubation for 16-18 h at 37ºC on an orbital shaker (200 rpm). The pAB-
6xHis

_IgAH was isolated from the O/N culture as previously described. The isolated pAB-
6xHis

_IgAH was digested with NotI and EcoRI RE's to confirm that the plasmid did indeed contain 
the IgAH insert. The reaction mixture contained 1 µl 10x FastDigest buffer, 0.5 µl NotI RE, 0.5 µl 
EcoRI RE, 3 µl pDNA (130.6 µg/µl) and 5 µl Milli-Q
®
 water. The reaction was incubated for 13 
min at 37 ºC followed by a heat inactivation step for 5 min at 80 ºC. The product was purified by 
means of the DNA Clean & Concentrator

-5 Kit (Zymo Research, USA) and analysed on a 1% 
agarose gel containing EtBr (0.5 µg/ml) for visualisation.  
Isolated pAB-6xHis

_IgAH insert was also sequenced to confirm that the IgAH insert had the correct 
orientation and sequence. The sequencing reactions contained 1 µl BigDye
®
 Terminator mix (v3.1, 
Applied Biosystems, USA), 3 µl Half-Dye Mix (Bioline, UK), 3 µl pDNA (300 ng) and 3 µl pHF 
forward primer (3.3 pmol/µl). For the reverse sequence reaction the same components at the same 
concentrations were used with the exception that only the mR reverse primer was used. The 
parameters of the Veriti

 96 Well Thermal Cycler (Applied Biosystems) was set to 35 cycles of 
96ºC (10 sec), 52ºC (30 sec), 60ºC (4 min) and a final step of 60ºC (10 min) followed by a cooling 
step to 15ºC. The samples were then sent to the Central Analytical Facility (CAF) DNA sequencing 
unit of the University of Stellenbosch, South Africa for analyses using an ABI® 3100 Genetic 
Analyser (Applied Biosystems, USA). The resulting sequences were analysed by aligning the 
obtained sequence to the IgAH sequence from NCBI (Accession number: JN709445.1) by means of 
the BioEdit sequence alignment editor (version 7.2.5).  
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Table 4.1 Primer sequences for the pAB-6xHis

 transfer plasmid 










 3945-3973 bp 
(AB Vector, 
2014) 
mR 5'- CGTGTCGGGTTTAACATTACGGATT-3' pAB-6xHis
 4284-4308 bp 
(AB Vector, 
2014) 
Primers provided by Prof Pieter Swart (Department of Biochemistry, Stellenbosch University) 
* According to the pAB-6xHis

 transfer plasmid map as supplied by AB vector. 
4.2.2 Culturing insect host cell line 
4.2.2.1 Monolayer cultures 
An aliquot of Spodoptera frugipedra (Sf9) cells stored in liquid nitrogen was kindly supplied by 
Prof. Pieter Swart (Department of Biochemistry, University of Stellenbosch). Cell densities were 
first determined by counting the cells with a haemocytometer (Neubauer) and cell viability was 
assessed by the Tryptan Blue exclusion method (Johnson et al., 2013). In order to count the cells the 
aliquot was thawed in a 28ºC water bath and 20 µl of cells were mixed with 20 µl 0.4% Trypan 
Blue solution (Life Technologies,USA) and 20 µl of this mixture pipetted into a haemocytometer 
(Neubauer). The cells were counted by means of a microscope (Olympus CKX 41) at a 





complete TNM-FH medium (named after Dr. W.F. Hink who modified Grace's medium for the 





 tissue culture flasks (Greiner bio-one) and grown as monolayers in a non-
humidified, ambient air-regulated incubator at 27ºC. Passages of the monolayers were performed at 
90-95% confluency by dislodging the cells, with a method known as sloughing, from the surface of 
the 75 cm
2
 tissue culture flask and counting the cells as well as assessing the cell viability of the 





 (dilutions made with complete TNM-FH media) in a new 75 cm
2
 tissue culture flask and 
incubated as before. 
The complete TNM-FH medium consisted of Grace's insect cell culture medium containing L-
glutamine (Gibco
®
, Life Technologies) which was supplemented with 10% fetal bovine serum 
(FBS) (Biochrom: FBS superior, standardized (cat no. S0615, Merck)), 3.303 g/L lactalbumin 
hydrolysate (Sigma), 3.330 g/L yeastolate (BD Biosciences), 0.35 g/L sodium bicarbonate (Sigma), 
100 U/ml Penicillin-Streptomycin (PenStrep) (Sigma), 10 µg/ml gentamicin (Sigma) and 0.25 
µgl/ml amphotericin B (Gibco
®
, Life Technologies). The media was prepared by adding Grace's 
insect cell culture powder (Gibco
®
, Life Technologies) to a 1 L Schott bottle containing 700 ml 





water. This was followed by the addition of 3.303 g of lactalbumin hydrolysate, 
3.330 g yeastolate and 0.35 g sodium bicarbonate. The pH was set to 6 and sterile Milli-Q
® 
water 
was added to a final volume of 1 L. The medium was passed through a glass fiber prefilter (Merc) 






pump (Millipore). A sample was taken from the media and incubated at 37ºC to ensure that it was 
sterile. Subsequently complete TNM-FH media was prepared by adding FBS, gentamicin, 
amphotericin B and PenStrep to the prepared media and stored at 4ºC. 
4.2.2.2 Suspension cultures 
After about three passages in which regular exponential growth with viability of greater than 90% 
was obtained with the monolayer cultures, they were transferred to an Erlenmeyer flask to form a 
suspension culture. A minimum density of 0.5 x 10
6
 cells/ml is required to start a suspension culture 
from an adherent culture and therefore 0.5 x 10
6 
cells/ml were suspended in 70 ml complete TNM-
FH medium in a sterile 150 ml Erlenmeyer flask containing 0.1% Pluronic® F-68 (Gibco, Life 
technologies). The cultures where agitated continuously at 120 rpm at 27ºC (Ecotron, Infors HT) 
and passaged to cell densities of 3 x 10
5
 cells/ml until they reached a density of 2 x 10
6 
to 4 x 10
6
 
cells/ml after 3-4 days. Passages were done by using the haemocytometer and Trypan Blue 
exclusion method as described previously to determine the amount of cells and their viability. They 
were subsequently again seeded at the recommended cell densities in complete TNM-FH media in a 
150 ml Erlenmeyer flask. 
4.2.3 Production of the recombinant virus by means of co-transfection of Sf9 cells 
4.2.3.1 Preparation of Sf9 monolayers 
Sf9 monolayers were prepared from suspension cultures by seeding a 9.6 cm
2 
6-well cell culture 





 per well to obtain 60% confluency for efficient baculovirus replication. The cells were 
incubated at 27ºC in a non-humidified ambient air-regulated incubator for 1 h in order for the cells 
to attach to the surface of each well. Following the incubation period the TNM-FH medium was 
removed and each well washed twice with 1 ml 1 x PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.2) for the removal of residual FBS and antibiotics. 
Incomplete TNM-FH media (2 ml) containing L-glutamine and sodium bicarbonate but no FBS or 
antibiotics, were added to each well.  
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4.2.3.2 P0 virus production by homologous recombination and co-transfection 
A DNA-profectin mixture was prepared in a 1.5 ml Eppendorf tube by adding 5 µl ProFold

-ER1 
linearised baculovirus DNA (AB vector) to 100 ng pAB-6xHis

_IgAH plasmid and adding sterilized 
Milli-Q
® 
water to a final volume of 50 µl. The ProFectin
 
transfection reagent (AB vector) was 
prepared by diluting it 1:10 in Milli-Q
®
 water to a final volume of 50 µl. This was then added 
dropwise to the mixture of ProFold

-ER1 linearised baculovirus DNA and pAB-6xHis

_IgAH 
plasmid resulting in a final volume of 100 µl. The DNA-ProFectin

emulsion was added dropwise 
to the monolayer of insect cells in the 6-well plate (100 µl per well). The controls included a No 
control (NC) and Green control (GC) (AB vector). NC virus is a negative control which is identical 
to the wild type Autographa californica nuclearpolyhedrosis virus with the only exception being 
that it does not express polyhedrin or any other protein (AB vector). GC virus which is positive 
control, expresses Aequorea victoria green-fluorescent protein (GFP) which can be used for 
detection of virus propagation (AB vector). Of each control, 10 µl was added to two wells of the 6-
well plate respectively. Three of the wells did not receive any virus and was referred to as the 
untransfected (UT) wells. This was followed by incubation at 27ºC for 24 h before the addition of 1 
ml complete TNM-FH media containing 10% FBS and antibiotics. The 6-well plate was incubated 
for a further 60 h at 27ºC. After 60 h the monolayer was gently resuspended by pipetting the media 




 tissue culture flasks 
(Greiner bio-one) containing 5 ml complete TNM-FH medium for each sample. These flasks were 
incubated for 4 days at 27ºC. Following the 4 day incubation the virus containing medium was 
transferred to a 15 ml Falcon
®
 tube and centrifuged (Eppendorf Centrifuge 5702) at 376 x g for 15 
min. The supernatant containing the P0 virus was transferred to a sterile 15 ml Falcon
®
 tube and 
stored at 4ºC protected from light. 
4.2.4 Production of higher titer P1 virus 
As initial P0 virus stocks are of a titer which is too low for protein expression studies they have to 
be amplified. Therefore a T75 flask was seeded with Sf9 cells from a monolayer culture in complete 




 to obtain a confluency of 25%. P0 virus stock (500 µl) was 
added to the monolayer and incubated for 4 days at 27ºC. After 4 days the media of these cultures 
which contained the P1 virus stock could be harvested. The media containing the virus was 
transferred to a 15 ml Falcon
®
 tube and centrifuged (Eppendorf centrifuge 5702) at 1500 rpm for 15 
min. The supernatant (P1 virus stock) was transferred to a sterile 15 ml Falcon
®
 tube and stored at 
4ºC protected from light.  
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4.2.5 Production of protein on small scale 
Sf9 suspension culture cells that reached a cell density of between 2 x 10
6
- 4 x 10
6
 was used to seed 




(95% confluency) in 2 ml complete TNM-FH medium per 
well and incubated for 1 h at 27ºC. Three wells were infected with 200 µl P1 virus. Two of the 
wells were infected with 20 µl GC and NC respectively. The last well was not infected with any 
virus and served as an UT control. The plate was incubated at 27ºC and the ProFold-ER1

_IgAH 
transfected samples were collected at 48 h, 60 h and 72 h respectively. The GC, NC and UT 
samples were collected at 60 h.  
Samples were collected by firstly removing the medium from each well and transferring it to a 2 ml 
Eppendorf tube followed by centrifugation for 3 min at 376 x g. The supernatant was then removed 
and represents the media which were also kept for analysis. The pellet represents the cells that were 
already dislodged from plate where the recombinant protein is expected. Secondly, each well was 
washed with 1 ml PBS buffer which was transferred from the well to the Eppendorf tube containing 
the pellet and used to resuspend the pellet. The resuspended pellet was again centrifuged at 376 x g 
for 3 min followed by discarding of the supernatant. To each of the wells 100 µl lysis buffer (50 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA and 0.5% Triton X 100) was added which was 
used to dislodge the monolayers. The dislodged monolayer was transferred again to the Eppendorf 
tube containing the pellet followed by resuspension of the pellet (this was done for each of the 
wells). The samples were stored at -20ºC until further analysed.  
4.2.6 Verification of the expressed IgAH proteins by means of western blot 
4.2.6.1 Western Blot with anti-HisProbe-HRP antibodies 
All of the samples containing the expressed protein were analyzed on a SDS-PAGE gel as in section 
3.2.7.2. The only exception was that 30 µl of the 60 h and 72 h samples were centrifuged for 15 min 
at 17 000 x g. The supernatant was transferred to a 1.5 ml Eppendorf tube containing 30 µl 
treatment buffer and12 µl loading dye. The pellet was resuspended in 30 µl treatment buffer and 12 
µl loading dye was added. The GC, NC, UT and 48 h samples were handled as in section 3.2.7.2 but 
all samples were boiled for 13 min instead of 3 min. The samples were loaded (15 µl of each 
sample) onto a SDS-PAGE gel and the gel was electrophoresed as in section 3.2.7.2. 
Proteins were transferred from a 12% SDS-PAGE gel (as described in section 3.2.7.2 ) to a 0.45 µm 
nitrocellulose membrane (Schleicher & Schuell, Sigma) by electrophoresis (up to 1 A; 25 V for 30 
min) using the Trans-Blot
®
 Turbo Blotting System (Bio-rad). The nitrocellulose membrane was 
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placed in blocking buffer (25 mM Tris-base, 0.15 M NaCl, pH7.2 containing 10% BSA) to block 
non-specific binding, for 1 h at RT with agitation (Gyro Twister, Labnet). The membrane was 
washed twice with Tris-buffered saline containing Tween (TBST) (25 mM Tris-base, 0.15 M NaCl 
and 0.05% Tween
®
 20, pH 7.2) for 10 min each at 37ºC with agitation (hybridization oven/shaker, 
USA) This was followed by the addition of the HisProbe-HRP (Thermo Scientific) working 
solution (HisProbe diluted 1:5000 in blocking buffer) and incubation for 1 h at 37ºC with agitation. 
The HisProbe-HRP working solution was discarded and the membrane was washed four times in 
TBST buffer for 10 min each at 37ºC with agitation. The membrane was subsequently developed 
for 2 sec to 30 min in a solution containing 0.05% (w/v) 4-chloro-1-naphthol, 16% (v/v) methanol, 
30 ml 1xPBS and 0.025% (v/v) H2O2.  
4.2.6.2 Western Blot with rabbit anti-IgA antibodies 
Proteins were transferred from a SDS-PAGE gel as in section 4.2.6.1 and the membrane was 
washed in PBS-Tween (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.5 mM KH2PO4, pH 
7.2 containing 0.1% (v/v) Tween
®
 20) for 10 min at 37ºC with agitation (hybridization oven/shaker, 
USA). The PBS-Tween was removed and non-specific binding was blocked by incubating the blot 
in casein buffer (10 mM Tris-HCl, 154 mM NaCl, 0.5% fat-free milk powder and 0.02% 
Thimerosal, pH 7.6) for 1 h at 37ºC with agitation (hybridization oven/shaker, USA). Following the 
blocking step the membrane was washed three times with PBS-Tween for 5 min each at 37ºC with 
agitation. Rabbit anti-ostrich IgA diluted 1:500 in casein-Tween (casein buffer, pH 7.6 containing 
0.1% (v/v) Tween
®
20), was added to the membrane and incubated O/N at 4ºC with agitation on a 
Gyro Twister (Labnet). The anti-ostrich IgA antibodies were provided by Dr. A. Botes, Department 
of Biochemistry, Stellenbosch University and were previously developed against IgA isolated from 
ostrich nasal secretions.  
Following incubation with the primary antibody the membrane was washed three times with PBS-
Tween for 5 min each at 37ºC with agitation. Subsequently goat anti-rabbit IgG (Sigma) diluted 
1:500 in casein-Tween was added to the membrane and incubated for 1 h at 37ºC with agitation. 
The membrane was washed three times with PBS-Tween for 5 min at 37ºC with agitation. This was 
followed by the addition of peroxidase anti-peroxidase (PAP) soluble complex antibody produced 
in rabbit (diluted 1:500 in casein-Tween) which was incubated for 1 h at 37ºC with agitation. The 
PAP was removed after the hour incubation and the membrane washed three times with PBS-Tween 
for 5 min each at 37ºC with agitation. This was followed by the development of the membrane as 
described in section 4.2.6.1. 
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4.2.7 PCR amplification of insert obtained in the P1 recombinant virus 
The gene inserted into the ProFold

-ER1 baculovirus vector was PCR amplified from the 
recombinant ProFold

-ER1_IgAH P1 stocks, with the use of the pHF and mR primers. Four 
microliter of the P1 virus stocks were added to 25 µl GES buffer (0.1 M glycine-NaOH, pH 9.0, 50 
mM NaCl, 1 mM EDTA, pH 8.0, 0.5% (v/v) Triton X-100) respectively and boiled at 95ºC for 10 
min. This virus sample mixture was used in the following reaction conditions: 1 µl 10x reaction 
buffer, 0.4 µl dNTP's (5 mM), 0.6 µl MgCl2 (25 mM), 0.5 µl pHF (20 pmol/µl), 0.5 µl mR (20 
pmol/µl), 0.1 µl Super-Therm polymerase (5 U/µl), 1.5 µl virus sample mixture and 5.4 µl Milli-Q
® 
water. The parameters for the Veriti

 96 Well Thermal Cycler (Applied Biosystems) used were as 
follow, an initial step of 5 min (95ºC), followed by 25 cycles of 20 sec (98ºC), 15 sec (58ºC), 40 sec 
(72ºC) with a final step (single cycle) of 5 min (72ºC) followed by cooling to 15ºC. The PCR 
products were analysed on a 1% agarose gel containing EtBr (0.5 µg/ml) for visualisation of the 
products under UV light and electrophoresed as in section 4.2.1.2. 
4.3 Results 
4.3.1 Sub-cloning of the IgAH gene into the pAB-6xHis

 baculovirus transfer vector 
4.3.1.1 Amplification and isolation of the IgAH gene 
The IgAH gene could be amplified successfully with all the annealing temperatures as indicated by 
the red block in Figure 4.2 A. The PCR product amplified with an annealing temperature of 66ºC 
(lane 1) yielded the brightest band at a size of 1300 bp representing the IgAH gene, indicated in the 
red block, which indicates a higher concentration, with the least non-specific binding as the 
surrounding bands are lighter. The annealing temperature of 66ºC was therefore used to amplify the 
IgAH gene and the gene was successfully isolated from the 0.5% agarose gel as a single band could 
be seen in Figure 4.2 B with a size of 1300 bp after purification. 




Figure 4.2 1% Agarose gel showing the results of the PCR amplification of the IgAH gene using the pGEX_IgAH 
plasmid as template. (A) Optimization of annealing temperatures. MM: GeneRuler

 (Fermentas), Lane 1: 
Annealing temperature 66ºC, Lane 2: Annealing temperature 64ºC, Lane 3: Annealing temperature 62ºC, Lane 4: 
Annealing temperature 60ºC, Lane 5: Annealing temperature 58ºC, Lane 6: Annealing temperature 56ºC. (B) PCR 
product excised and purified from the agarose gel. MM: GeneRuler

 (Fermentas), Lane 1: Isolated IgAH with size 
of 1300 bp. 
4.3.1.2 Restriction enzyme digestion of the pAB-6xHis transfer plasmid and IgAH gene 
The pAB-6xHis

 transfer plasmid (9698 bp) was successfully increased and digested by the 
selected enzymes as shown in Figure 4.3 in lane 4-7 as the digested plasmid produced a band at 
about 10 000 bp on a agarose gel. The digestion of the IgAH gene (1298 bp) as in lane 1-3 of Figure 
4.3 did not result in more than one band. This indicates that the gene only contained one digestion 
site for each of the enzymes as incorporated during the amplification of the gene by means of the 
designed primers and the gene of interest was not cut at unwanted sites.  
 
Figure 4.3  Products produced after digestion and cleanup of the IgAH gene and pAB-6xHis
 plasmid as analysed 
on a 1% agarose gel. MM: GeneRuler

 (Fermentas), Lane 1-3: Digested IgAH, Lane 4-7: Digested pAB-6xHis
 
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4.3.1.3 Ligation of the IgAH gene and the pAB-6xHis

 plasmid 
The colony PCR confirmed the presence of the IgAH gene in most of the plasmids of the tested 
colonies as shown in Figure 4.4. Representing the IgAH gene a band of 1600 bp was obtained for all 
of the tested colonies except the ones in lanes 4 and 11. Therefore cloning of the IgAH gene into the 
pAB-6xHis

 plasmid by means of restriction enzymes was successful. The positive control used, 
which is represented in lane 2, was only the pAB-6xHis

 plasmid without any insert as confirmed 
by the band of 400 bp. The negative control in lane 1 did not result in any band. Sequencing results 
also confirmed that the pAB-6xHis

 transfer plasmid contained the correct sequence representing 
the IgAH gene.  
 
Figure 4.4 Colony PCR products on a 1% agarose gel. MM: GeneRuler

 (Fermentas), Lane 1: Negative Control, 





_IgAH was also digested with EcoRI and NotI to ensure that the insert was indeed 
the IgAH gene with a size of 1300 bp. As indicated in Figure 4.5 only two bands were seen on the 
gel namely the 10 000 bp representing the pAB-6xHis

 plasmid and a band at 1300 bp representing 
the IgAH gene. 
 
Figure 4.5 1% agarose gel of the RE digested pAB-6xHis_IgAH plasmid.MM: GeneRuler

 (Fermentas), Lane 1-
2: pAB-6xHis_IgAH plasmid digested with NotI and EcoRI resulting in two bands. 















MM 1  2   3
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4.3.2 Production of the recombinant virus by means of co-transfection of Sf9 cell 
Cells were considered as infected when they became enlarged and non-adherent as compared to the 
UT control with smaller cells that still adhered to the surface of the plate. As the virus needs to be in 
a circular form to be able to infect cells it was assumed that the double homologous cross over event 
took place and that the ProFold

-ER1 baculovirus vector contained the IgAH gene. Without the 
double homologous cross over event taking place the virus would still be linear and not able to 
infect the cells. Therefore enlargement of the cells would be highly unlikely. It was also visible that 
the cells were infected as indicated in Figure 4.6 A and B as they appeared black under UV due to 
the expression of GFP, as compared to the NC in Figure 4.6 C which had no black cells. 
 
Figure 4.6 Cells infected with (A) the ProFold

-ER1_IgAH virus, (B) GC and (C) NC virus. The cells that were 
infected by the ProFold

-ER1_IgAH and GC viruses appear black under UV due to the expression of GFP by the 
viruses. 
4.3.3 Production of protein on small scale 
The IgAH protein (46.5 kDa) was expected to be 51.6 kDa including the 6xHis-tag and thrombin 
site. After 48 h, 60 h and 72 h a protein product was observed between 46-58 kDa on the SDS-
PAGE gel (indicated by the arrow for lanes 4-8 in Figure 4.7) which was not present in the control 
samples (Lane 1-3).  
 
Figure 4.7 12% SDS-PAGE analysis of the IgAH protein expressed by means of the baculovirus-insect expression 
system. MM: Color Prestained Protein Standard, Broad Range (BioLabs
®
 Inc., New England). Lane 1: GC after 
60 h. Lane 2: NC after 60 h. Lane 3: UT after 60 h. Lane 4: 48 h expression of IgAH. Lane 5: 60 h expression of 
IgAH, supernatant after centrifugation. Lane 6: 60 h expression of IgAH, pellet after centrifugation. Lane 7: 72 h 





MM 1      2       3      4      5       6     7      8
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4.3.4 Verification of the expressed IgAH proteins by means of western blot 
4.3.4.1 Western Blot with anti-HisProbe-HRP antibodies 
The same band as in Figure 4.7, indicated by the arrow (between 38 kDa and 52 kDa), was also 
visible in lanes 2-4 in Figure 4.8 as detected by the HisProbe-HRP antibodies during western blot 
analysis.  
 





). Lane 1: NC after 60h. Lane 2: 48 h expression of IgAH. Lane 3: 60 h expression 
of IgAH. Lane 4: 72 h expression of IgAH. 
 
4.3.4.2 Western Blot with rabbit anti-IgA antibodies 
Western blot analysis using the anti-ostrich IgA antibody resulted in a product of the same size as 
the western blot analysis with the HisProbe-HRP antibody as shown in Figure 4.9 between 38 kDa 
and 52 kDa, lanes 2-4 indicated by the arrow. Other bands seen in Figure 4.9 can be ascribed to 
non-specific binding as these bands are also visible in lane 1 which is a control sample. 
 





). Lane 1: NC after 60h. Lane 2: 48 h expression of IgAH. Lane 3: 60 h expression 
of IgAH. Lane 4: 72 h expression of IgAH. 
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4.3.5 PCR amplification of insert in the P1 recombinant virus 
The PCR product amplified from the ProFold

-ER1_IgAH recombinant virus was 1600 bp as shown 
in Figure 4.10 lanes 4-9. The 1600 bps band correspond with the size of the IgAH gene, thus 
homologous recombination was successful. 
 
Figure 4.10 1% agarose gel of PCR products amplified form the ProFold

-ER1_IgAH recombinant virus. MM: 
Generuler

(Fermentas), Lane 1: negative control. Lane 2: Positive control (pAB-6xHis

_IgAH). Lane 3: open. 
Lane 4-9: PCR product obtained from P1 ProFold

-ER1_IgAH recombinant virus.  
 
4.4 Discussion 
Administering a vaccine mucosally may result in an IgA immune response which can be measured 
by means of ELISA. Secondary antibodies are, however, necessary for this technique and as the 
focus of this study is ostriches, IgA needs to be isolated form ostrich samples for the production of 
such secondary antibodies. However, since the class of antibody is determined by the heavy chain 
of the antibody it is not necessary to use the entire antibody for the production of these secondary 
antibodies. 
In this study the gene representing the heavy chain constant region of the IgA antibody (IgAH) was 
inserted into the ProFold

-ER1 virus. The recombinant ProFold

-ER1_IgAH virus was used to 
infect Sf9 cells and the protein of interest was produced. It was however not clear from the SDS-
PAGE gel (Figure 4.7) that the IgAH protein was produced, which might have been due to a low 
yield. A PCR was done to amplify the IgAH gene from the ProFold

-ER1 virus to confirm that the 
gene of interest was present in the ProFold

-ER1 virus. However, the P0 stock had a virus titer that 
was too low for detection and the PCR was done with the P1 virus stock. The GES buffer was used 
in the PCR protocol as it improved viral template release (La Notte et al., 1997), and a band was 
amplified form the ProFold

-ER1 virus which corresponded with the band size obtained from 
colony PCR. This confirmed that homologous recombination occurred successfully and that the 
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gene of interest was successfully cloned into the ProFold

-ER1 virus. Furthermore GFP expression 
was also observed which indicated that the virus was producing the protein of interest. Western blot 
analysis confirmed expression of the IgAH protein yielding a band between 38 kDa and 52 kDa as 
detected by HisProbe-HRP and rabbit anti-ostrich IgA antibodies. 
The size observed on the western blot with both the HisProbe-HRP and rabbit anti-ostrich IgA 
antibodies deviated slightly from the expected size of the IgAH protein. As homologous 
recombination was successful and the IgAH gene was present in the ProFold

-ER1 virus the size 
difference observed might be ascribed to glycosylation or other post-translational modifications. 
Glycoproteins behave aberrantly on SDS-PAGE gels (Roy and Kumar, 2014) and it was found in a 
study by Barnett et al. (1994) that the electrophorectic ability of the protein can vary due to 
glycosylation. It is therefore concluded that the IgAH protein was successfully expressed. In order to 
isolate the IgAH protein in sufficient quantities the virus should be amplified and more cells should 
be infected for an increased production of the IgAH protein.  
As IgAH protein production was successful and anti-ostrich IgA antibodies were able to detect the 
protein, it is confirmed that the protein representing the IgAH can still be detected by anti-ostrich 
IgA antibodies. Conversely therefore, using the IgAH protein for the production of secondary 
antibodies should be successful and will ensure a reproducible source to use for the production of 
secondary antibodies. 
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5. Concluding remarks and future perspectives 
The first objective of this study was to re-evaluate two previously developed DNA vaccines against 
Mycoplasma nasistruthionis sp. nov. str. Ms03 in a vaccination trial to determine the ability of the 
vaccines to elicit an immune response in ostriches. No statistically significant primary immune 
responses were elicited by either of the vaccines whereas a secondary immune response was elicited 
by both vaccines at all of the doses except for the pCI-neo_oppA 1200 µg/ml dose. This is an 
indication that the booster administration is important in eliciting adequate immune responses 
against the vaccines. Adequate time should be given for the production of both primary and 
secondary immune responses against the vaccines to ensure the development of immune memory. 
The ability of the vaccines to protect ostriches against Ms03 infections should however be 
established by challenging the ostriches with the pathogen. 
DNA vaccine responses were evaluated by means of the ELISA technique which required isolation 
of recombinant OppA protein for coating of the ELISA plate. The recombinant OppA protein was 
isolated by means of affinity chromatography, but more than one batch had to be isolated since the 
yield of isolated OppA was not high enough for evaluation of all serum samples. Although an 
increase in incubation time on the column during the binding step resulted in a higher yield of 
OppA proteins, increasing the incubation time even further should be considered in future isolation 
attempts. This might result in a high enough yield of isolated OppA to allow for all ELISA analysis 
using a single batch of isolated protein. This will ensure additional consistency and accuracy.  
Since mycoplasmas infect the mucosal surfaces of the ostrich respiratory tract, mucosal 
administration of the DNA vaccines should also be considered. The immune response elicited will 
be a mucosal immune response, and therefore IgA needs to be measured by ELISA. The second 
objective of this study was therefore to produce IgAH antibodies in the baculovirus-insect 
expression system. Sub-cloning of the IgAH gene was successful and following homologous 
recombination between the virus and transfer plasmid containing the IgAH gene, the recombinant 
virus containing the IgAH gene was produced.  
The IgAH protein was successfully expressed by means of the baculovirus-insect system as verified 
by western blot analysis but expression levels were low. However, large amounts of IgAH are not 
required for vaccination of rabbits and may therefore be adequate. To increase expression levels the 
ProFold

-ER1_IgAH virus should be titrated in order to infect Sf9 insect cells at the correct 
multiplicity of infection for effective amplification of the virus as well as to increase expression of 
the IgAH protein for subsequent isolation by means of immobilised metal affinity chromatography 
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(IMAC). As the previously produced rabbit anti-ostrich IgA antibodies were able to detect the IgAH 
protein during western blot analysis, secondary antibodies produced in the rabbit against the IgAH 
protein should not influence the ability of the ELISA to detect the IgA antibodies elicited against a 
mucosal vaccine. The IgAH protein produced in insect cells can therefore be administered to the 
rabbit for production of secondary antibodies for future use in the ELISA technique to assess 
mucosal IgA immune responses in mucosally vaccinated ostriches.   
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7.1 Addendum A 
This addendum contains the results of the statistical analysis as obtained using Agrobase 
Generation II
®
 for the ostrich vaccination trial data. 
The humoral anti-OppA response elicited by the ostriches vaccinated by either pCI-neo_oppA or 
VR1020_oppA vaccines were analysed by means of ELISA with a 1:100 and 1:500 serum dilution 
factor. The ELISA results obtained for both the dilution factors was used for an analysis of variance 
(ANOVA) calculation and subsequent least significant difference (LSD) calculations. An ANOVA 
and LSD calculation was also done for the weight data. 
ANALYSIS OF VARIANCE 
pCI-neo 1:100, 2015 
Variable: Response to DNA vaccine pCI-neo_oppA (1:100) 
Source df SS MS F-value Pr>F 
Total 298 50.943 
   
FAC_A 3 0.548 0.183 1.52 0.2104 
FAC_B 3 14.188 4.729 39.25 0.00000 
FAC_A by FAC_B 9 2.106 0.234 1.94 0.0462 
Residual 283 34.101 0.12 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 0.671 R-squared = 0.3306 C.V. = 51.74% 
C.V = coefficient of variance 
LSD for FAC_A = 0.1118 S.E.D = 0.0571 r = 74.0 
T(2-sided a=0.050, 283 df) = 1.9684 MSE = 0.12050 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_A 
Averages 
Level Y Cv Rank 
2 0.73 60.6 1pCIneo 600 
3 0.7 51.7 2pCIneo 1200 
1 0.64 80.8 3 pCIneo 100 
4 0.62 51.3 4 Control 
 
LSD for FAC_B = 0.1118 S.E.D = 0.0571 r = 74.0 
T(2-sided a=0.050, 283 df) = 1.9684 MSE = 0.12050 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 





Level Y Cv Rank 
9 1.05 47.2 1 Week 9 
6 0.61 51.9 2 Week 6 
0 0.54 56.5 3 
3 0.49 52.3 4 Week 3 
 
LSD for FAC_A*FAC_B = 0.2235 S.E.D = 0.1136 r = 18.7 
T(2-sided a=0.050, 283 df) = 1.9684 MSE = 0.12050 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.348 0.000 0.000 0.595 0.000 0.000 1.207 
2 0.000 0.000 0.581 0.000 0.000 0.580 0.000 0.000 1.129 
3 0.000 0.000 0.494 0.000 0.000 0.679 0.000 0.000 1.011 
4 0.000 0.000 0.538 0.000 0.000 0.568 0.000 0.000 0.838 
 
ANALYSIS OF VARIANCE 
pCI-neo 1:100, 2015 
Variable: Weight 
Source df SS MS F-value Pr>F 
Total 223 20685.410 
   
FAC_A 3 71.845 23.984 0.96 0.4111 
FAC_B 2 15302.793 7651.397 307.65 0.0000 
FAC_A by FAC_B 6 38.214 6.369 0.26 0.9564 
Residual 212 5272.558 24.871 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 38.490 R-squared = 0.7451 C.V. = 12.96% 
C.V = coefficient of variance 
LSD for FAC_A = 1.8578 S.E.D = 0.9425 r = 56.0 
T(2-sided a=0.050, 212 df) = 1.9712 MSE = 24.87055 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error.  





Level Y Cv Rank 
4 39.13 24.9 1 Control 
3 38.97 24.5 2 pCIneo 1200 
1 38.21 25.0 3 pCIneo 100 
2 37.65 27.9 4 pCIneo 600 
 
LSD for FAC_B = 0.1118 S.E.D = 0.0571 r = 74.0 
T(2-sided a=0.050, 283 df) = 1.9684 MSE = 0.12050 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_B 
Averages 
Level Y Cv Rank 
9 44.60 11.9 1 Week 9 
6 44.10 12.9 2 Week 6 
0 26.77 13.4 3 
 
LSD for FAC_A*FAC_B = 3.2178 S.E.D = 1.6324 r = 18.7 
T(2-sided a=0.050, 212 df) = 1.9712 MSE = 24.87055 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.000 0.000 0.000 43.255 0.000 0.000 44.868 
2 0.000 0.000 0.000 0.000 0.000 43.273 0.000 0.000 43.735 
3 0.000 0.000 0.000 0.000 0.000 44.778 0.000 0.000 45.395 
4 0.000 0.000 0.000 0.000 0.000 45.118 0.000 0.000 44.412 
Data used for statistical analysis of the pCI-neo_oppA vaccine results using a 1:100 serum dilution 
factor. The data is arranged in columns, each containing the ostrich number, treatment received (trt), 
time (in weeks), response obtained from ELISA analysis (resp) and weight of the ostriches, read 
from top to bottom and left to right. 




0.304 22.5 166 0 
pClneo 
100 







0.245 27 167 0 
pClneo 
100 







0.755 34 168 0 
pClneo 
100 







0.545 27 169 0 
pClneo 
100 







0.336 30 170 0 
pClneo 
100 
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0.205 22.5 216 0 
pClneo 
1200 







0.359 22.5 217 0 
pClneo 
1200 







0.556 29 218 0 
pClneo 
1200 







0.356 30.5 219 0 
pClneo 
1200 

















0.396 24.5 141 0 control 0.829 29.5 
184 3 
pClneo 




0.481 28.5 142 0 control 0.448 32.5 
185 3 
pClneo 




0.598 27.5 143 0 control 0.759 24.5 
186 3 
pClneo 




0.825 33.5 144 0 control 0.967 30 
187 3 
pClneo 




0.421 22.5 146 0 control 0.251 31 
188 3 
pClneo 




0.322 21.5 147 0 control 0.496 29.5 
189 3 
pClneo 




0.556 26 149 0 control 0.98 29.5 
190 3 
pClneo 




0.281 21 150 0 control 0.196 26 
191 3 
pClneo 




0.328 26.5 151 0 control 0.328 26 
192 3 
pClneo 




0.372 26 152 0 control 0.157 21 
193 3 
pClneo 




0.428 31.5 153 0 control 0.249 27.5 
194 3 
pClneo 




0.43 24 154 0 control 0.725 26 
195 3 
pClneo 




0.457 32.5 155 0 control 0.461 33.5 
196 3 
pClneo 




1.534 29 156 0 control 0.266 29.5 
197 3 
pClneo 




0.982 22 157 0 control 0.919 22.5 
198 3 
pClneo 




0.429 23.5 158 0 control 0.184 25 
199 3 
pClneo 




0.905 19.5 160 0 control 0.731 30 
200 3 
pClneo 




















































































































































































1200 0.678 -9.00 
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*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
219 3 
pClneo 
1200 0.704 -9.00 184 6 
pClneo 






1200 0.500 -9.00 185 6 
pClneo 














0.155 -9.00 187 6 
pClneo 





0.411 -9.00 188 6 
pClneo 





0.760 -9.00 189 6 
pClneo 





0.529 -9.00 190 6 
pClneo 





0.627 -9.00 191 6 
pClneo 





0.527 -9.00 192 6 
pClneo 





0.489 -9.00 193 6 
pClneo 





1.284 -9.00 194 6 
pClneo 





0.397 -9.00 195 6 
pClneo 





0.348 -9.00 196 6 
pClneo 
600 0.516 33.50 161 9 
pClneo 
100 1.209 41.00 
154 3 
control 
0.616 -9.00 197 6 
pClneo 
600 0.601 38.50 162 9 
pClneo 
100 0.574 49.50 
155 3 
control 
0.489 -9.00 198 6 
pClneo 
600 0.851 41.50 163 9 
pClneo 
100 1.042 54.00 
156 3 
control 




9.000 -9.00 164 9 
pClneo 
100 2.257 46.00 
157 3 
control 
1.050 -9.00 200 6 
pClneo 
600 1.068 40.50 165 9 
pClneo 
100 1.296 48.00 
158 3 
control 
0.156 -9.00 201 6 
pClneo 
1200 0.552 51.50 166 9 
pClneo 
100 0.642 45.50 
160 3 
control 
0.263 -9.00 202 6 
pClneo 
1200 0.446 49.00 167 9 
pClneo 
100 1.696 52.00 
161 6 
pClneo 
100 0.373 42.50 203 6 
pClneo 







100 0.266 47.00 204 6 
pClneo 
1200 0.258 36.50 169 9 
pClneo 
100 0.529 44.00 
163 6 
pClneo 
100 0.922 50.00 205 6 
pClneo 
1200 0.902 40.50 170 9 
pClneo 
100 2.195 34.50 
164 6 
pClneo 
100 1.470 44.00 206 6 
pClneo 
1200 0.723 46.00 171 9 
pClneo 
100 0.451 47.00 
165 6 
pClneo 
100 1.484 48.00 207 6 
pClneo 
1200 1.366 33.00 172 9 
pClneo 
100 2.299 37.50 
166 6 
pClneo 
100 0.328 45.50 208 6 
pClneo 
1200 0.605 50.00 173 9 
pClneo 
100 0.731 43.00 
167 6 
pClneo 
100 0.134 51.50 209 6 
pClneo 
1200 0.550 46.00 174 9 
pClneo 
100 1.378 45.00 
168 6 
pClneo 
100 0.313 38.00 210 6 
pClneo 
1200 0.289 51.00 175 9 
pClneo 
100 0.534 48.00 
169 6 
pClneo 
100 0.622 45 211 6 
pClneo 
1200 0.771 45.00 176 9 
pClneo 
100 0.881 39.50 
170 6 
pClneo 
100 0.653 34.00 212 6 
pClneo 
1200 1.426 47.00 177 9 
pClneo 
100 0.844 37.50 
171 6 
pClneo 
100 0.338 44.00 213 6 
pClneo 
1200 0.570 44.50 178 9 
pClneo 
100 1.772 44.50 
172 6 
pClneo 
100 0.831 33.50 214 6 
pClneo 
1200 0.383 47.00 179 9 
pClneo 
100 0.992 47.00 
173 6 
pClneo 
100 0.254 47.50 215 6 
pClneo 
1200 0.456 44.00 180 9 
pClneo 
100 1.631 49.00 
174 6 
pClneo 
100 0.922 43.00 216 6 
pClneo 
1200 0.356 44.50 181 9 
pClneo 
600 0.371 41.50 
175 6 
pClneo 
100 0.237 47.00 217 6 
pClneo 
1200 0.910 44.50 182 9 
pClneo 
600 0.600 49.00 
176 6 
pClneo 
100 0.385 37.50 218 6 
pClneo 
1200 0.839 52.50 183 9 
pClneo 
600 2.261 43.50 
177 6 
pClneo 
100 0.626 38.50 219 6 
pClneo 
1200 0.936 43.00 184 9 
pClneo 
600 0.966 46.00 
178 6 
pClneo 
100 0.386 44.50 220 6 
pClneo 
1200 0.366 49.00 185 9 
pClneo 





9.000 42.00 141 6 
control 







100 0.773 41.50 142 6 
control 
0.222 47.00 187 9 
pClneo 
600 1.220 44.00 
181 6 
pClneo 
600 0.421 38.50 143 6 
control 
0.434 30.00 188 9 
pClneo 
600 0.615 38.00 
182 6 
pClneo 
600 0.617 48.00 144 6 
control 
0.568 46.50 189 9 
pClneo 
600 0.965 48.00 
183 6 
pClneo 
600 1.113 44.50 146 6 
control 
0.450 44.00 190 9 
pClneo 
600 0.587 44.00 




*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
191 9 
pClneo 
600 1.314 52.00 207 9 
pClneo 





600 1.952 33.50 208 9 
pClneo 





600 0.446 48.50 209 9 
pClneo 





600 1.642 49.00 210 9 
pClneo 





600 1.131 43.50 141 9 
control 





600 -9.000 -9.00 142 9 
control 
0.304 46.00 211 9 
pClneo 
1200 1.511 46.50 
197 9 
pClneo 
600 -9.000 -9.00 143 9 
control 







600 1.594 38.50 144 9 
control 
0.796 40.00 213 9 
pClneo 
1200 1.343 42.00 
199 9 
pClneo 
600 1.450 43.50 146 9 
control 
1.390 45.00 214 9 
pClneo 
1200 0.884 46.00 
200 9 
pClneo 
600 1.318 47.00 147 9 
control 
0.834 47.50 215 9 
pClneo 
1200 0.496 44.00 
201 9 
pClneo 
1200 1.427 48.00 149 9 
control 
0.913 46.50 216 9 
pClneo 
1200 0.325 41.50 
202 9 
pClneo 
1200 0.701 49.50 150 9 
control 
0.715 42.00 217 9 
pClneo 
1200 1.062 44.50 
203 9 
pClneo 
1200 1.365 53.50 151 9 
control 
0.763 31.50 218 9 
pClneo 
1200 0.787 50.50 
204 9 
pClneo 
1200 0.679 37.00 152 9 
control 
0.859 50.50 219 9 
pClneo 
1200 1.657 47.00 
205 9 
pClneo 
1200 1.543 44.50 153 9 
control 
0.772 54.00 220 9 
pClneo 
1200 0.571 45.50 
206 9 
pClneo 
1200 1.316 43.50 154 9 
control 
0.787 43.50 
*Ostrich-number of ostrich; TRT- Treatment received; Time- Time in weeks; RESP- Titre response; Weight- weight of 
specific ostrich 
ANALYSIS OF VARIANCE 
VR1020 1:100, 2015 
Variable: Response to DNA vaccine VR1020_oppA (1:100) 
Source Df SS MS F-value Pr>F 
Total 299 117.577 
   
FAC_A 3 6.545 2.182 11.54 0.0000 
FAC_B 3 47.351 15.784 83.45 0.0000 
FAC_A by FAC_B 9 9.966 1.107 5.85 0.0000 
Residual 284 53.715 0.189 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 0.808 R-squared = 0.5432 C.V. = 53.82% 
C.V = coefficient of variance 
LSD for FAC_A = 0.1398 S.E.D = 0.0710 r = 75.0 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.18914 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error  





Level Y Cv Rank 
2 1.01 79.8 1 VR1020 600 
3 0.88 76.1 2 VR1020 1200 
1 0.72 77.6 3 VR1020 100 
4 0.62 51.3 4 Control 
 
LSD for FAC_B = 0.1398 S.E.D = 0.0710 r = 75.0 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.18914 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_B 
Averages 
Level Y Cv Rank 
9 1.05 52.1 1 Week 9 
6 0.63 45.8 2 Week 6 
0 0.58 60.8 3 Week 3 
3 0.52 67.9 4 
 
LSD for FAC_A*FAC_B = 0.2796 S.E.D = 0.1420 r = 18.8 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.18914 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.464 0.000 0.000 0.564 0.000 0.000 1.319 
2 0.000 0.000 0.700 0.000 0.000 0.737 0.000 0.000 2.078 
3 0.000 0.000 0.638 0.000 0.000 0.666 0.000 0.000 1.751 
4 0.000 0.000 0.538 0.000 0.000 0.568 0.000 0.000 0.838 
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ANALYSIS OF VARIANCE 
VR1020 1:100, 2015 
Variable: Weight 
Source df SS MS F-value Pr>F 
Total 224 21669.723 
   
FAC_A 3 420.716 140.239 5.91 0.0007 
FAC_B 2 16075.611 8037.806 338.90 0.0000 
FAC_A by FAC_B 6 121.659 20.277 0.85 0.5290 
Residual 213 5051.736 23.717 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 38.814 R-squared = 0.7669 C.V. = 12.55% 
C.V = coefficient of variance 
 
LSD for FAC_A = 1.8101 S.E.D = 0.9203 r = 56.0 
T(2-sided a=0.050, 213 df) = 1.9712 MSE = 23.71707 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_A 
Averages 
Level Y Cv Rank 
1 40.88 27.0 1 VR1020 100 
4 39.13 24.9  2 Control 
3 37.81 25.0 3 VR1020 1200 
2 37.44 24.2 4 VR1020 600 
 
LSD for FAC_B = 1.5676 S.E.D = 0.7953 r = 75.0 
T(2-sided a=0.050, 213 df) = 1.9712 MSE = 23.71707 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_B 
Averages 
Level Y Cv Rank 
6 45.04 11.7 1 Week 6 
9 44.52 13.3 2 Week 9 
0 26.88 13.4 3 
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LSD for FAC_A*FAC_B = 3.1352 S.E.D = 1.5905 r = 18.8 
T(2-sided a=0.050, 213 df) = 1.9712 MSE = 23.71707 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.000 0.000 0.000 47.875 0.000 0.000 47.237 
2 0.000 0.000 0.000 0.000 0.000 42.556 0.000 0.000 43.583 
3 0.000 0.000 0.000 0.000 0.000 44.625 0.000 0.000 42.850 
4 0.000 0.000 0.000 0.000 0.000 45.118 0.000 0.000 44.412 
 
Data used for statistical analysis of the VR1020_oppA vaccine results using a 1:100 serum dilution 
factor. The data is arranged in columns, each containing the ostrich number, treatment received (trt), 
time (in weeks), response obtained from ELISA analysis (resp) and weight of the ostriches, read 
from top to bottom and left to right. 




0.293 31.50 244 0 
VR1020 
600 







0.644 29.00 245 0 
VR1020 
600 







0.571 27.50 246 0 
VR1020 
600 







1.008 25.00 247 0 
VR1020 
600 







0.424 33.00 248 0 
VR1020 
600 







0.419 27.50 249 0 
VR1020 
600 







0.787 22.00 250 0 
VR1020 
600 







0.256 29.50 251 0 
VR1020 
600 







0.372 18.50 252 0 
VR1020 
600 







0.288 26.00 253 0 
VR1020 
600 







0.244 24.00 254 0 
VR1020 
600 







1.994 25.00 255 0 
VR1020 
600 







0.175 25.00 256 0 
VR1020 
600 







0.230 31.00 257 0 
VR1020 
600 




0.416 29.00 258 0 
VR1020 
600 




0.140 28.50 260 0 
VR1020 
600 




0.700 28.00 261 0 
VR1020 
1200 




0.493 32.00 262 0 
VR1020 
1200 




0.731 28.50 263 0 
VR1020 
1200 




0.598 30.00 264 0 
VR1020 
1200 




0.621 27.50 265 0 
VR1020 
1200 




0.250 30.50 266 0 
VR1020 
1200 




0.502 24.00 267 0 
VR1020 
1200 
0.261 21.50 152 0 control 0.157 21.00 
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*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
153 0 control 0.249 27.50 256 3 
VR1020 
600 




154 0 control 0.725 26.00 257 3 
VR1020 
600 




155 0 control 0.461 33.50 258 3 
VR1020 
600 




156 0 control 0.266 29.50 260 3 
VR1020 
600 




157 0 control 0.919 22.50 261 3 
VR1020 
1200 




158 0 control 0.184 25.00 262 3 
VR1020 
1200 




160 0 control 0.731 30.00 263 3 
VR1020 
1200 







0.332 -9.00 264 3 
VR1020 
1200 







0.777 -9.00 265 3 
VR1020 
1200 







0.974 -9.00 266 3 
VR1020 
1200 







0.499 -9.00 267 3 
VR1020 
1200 







0.346 -9.00 268 3 
VR1020 
1200 







0.385 -9.00 269 3 
VR1020 
1200 







0.578 -9.00 270 3 
VR1020 
1200 







0.181 -9.00 271 3 
VR1020 
1200 







0.484 -9.00 272 3 
VR1020 
1200 







0.254 -9.00 273 3 
VR1020 
1200 







0.284 -9.00 274 3 
VR1020 
1200 







0.921 -9.00 275 3 
VR1020 
1200 







0.219 -9.00 276 3 
VR1020 
1200 







0.580 -9.00 277 3 
VR1020 
1200 







0.595 -9.00 278 3 
VR1020 
1200 







0.155 -9.00 279 3 
VR1020 
1200 







0.460 -9.00 280 3 
VR1020 
1200 






























































































































1.687 -9.00 221 6 
VR1020 
100 
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100 0.528 43.00 268 9 
VR1020 







100 0.884 41.00 269 9 
VR1020 







100 1.501 47.50 270 9 
VR1020 







100 0.480 40.00 271 9 
VR1020 







100 1.046 52.50 272 9 
VR1020 



































































141 6 control 0.892 49.00 
241 9 
VR1020 





142 6 control 0.222 47.00 
242 9 
VR1020 





143 6 control 0.434 30.00 
243 9 
VR1020 
600 0.812 42.50 
141 9 control 1.145 43.50 
144 6 control 0.568 46.50 
244 9 
VR1020 
600 2.314 42.50 
142 9 control 0.304 46.00 
146 6 control 0.450 44.00 
245 9 
VR1020 
600 2.934 49.00 
143 9 control 0.648 34.00 
147 6 control -9.000 49.00 
246 9 
VR1020 
600 2.975 34.00 
144 9 control 0.796 40.00 
149 6 control 0.762 46.00 
247 9 
VR1020 
600 2.379 48.00 
146 9 control 1.390 45.00 
150 6 control 0.515 44.50 
248 9 
VR1020 
600 0.950 45.00 
147 9 control 0.834 47.50 
151 6 control 0.722 34.50 
249 9 
VR1020 
600 2.503 41.00 
149 9 control 0.913 46.50 
152 6 control 0.500 46.00 
250 9 
VR1020 
600 -9.000 -9.00 
150 9 control 0.715 42.00 
153 6 control 0.381 52.50 
251 9 
VR1020 
600 1.375 37.50 
151 9 control 0.763 31.50 
154 6 control 0.758 46.50 
252 9 
VR1020 
600 1.692 54.00 
152 9 control 0.859 50.50 
155 6 control 0.483 54.00 
253 9 
VR1020 
600 2.922 47.00 153 9 
control 
0.772 54.00 
156 6 control 0.220 46.50 
254 9 
VR1020 
600 1.217 42.50 154 9 
control 
0.787 43.50 
157 6 control 1.314 37.50 
255 9 
VR1020 
600 1.980 44.00 155 9 
control 
0.883 53.50 
158 6 control 0.501 40.50 
256 9 
VR1020 
600 1.024 45.50 156 9 
control 
0.416 40.50 
160 6 control 0.385 53.00 
257 9 
VR1020 


































1200 1.962 55.50 
*Ostrich-number of ostrich; TRT- Treatment received; Time- Time in weeks; RESP- Titre response; Weight- weight of 
specific ostrich 
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pCI-neo 1:500, 2015 
Variable: Response to DNA vaccine pCI-neo_oppA (1:500) 
Source df SS MS F-value Pr>F 
Total 299 8.285 
   
FAC_A 3 0.488 0.163 7.56 0.0001 
FAC_B 3 1.440 0.480 22.28 0.0000 
FAC_A by FAC_B 9 0.238 0.026 1.23 0.2774 
Residual 284 6.119 0.022 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 0.170 R-squared = 0.2615 C.V. = 86.11% 
C.V = coefficient of variance 
LSD for FAC_A = 0.0472 S.E.D = 0.0240 r = 75.0 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.02154 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_A 
Averages 
Level Y Cv Rank 
1 0.22 98.6 1 pCIneo 100 
3 0.20 94.2 2 pCIneo 1200 
2 0.13 83.5 3 pCIneo 60 
4 0.13 72.3 4 Control 
 
LSD for FAC_B = 0.0472 S.E.D = 0.0240 r = 75.0 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.02154 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_B 
Averages 
Level Y Cv Rank 
9 0.29 87.2 1 Week 9 
6 0.14 83.5 2 Week 6 
3 0.13 55.0 3 Week 3 
0 0.12 72.1 4 
 
LSD for FAC_A*FAC_B = 0.0944 S.E.D = 0.0479 r = 18.8 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.02154 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
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Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.159 0.000 0.000 0.197 0.000 0.000 0.394 
2 0.000 0.000 0.111 0.000 0.000 0.114 0.000 0.000 0.206 
3 0.000 0.000 0.129 0.000 0.000 0.155 0.000 0.000 0.363 
4 0.000 0.000 0.114 0.000 0.000 0.105 0.000 0.000 0.203 
ANALYSIS OF VARIANCE 
pCIneo 1:500, 2015 
Variable: Weight 
Source df SS MS F-value Pr>F 
Total 223 20685.410 
   
FAC_A 3 71.845 23.948 0.96 0.4111 
FAC_B 2 15302.793 7651.397 307.65 0.0000 
FAC_A by FAC_B 6 38.214 6.369 0.26 0.9564 
Residual 212 5272.558 24.871 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 38.490 R-squared = 0.7451 C.V. = 12.96% 
C.V = coefficient of variance 
LSD for FAC_A = 1.8578 S.E.D = 0.9425 r = 56.0 
T(2-sided a=0.050, 212 df) = 1.9712 MSE = 24.87055 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
FAC_A 
Averages 
Level Y Cv Rank 
4 39.13 24.9 1 Control 
3 38.97 24.5 2 pCIneo 1200 
1 38.21 25.0 3 pCIneo 100 
2 37.65 27.9 4 pCIneo 600 
 
LSD for FAC_B = 1.6089 S.E.D = 0.8199 r = 74.0 
T(2-sided a=0.050, 212 df) = 1.9712 MSE = 24.87055 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error  





Level Y Cv Rank 
9 44.60 11.9 1 Week 9 
6 44.10 12.9 2 Week 6 
0 26.77 13.4 3 
 
LSD for FAC_A*FAC_B = 3.2178 S.E.D = 1.6324 r = 18.7 
T(2-sided a=0.050, 212 df) = 1.9712 MSE = 24.87055 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.000 0.000 0.000 43.225 0.000 0.000 44.868 
2 0.000 0.000 0.000 0.000 0.000 43.273 0.000 0.000 43.735 
3 0.000 0.000 0.000 0.000 0.000 44.778 0.000 0.000 45.395 
4 0.000 0.000 0.000 0.000 0.000 45.118 0.000 0.000 44.412 
 
Data used for statistical analysis of the pCI-neo_oppA vaccine results using a 1:500 serum dilution 
factor. The data is arranged in columns, each containing the ostrich number, treatment received (trt), 
time (in weeks), response obtained from ELISA analysis (resp) and weight of the ostriches, read 
from top to bottom and left to right 
*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
161 0 
pClneo 
100 0.225 22.5 175 0 
pClneo 







100 0.172 27 176 0 
pClneo 







100 0.39 34 177 0 
pClneo 







100 0.179 27 178 0 
pClneo 







100 0.147 30 179 0 
pClneo 







100 0.138 28.5 180 0 
pClneo 







100 0.148 26.5 181 0 
pClneo 







100 0.178 21.5 190 0 
pClneo 







100 0.296 28.5 191 0 
pClneo 







100 0.012 21 192 0 
pClneo 
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0.013 25.5 184 3 
pClneo 
600 




0.195 29 185 3 
pClneo 
600 
0.084 -9.00 149 3 control 0.092 -9.00 
141 0 control 0.135 29.5 186 3 
pClneo 
600 
0.080 -9.00 150 3 control 0.076 -9.00 
142 0 control 0.122 32.5 187 3 
pClneo 
600 
0.219 -9.00 151 3 control 0.288 -9.00 
143 0 control 0.161 24.5 188 3 
pClneo 
600 
0.046 -9.00 152 3 control 0.158 -9.00 
144 0 control 0.265 30.00 189 3 
pClneo 
600 
0.135 -9.00 153 3 control 0.061 -9.00 
146 0 control 0.042 31.00 190 3 
pClneo 
600 
0.073 -9.00 154 3 control 0.089 -9.00 
147 0 control 0.054 29.50 191 3 
pClneo 
600 
0.069 -9.00 155 3 control 0.073 -9.00 
149 0 control 0.141 29.50 192 3 
pClneo 
600 
0.073 -9.00 156 3 control 0.056 -9.00 
150 0 control 0.048 26.00 193 3 
pClneo 
600 
0.062 -9.00 157 3 control 0.203 -9.00 
151 0 control 0.044 26.00 194 3 
pClneo 
600 
0.162 -9.00 158 3 control 0.039 -9.00 
152 0 control 0.047 21.00 195 3 
pClneo 
600 
0.046 -9.00 160 3 control 0.048 -9.00 
153 0 control 0.034 27.50 196 3 
pClneo 
600 




154 0 control 0.074 26.00 197 3 
pClneo 
600 




155 0 control 0.094 33.50 198 3 
pClneo 
600 




156 0 control 0.051 29.50 199 3 
pClneo 
600 




157 0 control 0.162 22.50 200 3 
pClneo 
600 




158 0 control 0.043 25.00 201 3 
pClneo 
1200 




160 0 control 0.047 30.00 202 3 
pClneo 
1200 







0.172 -9.00 203 3 
pClneo 
1200 







0.267 -9.00 204 3 
pClneo 
1200 







0.274 -9.00 205 3 
pClneo 
1200 







0.234 -9.00 206 3 
pClneo 
1200 







0.182 -9.00 207 3 
pClneo 
1200 







0.209 -9.00 208 3 
pClneo 
1200 







0.188 -9.00 209 3 
pClneo 
1200 







0.043 -9.00 210 3 
pClneo 
1200 







0.250 -9.00 211 3 
pClneo 
1200 







0.228 -9.00 212 3 
pClneo 
1200 







0.164 -9.00 213 3 
pClneo 
1200 







0.061 -9.00 214 3 
pClneo 
1200 







0.133 -9.00 215 3 
pClneo 
1200 







0.156 -9.00 216 3 
pClneo 
1200 







0.106 -9.00 217 3 
pClneo 
1200 







0.062 -9.00 218 3 
pClneo 
1200 







0.126 -9.00 219 3 
pClneo 
1200 







0.090 -9.00 220 3 
pClneo 
1200 
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0.081 38.50 161 9 
pClneo 
100 







0.114 41.50 162 9 
pClneo 
100 







-9.000 -9.00 163 9 
pClneo 
100 







0.093 40.50 164 9 
pClneo 
100 







0.085 51.50 165 9 
pClneo 
100 







0.045 49.00 166 9 
pClneo 
100 







0.203 51.50 167 9 
pClneo 
100 







0.155 36.50 168 9 
pClneo 
100 







0.098 40.50 169 9 
pClneo 
100 







0.073 46.00 170 9 
pClneo 
100 







0.612 33.00 171 9 
pClneo 
100 







0.391 50.00 172 9 
pClneo 
100 







0.201 46.00 173 9 
pClneo 
100 







0.104 51.00 174 9 
pClneo 
100 







0.144 45.00 175 9 
pClneo 
100 







0.542 47.00 176 9 
pClneo 
100 







0.263 44.50 177 9 
pClneo 
100 







0.089 47.00 178 9 
pClneo 
100 







0.063 44.00 179 9 
pClneo 
100 







0.065 44.50 180 9 
pClneo 
100 




0.058 44.50 181 9 
pClneo 
600 




0.058 52.50 182 9 
pClneo 
600 




0.052 43.00 183 9 
pClneo 
600 




0.380 49.00 184 9 
pClneo 
600 
0.246 46.00 146 9 control 0.246 45.00 
141 6 control 0.174 49.00 185 9 
pClneo 
600 
0.164 34.00 147 9 control 0.069 47.50 
142 6 control 0.068 47.00 186 9 
pClneo 
600 
-9.000 -9.00 149 9 control 0.239 46.50 
143 6 control 0.185 30.00 187 9 
pClneo 
600 
0.180 44.00 150 9 control 0.099 42.00 
144 6 control 0.215 46.50 188 9 
pClneo 
600 
0.073 38.00 151 9 control 0.136 31.50 
146 6 control 0.048 44.00 189 9 
pClneo 
600 
0.318 48.00 152 9 control 0.122 50.50 
147 6 control -9.000 49.00 190 9 
pClneo 
600 
0.202 44.00 153 9 control 0.182 54.00 
149 6 control 0.201 46.00 191 9 
pClneo 
600 
0.152 52.00 154 9 control 0.180 43.50 
150 6 control 0.060 44.50 192 9 
pClneo 
600 
0.538 33.50 155 9 control 0.304 53.50 
151 6 control 0.032 34.50 193 9 
pClneo 
600 
0.071 48.50 156 9 control 0.159 40.50 
152 6 control 0.052 46.00 194 9 
pClneo 
600 
0.111 49.00 157 9 control 0.565 40.00 
153 6 control 0.040 52.50 195 9 
pClneo 
600 
0.116 43.50 158 9 control 0.197 43.50 
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*Ostrich Time TRT RESP Weight 
160 9 control 0.082 53.50 
*Ostrich-number of ostrich; TRT- Treatment received; Time- Time in weeks; RESP- Titre response; Weight- weight of 
specific ostrich 
 
ANALYSIS OF VARIANCE 
VR1020 1:500, 2015 
Variable: Response to DNA vaccine VR1020_oppA (1:500) 
Source df SS MS F-value Pr>F 
Total 299 50.836 
   
FAC_A 3 2.269 0.756 6.96 0.0002 
FAC_B 3 12.918 4.306 39.60 0.0000 
FAC_A by FAC_B 9 4.770 0.530 4.88 0.0000 
Residual 284 30.879 0.109 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 0.248 R-squared = 0.3926 C.V. = 133.1% 
C.V = coefficient of variance 
LSD for FAC_A = 0.1060 S.E.D = 0.0538 r = 75.0 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.10873 




Level Y Cv Rank 
2 0.35 156.6 1 VR1020 600 
3 0.31 172.3 2 VR1020 1200 
1 0.20 119.9 3 VR1020 100 
4 0.13 71.8 4 Control 
 
LSD for FAC_B = 0.1060 S.E.D = 0.0538 r = 75.0 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.10873 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error  





Level Y Cv Rank 
9 0.61 113.7 1 Week 9 
6 0.14 66.7 2 Week 6 
0 0.13 73.9 3 Week 3 
3 0.11 75.7 4 
 
LSD for FAC_A*FAC_B = 0.2120 S.E.D = 0.1077 r = 18.8 
T(2-sided a=0.050, 284 df) = 1.9684 MSE = 0.10873 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.117 0.000 0.000 0.132 0.000 0.000 0.427 
2 0.000 0.000 0.159 0.000 0.000 0.139 0.000 0.000 0.997 
3 0.000 0.000 0.142 0.000 0.000 0.166 0.000 0.000 0.810 
4 0.000 0.000 0.114 0.000 0.000 0.105 0.000 0.000 0.203 
 
ANALYSIS OF VARIANCE 
VR1020 1:500, 2015 
Variable: Weight 
Source Df SS MS F-value Pr>F 
Total 224 21669.723 
   
FAC_A 3 420.716 140.239 5.91 0.0007 
FAC_B 2 16075.611 8037.806 338.90 0.0000 
FAC_A by FAC_B 6 121.659 20.277 0.85 0.5290 
Residual 213 5051.736 23.717 
  
df = degrees of freedom; SS = Sum of Squares; MS = Mean of Sum of Squares.  
Grand mean = 38.814 R-squared = 0.7669 C.V. = 12.55% 
C.V = coefficient of variance 
LSD for FAC_A = 1.8101 S.E.D = 0.9203 r = 56.0 
T(2-sided a=0.050, 213 df) = 1.9712 MSE = 23.71707 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error  





Level Y Cv Rank 
1 40.88 27.0 1 VR1020 100 
4 39.13 24.9 2 Control 
3 37.81 25.0 3 VR1020 1200 
2 37.44 24.2 4 VR1020 600 
 
LSD for FAC_B = 1.5676 S.E.D = 0.7953 r = 75.0 
T(2-sided a=0.050, 213 df) = 1.9712 MSE = 23.71707 




Level Y Cv Rank 
6 45.04 11.7 1 Week 6 
9 44.52 13.3 2 Week 9 
0 26.88 13.4 3 
 
LSD for FAC_A*FAC_B = 3.1352 S.E.D = 1.5905 r = 18.8 
T(2-sided a=0.050, 213 df) = 1.9712 MSE = 23.71707 
LSD = Least significant difference; S.E.D = Standard Error of Difference; MSE = Mean Squared Error 
Two-way table for FAC_A*FAC_B, n=19 
 1 2 3 4 5 6 7 8 9 
1 0.000 0.000 0.000 0.000 0.000 47.875 0.000 0.000 47.237 
2 0.000 0.000 0.000 0.000 0.000 42.556 0.000 0.000 43.583 
3 0.000 0.000 0.000 0.000 0.000 44.625 0.000 0.000 42.850 
4 0.000 0.000 0.000 0.000 0.000 45.118 0.000 0.000 44.412 
 
Data used for statistical analysis of the VR1020_oppA vaccine results using a 1:500 serum dilution 
factor. The data is arranged in columns, each containing the ostrich number, treatment received (trt), 
time (in weeks), response obtained from ELISA analysis (resp) and weight of the ostriches, read 
from top to bottom and left to right 
*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
221 0 
VR1020 
100 0.064 31.50 223 0 
VR1020 
100 0.093 27.50 225 0 
VR1020 
100 0.074 33.00 
222 0 
VR1020 
100 0.136 29.00 224 0 
VR1020 
100 0.123 25.00 226 0 
VR1020 
100 0.061 27.50 
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*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
227 0 
VR1020 
100 0.156 22.00 270 0 
VR1020 
1200 0.043 23.50 236 3 
VR1020 
100 0.197 -9.00 
228 0 
VR1020 
100 0.049 29.50 271 0 
VR1020 
1200 0.186 28.50 237 3 
VR1020 
100 0.131 -9.00 
229 0 
VR1020 
100 0.061 18.50 272 0 
VR1020 
1200 0.067 26.00 238 3 
VR1020 
100 0.203 -9.00 
230 0 
VR1020 
100 0.034 26.00 273 0 
VR1020 
1200 0.238 23.00 239 3 
VR1020 
100 0.121 -9.00 
231 0 
VR1020 
100 0.038 24.00 274 0 
VR1020 
1200 0.562 26.50 240 3 
VR1020 
100 0.107 -9.00 
232 0 
VR1020 
100 0.223 25.00 275 0 
VR1020 
1200 0.103 19.50 241 3 
VR1020 
600 0.124 -9.00 
233 0 
VR1020 
100 0.185 25.00 277 0 
VR1020 
1200 0.069 32.00 240 3 
VR1020 
100 0.107 -9.00 
234 0 
VR1020 
100 0.126 31.00 278 0 
VR1020 
1200 0.050 26.50 241 3 
VR1020 
600 0.124 -9.00 
235 0 
VR1020 
100 0.177 29.00 279 0 
VR1020 
1200 0.123 23.50 242 3 
VR1020 
600 0.124 -9.00 
236 0 
VR1020 
100 0.073 28.50 280 0 
VR1020 
1200 0.097 21.00 243 3 
VR1020 
600 0.073 -9.00 
237 0 
VR1020 
100 0.268 28.00 141 0 
control 
0.135 29.50 244 3 
VR1020 
600 0.121 -9.00 
238 0 
VR1020 
100 0.107 32.00 142 0 
control 
0.122 32.50 245 3 
VR1020 
600 0.134 -9.00 
239 0 
VR1020 
100 0.237 28.50 143 0 
control 
0.161 24.50 246 3 
VR1020 
600 0.165 -9.00 
240 0 
VR1020 
100 0.092 30.00 144 0 
control 
0.265 30.00 247 3 
VR1020 
600 0.591 -9.00 
241 0 
VR1020 
600 0.115 27.50 146 0 
control 
0.042 31.00 248 3 
VR1020 
600 0.024 -9.00 
242 0 
VR1020 
600 0.029 30.50 147 0 
control 
0.054 29.50 249 3 
VR1020 
600 0.142 -9.00 
243 0 
VR1020 
600 0.052 24.00 149 0 
control 
0.141 29.50 250 3 
VR1020 
600 0.094 -9.00 
244 0 
VR1020 
600 0.083 28.00 150 0 
control 
0.048 26.00 251 3 
VR1020 
600 0.159 -9.00 
245 0 
VR1020 
600 0.068 32.00 151 0 
control 
0.044 26.00 252 3 
VR1020 
600 0.156 -9.00 
246 0 
VR1020 
600 0.091 24.50 152 0 
control 
0.047 21.00 253 3 
VR1020 
600 0.093 -9.00 
247 0 
VR1020 
600 0.208 24.50 153 0 
control 
0.034 27.50 254 3 
VR1020 
600 0.079 -9.00 
248 0 
VR1020 
600 0.024 28.00 154 0 
control 
0.074 26.00 255 3 
VR1020 
600 0.417 -9.00 
249 0 
VR1020 
600 0.134 24.00 155 0 
control 
0.094 33.50 256 3 
VR1020 
600 0.034 -9.00 
250 0 
VR1020 
600 0.046 15.00 156 0 
control 
0.051 29.50 257 3 
VR1020 
600 0.045 -9.00 
251 0 
VR1020 
600 0.152 28.00 157 0 
control 
0.162 22.50 258 3 
VR1020 
600 0.406 -9.00 
252 0 
VR1020 
600 0.217 26.50 158 0 
control 
0.043 25.00 260 3 
VR1020 
600 0.065 -9.00 
253 0 
VR1020 
600 0.198 32.00 160 0 
control 
0.083 30.00 261 3 
VR1020 
1200 0.355 -9.00 
254 0 
VR1020 
600 0.061 26.00 221 3 
VR1020 
100 0.084 -9.00 262 3 
VR1020 
1200 0.169 -9.00 
255 0 
VR1020 
600 0.347 24.00 222 3 
VR1020 
100 0.098 -9.00 263 3 
VR1020 
1200 0.070 -9.00 
256 0 
VR1020 
600 0.055 25.50 223 3 
VR1020 
100 0.108 -9.00 264 3 
VR1020 
1200 0.061 -9.00 
257 0 
VR1020 
600 0.055 24.50 224 3 
VR1020 
100 0.071 -9.00 265 3 
VR1020 
1200 0.181 -9.00 
258 0 
VR1020 
600 0.174 25.50 225 3 
VR1020 
100 0.061 -9.00 266 3 
VR1020 
1200 0.069 -9.00 
260 0 
VR1020 
600 0.046 27.50 226 3 
VR1020 
100 0.074 -9.00 267 3 
VR1020 
1200 0.165 -9.00 
261 0 
VR1020 
1200 0.102 28.00 227 3 
VR1020 
100 0.153 -9.00 268 3 
VR1020 
1200 0.092 -9.00 
262 0 
VR1020 
1200 0.214 33.00 228 3 
VR1020 
100 0.059 -9.00 269 3 
VR1020 
1200 0.131 -9.00 
263 0 
VR1020 
1200 0.051 25.50 229 3 
VR1020 
100 0.079 -9.00 270 3 
VR1020 
1200 0.047 -9.00 
264 0 
VR1020 
1200 0.066 24.50 230 3 
VR1020 
100 0.026 -9.00 271 3 
VR1020 
1200 0.271 -9.00 
265 0 
VR1020 
1200 0.176 27.00 231 3 
VR1020 
100 0.058 -9.00 272 3 
VR1020 
1200 0.238 -9.00 
266 0 
VR1020 
1200 0.042 29.50 232 3 
VR1020 
100 0.099 -9.00 273 3 
VR1020 
1200 0.150 -9.00 
267 0 
VR1020 
1200 0.104 21.50 233 3 
VR1020 
100 0.181 -9.00 274 3 
VR1020 
1200 0.297 -9.00 
268 0 
VR1020 
1200 0.105 27.50 234 3 
VR1020 
100 0.247 -9.00 275 3 
VR1020 
1200 0.114 -9.00 
269 0 
VR1020 
1200 0.125 29.00 235 3 
VR1020 
100 0.179 -9.00 276 3 
VR1020 
1200 0.044 -9.00 
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*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
277 3 
VR1020 
1200 0.112 -9.00 244 6 
VR1020 












































































































































































































100 0.076 43.00 
221 6 
VR1020 







100 0.126 41.00 
222 6 
VR1020 







100 0.413 47.50 
223 6 
VR1020 







100 0.163 40.00 
224 6 
VR1020 







100 0.611 52.50 
225 6 
VR1020 







100 0.223 54.50 
226 6 
VR1020 







100 1.022 46.00 
227 6 
VR1020 







100 0.750 51.00 
228 6 
VR1020 







100 0.523 43.50 
229 6 
VR1020 







100 0.193 56.00 
230 6 
VR1020 







100 0.242 54.50 
231 6 
VR1020 







600 1.767 42.00 
232 6 
VR1020 







600 1.570 37.00 
233 6 
VR1020 







600 0.174 42.50 
234 6 
VR1020 







600 1.969 42.50 
235 6 
VR1020 
100 0.223 49.00 280 6 
VR1020 
1200 0.312 36.50 245 9 
VR1020 
600 1.835 49.00 
236 6 
VR1020 
100 0.157 51.50 141 6 
control 
0.174 49.00 246 9 
VR1020 
600 1.870 34.00 
237 6 
VR1020 
100 0.157 53.50 142 6 
control 
0.068 47.00 247 9 
VR1020 
600 0.849 48.00 
238 6 
VR1020 
100 0.455 47.00 143 6 
control 
0.185 30.00 248 9 
VR1020 
600 0.116 45.00 
239 6 
VR1020 
100 0.171 52.00 144 6 
control 
0.215 46.50 249 9 
VR1020 
600 0.639 41.00 
242 6 
VR1020 
600 0.104 44.50 146 6 
control 
0.048 44.00 250 9 
VR1020 
600 -9.000 -9.00 
243 6 
VR1020 
600 0.154 40.00 147 6 
control 
-
9.000 49.00 251 9 
VR1020 
600 0.190 37.50 
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*Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight *Ostrich Time TRT RESP Weight 
252 9 
VR1020 
600 0.321 54.00 268 9 
VR1020 





600 2.590 47.00 269 9 
VR1020 





600 0.199 42.50 270 9 
VR1020 





600 0.548 44.00 271 9 
VR1020 





600 0.478 45.50 272 9 
VR1020 





600 0.093 46.50 273 9 
VR1020 





600 1.483 41.00 274 9 
VR1020 





600 1.243 45.50 275 9 
VR1020 





1200 0.173 42.50 276 9 
VR1020 





1200 0.966 55.50 277 9 
VR1020 





1200 0.228 44.00 278 9 
VR1020 





1200 0.457 43.50 279 9 
VR1020 





1200 0.559 43.50 280 9 
VR1020 





1200 2.631 45.00 141 9 
control 





1200 0.402 45.00 142 9 
control 
0.128 46.00 160 9 
control 
0.082 53.50 
*Ostrich-number of ostrich; TRT- Treatment received; Time- Time in weeks; RESP- Titre response; Weight- weight of 
specific ostrich.  
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7.2 Addendum B 
Alignment of the IgAH gene to the partially sequenced Struthio camelus australis genome scaffold 
(NW_009271630.1). The part of the scaffold shown is from position 19081 to position 23141. The 
segments indicated in green match the genome scaffold whereas the segment indicated as yellow 
does not match the genome scaffold which might be as a result of an incomplete genome sequence. 
The IgAH is in the reverse compliment orientation in order to match the genome sequence which is 
expected as it was found that the IgA gene of duck, chicken and goose are in reverse orientation on 
the respective chromosomes. 
Ostrich      GTAGACAAGACCCTTCCAGTAGACAAGACCCTTCCAGTAGACTAGCTCAG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TTGGCTCTTCCAGTAGGCTAGACCCTTCCAGTAGACAAGACCCTTCCAGT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      AGACCAGCCCAGTTGGCTCTCCTAGTAGACTACACCCTTCCTGTAGTCAA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GACCCTTCCAGCAGCCTGGCCCAGTTGGCTCTCCCAGGAGGCTAGACCCT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TCCAGTAGTCAAGACCCTTCCAGCAGCCGAGACGCTTCCAGCAGCCTGGT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CCAGTTGGCTCTCCCAGTAGACTACATCCTTCCAGTAGACAAGACCCTTC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CAGCAGCCTGGTCCAGTTGGCTCTCCCAGGAGGCTAGACCCTTCCAGTAG 
IgA_H        ~~~~~~~~~CAGTAGCAGGTGATGTCGGCGTCGGCCAGGACCACCGAGAC 
 
Ostrich      GCTAGACCCTTCCAGTAGATGAGACCCTTCCAGCAGCCTGGCCCAGTTGG 
IgA_H        GTTGACGGCGGTGGGTTTACCCGAAGCCTTGTCCAGGCTCTTGTGGACGA 
 
Ostrich      CTCTCCCAGGAGGCTAGACCCTTCCAGTAGCCTAACTGGAACGGCCCACT 
IgA_H        AGGTGATGGGGATGCCCTCGTGCCCCACCACGCAGGCGAAGGAGTCGCCC 
 
Ostrich      TGACCCTCCCAGCAGGCTAGACTCTCCCAGTAGACTAACCCCTTCCCATG 
IgA_H        CGCTGCCACTCGTCCAATGGGACGCTCAGCTTGCTGTAGACCGTGTAGCC 
 
Ostrich      GCCTGGCCCAGTCGACTCTCCCAGTAGCCTAGGCTCTCCCAGCAGCCCTT 
IgA_H        CCCGCCGTCCTCCTTGGGGCCGAAGACGGCGAAGCTGTCGGGGGACACGG 
 
Ostrich      CCCAGTTGACTCCCCGAGTCGATTCGACTCTTCCAGCCAACTGGCCTAGA 
IgA_H        GGCGCTCTTGCTGCGTCCAGGTCACCAGGATGTCCTGAGGCCGGAAGCCC 
 
Ostrich      CCTGCTCTTCCCTCGCTGCCGACCCCGCTGTGCCCCCGGGGTGGGGGGCT 
IgA_H        GTGGCCAGGCAGGTCAAGGTGGCCATCTCCCCCCGGGCCAGCTCCTCCGC 
 
Ostrich      CAGAGCGGGGCAGAGGAGAAGGGCAGGAAAGGGTGAGCGCCTACCTAGTT 
IgA_H        TGGCGGGGCGAAGACGTAGACGGAGGGCGCCTGCACGGAGACGGCTAGTT 
 
Ostrich      CCTTCTGTGCAGATTTGGTGACGGGCGAGGAGAGCTCGGAGCTGGCCACG 
IgA_H        CCTTCTGTGCAGATTTGGTGACGGGCGAGGAGAGCTCGGAGCTGGCCACG 
 
Ostrich      GTGCAGGTGAAGACCTCGCCGGAGTTCCACTCCTCGGCGCACACCTTCAG 
IgA_H        GTGCAGGTGAAGACCTCGCCGGAGTTCCACTCCTCGGCGCACACCTTCAG 
 
Ostrich      CACGCTGGTGACGCGGTAGAGGCCATCGCCTTGCTGCACCGGCTCCTCGG 
IgA_H        CACGCTGGTGACGCGGTAGAGGCCATCGCCTTGCTGCACCGGCTCCTCGG 
 
Ostrich      AGGTCACGTCCAGAGCGCTGCCCTTCTGCCGCTGCCAGGAGAACCTGACG 
IgA_H        AGGTCACGTCCAGAGCGCTGCCCTTCTGCCGCTGCCAGGAGAACCTGACG 
 
Ostrich      TCGGCGGGCGTCTTGACGTTGGCCACCACGCAGGTGATGCTGGCGTTCTG 
IgA_H        TCGGCGGGCGTCTTGACGTTGGCCACCACGCAGGTGATGCTGGCGTTCTG 
 
Ostrich      GCTGAGGTAGAGGTCCTCCAAGGAAGGCGGGAGGATGGAGACCACGGGCA 
IgA_H        GCTGAGGTAGAGGTCCTCCAAGGAAGGCGGGAGGATGGAGACCACGGGCA 
 
Ostrich      GGGCGATATCTGGGTGGAGGGAGCAGCGTTGAGCGGGGGCTTGGCTCCCC 
IgA_H        GGGCGATAT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GGGCCCCGGCGCGCCCCGAACGCCCTTCCGTTTTGCAGGCGCGGCAACAG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TTTTCCCCACTGGAGCGTCCACGGCGGCTAGATCGCAGGGCGTTAGTACC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TACCCCAGCAGGCAGGAGCAAGATGCTTTTCAAGAAACTCTCTAGAGCAT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 




Ostrich      CGTTTTTGTTAAGTTGTTTTTTTCATCCGAGGATCGCTCAGTCCATCCAC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TTCCTTAATATGCTCTTTCGGTCTTCTGTTTTGTCTCCGAAGCTTTTTTT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TTTTTTTTTTTTTTTAAACAAACAGTTACAACATGAGACAGTTTCTCAGC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TTTAGTAAACAGGATTGTTCTGCTGACCTGGATTGAGTGTAGAGTCTGCC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GTGCGTTCATGCAGCTTCTAATCCGCCCGTGCATCTGTCCATCCATCCAC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CCAGCCAGCCAGCCACCAACCCACCCAGTCACCAACCCAACCATCCATCC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACCAACCCATCCATCCATCCATCCATCCATCCACCAAACCATCCATCCAT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CCATCTGTCCATCCGTCTGTCCATCCATCCATCCATCCATCCATCCATTC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACCAAACCATCCATCCATCCATCCATCCATCCATCCATCCATCCACCCAA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CCATCCATCCATCCCTCCATCTGTCCATCCANNNNNNNNNNNNNNNNNNN 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      NNNNNNNNNNNNNNNNNNNNNTCCATCCATCCATCCACCAACCCATCCAT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CCATCTGTCCGTCCATCCATCCGTCCATCCATCCATGCAGTCAATGCATG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CTCCCACTCATCCATCCTTGCATCCATTCGTGACCGCTAGCAAACCACGA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CCTCCCCGTTGCACCATGCCAGGGCCGCGTTCCCCACCTCGGACCCTCAC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CTGGGCAGGAGTTGCTGATGGTGCGCATGATCGGCTCCGTCAGCGACGCG 
IgA_H        CTGGGCAGGAGTTGCTGATGGTGCGCATGATCGGCTCCGTCAGCGACGCG 
 
Ostrich      TGGGACACTCGGCAAGCGAACTCGGAGCCCCGGTCCCAGCTTTGTCGGCT 
IgA_H        TGGGACACTCGGCAAGCGAACTCGGAGCCCCGGTCCCAGCTTTGTCGGCT 
 
Ostrich      GACGTTGACCTGACTCGACTGCACGGCCTGGTTGTTGGAGCACTTGTCGC 
IgA_H        GACGTTGACCTGACTCGACTGCACGGCCTGGTTGTTGGAGCACTTGTCGC 
 
Ostrich      AGCTGTAGTCCACCTGGGGCAGCGTCACCACCTCTCGGTTCTTCAGCCAT 
IgA_H        AGCTGTAGTCCACCTGGGGCAGCGTCACCACCTCTCGGTTCTTCAGCCAT 
 
Ostrich      TCCACTGTGGCCGGGCCGTCTGGGAGTCCCTCGATGAGGCAGAGCAGCAG 
IgA_H        TCCACTGTGGCTGGGCCGTCTGGGAGTCCCTCGATGAGGCAGAGCAGCAG 
 
Ostrich      GACCTCATCATTATTCTCTGAAAAGCTCAGGATTTTTACCTGTGGGTTGC 
IgA_H        GACCTCATCATTATTCTCTGAAAAGCTCAGGATTTTTACCTGTGGGTTGC 
 
Ostrich      TGCATAAGTCTGCAGAAAAAACAAGGAAATAACTGTAGTGATCAACCAAG 
IgA_H        TGCATAAGT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACCTCGTGCAATGCCGGGAGCAAGGCCAGGAGCTACCCCAGCACCTCTAG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GAAATGACCAAGACCTCGTGCAATGCCGGGAGCAAGGCCAGGAGCTACCC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CAGCACCTCTAGGAAATGACCAAGACCTCGTGCAATGCCGGGAGCAAGGC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CAGGAGCTACCCCAGCACCTCTAGGAAATGACCAAGACCTCGTGCAATGC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CGGGAGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGAAATGACCAAGAC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CTCGTGCAATGCCGGGAGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGA 
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IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      AATGACCAAGACCTCGTGCAATGCCGGGAGCAAGGCCAGGAGCTACCCCA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GCACCTCTAGGAAATGACCAAGACCTCGTGCAATGCCGGGAGCAAGGCCA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GGAGCTACCCCAGCACCTCTAGGAAATGACCAAGACCTCGTGCAATGCCG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      GGAGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGAAATGACCAAGACCT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      CGTGCAATGCCGGGAGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGAAA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TGACCAAGACCTCGTGCAATGCCGGGAGCAAGGCCAGGAGCTACCCCAGC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACCTCTAGGAAATGACCAAGACCTCGTGCAATGCCGGGAGCAAGGCCAGG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      AGCTACCCCAGCACCTCTAGGAAATGACCAAGACCTCGTGCAATGCCGGG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      AGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGAAATGACCAAGACCTCG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TGCAATGCCGGGAGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGAAATG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACACCAAGACCTCGTGTTGCTGCATAAGTCTGCAGAAAAAACAAGGAAAT 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACCTCTAGGAAATGACCAAGACCTCGTGCAATGCCGGGAGCAAGGCCAGG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      AGCTACCCCAGCACCTCTAGGAAATGACCAAGACCTCGTGCATTGCCGGG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      AGCAAGGCCAGGAGCTACCCCAGCACCTCTAGGAAATGACCAAGACCTCG 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TGCATTGCCGGGAGCAAGGCCAGGAGCAGCTCTAGCCCATTTAGGAGTCA 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      ACCAAGACGTCATGCAATGCTGGGAGCAACCCAGTTCCCCTTTGCCTTTC 
IgA_H        ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
 
Ostrich      TCACCTCCGATGTTCTTGGAGATTTCCGTGCTTGTGGGGCTGTGGTTCAC 
IgA_H        ~~~~CCCCGATGTTCTTGGAGATTTCCGTGCTTGTGGGGCTGTGGTTCAC 
 
Ostrich      GTTGCACTGGATGGCGTTGCCCTGCAGGTTGCTGGTGGGCGTCGTGAGCT 
IgA_H        GTTGCACTGGATGGCGTTGCCCTGCAGGTTGCTGGTGGGCGTCGTGAGCT 
 
Ostrich      GGCTGCTGAGGCTGTACAGGCTGTTGCTGACCACCACGGCCGGGTAGGTC 
IgA_H        GGCTGCTGAGGCTGTACAGGCTGTTGCTGACCACCACGGCCGGGTAGGTC 
 
Ostrich      AAGACCTCGTAGGGCTCGCTGGAAACCCAGGTGACGGTGGCGGTCTCGGG 
IgA_H        AAGACCTCGTAGGGCTCGCTGGAAACCCAGGTGACGGTGGCGGTCTCGGG 
 
Ostrich      GAAGAAGTCGTTCACGAGGCAGGCCACGGTGACGTTTCCCTCGTCGCAGC 
IgA_H        GAAGAAGTCGTTCACGAGGCAGGCCACGGTGACGTTTCCCTCGTCGCAGC 
 
Ostrich      CGCAGGGCTTGAGCGCGTAGACGTCGGGCGCTTTGGCCGTGGCTGCAAGG 
IgA_H        CGCAGGGCTTGAGCGCGTAGACGTCGGGCGCTTTGGCCGTGGC------- 
 
Ostrich      AGAAGGGAGAGGGCTGCGAGGGCGCCGGGGCTCGGGGTCTGCCGAAGGCC 
IgA_H        -------------------------------------------------- 
 
Ostrich      GCGAGCTTTCTGCAAGCTTTTGGGGCATCGCACGGATTGAAAACGAGCGT 
IgA_H        -------------------------------------------------- 
 
Ostrich      TGCGGGCACAGCTCGAAGCCGAGCATCGCGAGCACGGCTGGAAGATGATA 
IgA_H        -------------------------------------------------- 
 
Ostrich      ACCGTGTGCAT 
IgA_H        -----------  
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7.3 Addendum C 
Alignment of the IgA heavy chain constant secretory gene (secretory) (Accession number: 
AFA41928.1) with the IgA heavy chain constant region transmembrane gene (transmembrane) 
(Accession number: AFA41929.1). The end parts of the two genes that do not align with each other 
represents the secretion-coding sequence and membrane coding sequence respectively. The 
secretory IgAH consists of four domains where domain one consists of amino acid 2-103, domain 
two consists of amino acid 102-216, domain three consists of amino acid 204-302 and domain four 
of amino acid 308-422.  
 




























430 440 450 460
....|....|....|....|....|....|....|....|.
Secretory SVVLADADITCYX                            
Transmembrane EDAP.EGEEDVTNLWTAVTFVLLFLLSLCYSTGVTLFKVLX
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